The role of hypoxia in neuroinflammatory disease by Desai, RA
 
 
i 
 
 
 
 
 
 
 
THE ROLE OF HYPOXIA IN 
NEUROINFLAMMATORY 
DISEASE 
 
Roshni Anil Desai 
UCL Institute of Neurology 
 
 
 
A thesis submitted for the degree of 
Doctor of Philosophy (Ph.D) 
 
 
 
 
 
 
ii 
 
I, Roshni Anil Desai confirm that the research presented in this thesis is my own, unless 
stated otherwise.  
 
Studies on EAE (experimental autoimmune encephalomyelitis) and the LPS 
(lipopolysaccharide) dorsal column model were carried out in collaboration with Dr 
Andrew Davies, Ph.D. 
 
Resin sections were processed and prepared by Dr Daniel Morrison, Ph.D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
I would like to express my sincerest gratitude to my supervisors Professor Ken Smith 
and Dr Martin Smith, for their continuous support, patience and guidance throughout 
my Ph.D. I would also like to further express my gratitude to Ken for giving me the 
opportunity to work in his laboratory, his encouragement and advice has been 
invaluable. Ken has been an inspiration, and this project would not have been possible 
without him.  
I would also like to thank my colleagues and peers in the lab, in particular Dr Andrew 
Davies. He has been a pillar of strength during my Ph.D, with his continuous support 
advice, and words of encouragement when it all got too much. Many thanks also to Dr 
Daniel Morrison, Diogo Trigo and Peter Bloomfield, for their friendship and 
encouragement. I would also like to express my thanks to Dr Peter McIntosh for 
mentoring me when I first started in the lab. 
I would like to express my utmost thanks to my family and friends, but in particular my 
parents, and my brothers Kunal and Krish for their undeniable support and for instilling 
a belief in me that I am capable of anything I set my mind to. Finally I would like to 
thank Amish for all his encouragement and support during the write-up stage of my 
Ph.D.   
 
 
 
 
 
 
 
 
 
 
iv 
 
ABSTRACT 
Multiple sclerosis (MS) is an inflammatory demyelinating and degenerating disease of 
the central nervous system (CNS) that typically starts with a relapsing-remitting course 
of neurological deficits.  Among the enigmas in the disease are 1) the cause of the 
neurological deficits, 2) the cause of the demyelination, 3) the cause of the 
degeneration, and 4) the cause of the disease itself.  This thesis examines the novel 
hypothesis that tissue hypoxia might illuminate at least some of these enigmas.  Tissue 
hypoxia can easily account for loss of function in a tissue as heavily dependent on 
oxidative phosphorylation as the CNS, and it can similarly selectively kill cells such as 
oligodendrocytes and neurons/axons if they are reliant on oxidative metabolism.  
Hypoxia can also promote inflammation in tissues and thereby reduce the threshold for 
the initiation of inflammatory disease.  Three experimental models have been examined, 
namely experimental autoimmune encephalomyelilits (EAE, a common model of MS), 
an experimental model of the demyelinating Pattern III MS lesion, and animals rendered 
temporarily hypoxic due to placement in an atmosphere of 10% oxygen.  We provide 
chemical, physical and therapeutic evidence that tissue hypoxia is, in part, responsible 
for 1) neurological dysfunction in EAE, 2) the demyelination in the model Pattern III 
lesion, in association with nitric oxide and superoxide, 3) by extension, perhaps 
neurodegeneration, and 4) a sensitization of the CNS to pro-inflammatory conditions, 
including evidence of the special sensitivity of oligodendrocytes to hypoxia.  We 
conclude that true tissue hypoxia is a hitherto-unrecognised, but potentially important, 
factor in several of the cardinal characteristics of MS.   
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HYPOTHESES 
1. Hypoxia mediates neurological dysfunction in rMOG EAE and in the 
development of demyelination in the experimental Pattern III Lesion. 
 
2. Intrinsic regional and cellular vulnerabilities of the normal spinal cord to 
hypoxia render it susceptible to hypoxia-mediated damage. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1.0.0 Multiple Sclerosis 
Multiple sclerosis (MS) was first described by Charcot in the 1860s, and, more than a 
hundred years later, it remains the prototypical immune-associated, demyelinating 
disease of the central nervous system (CNS). Although largely idiopathic in nature, an 
interplay between viral infection (Cook et al., 1995; Herndon, 1996), genetics 
(Compston, 1997) and the environment (Weinshenker et al., 1989) has been implicated 
in the aetiology of MS. This enigmatic disease, traditionally considered a white matter 
phenomenon, is now realised also to affect the grey matter. The pathology is 
characterised by multifocal, perivascular inflammation and focal destruction of myelin, 
resulting in a typically relapsing, but ultimately progressive, degenerative disorder. The 
majority of MS patients initially follow a relapsing/remitting disease course 
(relapse/remitting MS; RRMS), associated with periodic relapses of neurological 
dysfunction, which are often related to a site of observable pathology (Compston and 
Coles 2008). This relapsing phase begins early in adulthood, but is extremely variable 
with regard to its nature and duration, and it is often subsequently followed by a 
progressive (secondary progressive MS; SPMS) disease course. In a small proportion of 
patients (10-20%), a progressive disease is exhibited from the onset in the absence of 
relapses (primary progressive MS; PPMS). Inflammatory demyelinating, focal white 
matter lesions appear to dominate the pathology in RRMS, whereas the progressive 
phase is associated with diffuse atrophy of the white and grey matter (Miller et al., 
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2002), in addition to subtle pathological changes in the normal appearing white matter 
(NAWM) (Allen and McKeown, 1979; De Groot et al., 2001). Anti-inflammatory, 
immunomodulatory and immunosuppressive therapies are regarded as only being 
effective during the early, relapsing stage of the disease (Leary and Thompson, 2003). 
Clinical manifestations of MS are heterogeneous, but are thought primarily to be 
a consequence of aberrant electrical properties of axons due to demyelination. However, 
increasing evidence suggests that inflammation, in the absence of demyelination, can 
also cause neurological dysfunction, (Moreau et al., 1994; Bitsch et al., 1999). The 
mechanisms responsible are not, however, understood, and form the basis of some of 
this thesis. The type of deficit exhibited is largely determined by the anatomical location 
of the lesion. Initial symptoms usually include, but not restricted to, limb weakness, 
sensory disturbances, visual problems, gait instability, and ataxia (Hauser and 
Oksenberg, 2006). As the disease progresses, bladder dysfunction, fatigue and heat 
insensitivity are common (Hauser and Oksenberg, 2006). In advanced disease, cognitive 
deficits have also been reported. Nevertheless, the variability of the neurological disease 
course, and the fact that much of the disease is clinically silent, has massive 
implications for therapy. 
Despite numerous histopathological studies and recent advances in magnetic 
resonance (MR) technology, the MS lesion is not well understood. The mechanism(s) 
responsible for the initiation and evolution of an MS lesion, and its correlation with the 
expression of a neurological deficit, are largely unknown, and will be a focus of this 
thesis.  
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1.2.0.0 Pathology of MS lesions  
The pathological hallmark of MS is the presence of large demyelinated lesions at any 
site in the CNS (Charcot, 1868), however, there is a predilection for the optic nerves, 
spinal cord, brain stem, periventricular areas (Stadelmann et al., 2011), and subpial grey 
matter (Bo et al., 2003). Characteristic features of white matter lesions include 
demyelination, oligodendrocyte loss (Lucchinetti et al., 1999; Barnett and Prineas, 
2004), preferential loss of small calibre axons (Evangelou et al., 2001), impaired 
remyelination (Chang et al., 2002) and astroglyosis. However, different molecular 
events take place in different regions of a given lesion, thereby making it difficult to 
unravel the molecular mechanisms involved in the pathogenesis of MS. Thus, the 
mechanisms involved in plaque formation are still unclear. Some researchers propose 
that the spectrum of lesion pathologies indicates pathogenic heterogeneity (Lucchinetti 
et al., 2000), whereas others have proposed that an initial homogeneous pathogenic 
mechanism is involved in the formation of a new lesion (Barnett and Prineas, 2004). 
Barnett and Prineas reported the presence of two different types of lesions within the 
same patient, and thus propose that a stage-dependent sequence of pathology occurs 
whereby a lesion may progress from the first stage (oligodendrocyte apoptosis) to the 
second stage (T-cell mediated inflammation) (Barnett et al., 2009).  
 
Traditionally, MS was considered as a disease predominantly affecting the white matter, 
but it is now clear that grey matter damage is a fundamental component of the disease 
that is affected from the earliest stages in both RRMS and PPMS, becoming more 
prominent in the secondary progressive stage (Kutzelnigg et al., 2005; Fisniku et al., 
2008; Fisher et al., 2008). Indeed, the presence of grey matter pathology is not 
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surprising given that the cell bodies of axons in white matter tracts reside within the 
grey matter. It is easy to appreciate how damage to the white matter may affect the grey 
matter and vice versa. Unlike demyelination in the white matter, cortical demyelination 
is thought to affect not only motor function but also cognitive function (de Stefano et 
al., 2003; Deloire et al., 2011). Moreover, cortical pathology not only plays a key role in 
clinical progression (Calabrese et al 2010), but its accumulation is thought to represent 
the transition from RRMS to SPMS (Stadelmann, 2011).  
It has previously been shown that cortical lesions may form secondary to white 
matter damage, due to Wallerian degeneration (Cifelli et al., 2002). However, more 
recent studies have shown that cortical demyelination not only occurs distal to white 
matter pathology (Bo et al., 2007; Antulov et al., 2011), but can also evolve faster than 
white matter pathology (Geurts and Barkhof, 2008; Calabrese et al., 2010). In contrast 
to white matter lesions, evidence of significant lymphocyte infiltration, BBB disruption 
and complement deposition has not yet been found in grey matter lesions (Bo et al., 
2003; Brink et al., 2005; van Horssen et al., 2007). Meningeal inflammation is often 
associated with cortical demyelination, particularly in the progressive stages of disease 
(Magliozzi et al., 2007, 2010; Howell et al., 2012), but it has more recently been 
described to additionally occur in the acute stages of disease (Lucchinetti et al., 2011). 
 
 1.2.1.0 Heterogeneity of Lesions 
Lucchinetti et al., (2000) classified MS lesions into four lesion subtypes; patterns I-IV, 
based on differences in immunological parameters among patients. Moreover, the 
pathology of all the lesions in a given individual was found to conform to one pattern 
(Lucchinetti et al., 2000; Konig et al., 2008). The lesion subtypes are described to differ 
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with regard to their morphological characteristics (Lucchinetti et al., 2000) and the 
mechanisms of tissue injury (Lassmann et al., 2001). Patterns I and II exhibit 
perivascular inflammation, with associated demyelination and evidence of 
remyelination. Deposition of immunoglobulin and complement are specific to Pattern II 
lesions. Pattern III lesions also contain an inflammatory infiltrate, but have ill-defined 
lesion boundary, selective loss of myelin associated glycoprotein (MAG), apoptosis of 
oligodendrocytic cells, and often a preserved rim of myelinated axons surrounding an 
inflamed blood vessel. Pattern IV lesions have well-defined boundaries comprising an 
inflammatory infiltrate dominated by T-lymphocytes and macrophages, with 
oligodendrocyte apoptosis confined to a rim of periplaque white matter adjacent to an 
area of active myelin destruction (Lucchinetti et al., 2000).  
 
1.2.2.0 Lesion Evolution in the white matter 
Classical active MS lesions are primarily found in patients with acute or relapsing 
disease, and initially exhibit an acute phenotype which develops to a more chronic form. 
Acute plaques are comprised of macrophages containing similar stages of myelin 
degradation, dispersed throughout the entire lesion (Lassmann, 2011). Chronic active 
plaques, are comprised of macrophages with early stages of myelin degradation 
concentrated at the lesion edge, whilst in the core, macrophages with later stages of 
myelin debris are observed, or they may have disappeared (Lassmann, 2011). The 
classical active lesions evolve in a concentric manner, whereby different stages of 
plaque formation are found in close vicinity. Four distinct zones of the lesion are 
recognised; the periplaque white matter, the initial ‘pre-phagocytic’ lesion, the early 
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active lesion and the late active lesion. These zones may vary in size, thus reflecting the 
speed of lesion development or their stage of evolution (Lassmann, 2011). 
 
1.2.2.1 Preactive lesion 
The white matter can appear to be normal upon superficial examination, by eye, or by 
MRI, but in reality the NAWM is often highly abnormal, showing biochemical and 
histological abnormalities (Allen and McKeown, 1979). One interesting feature is the 
presence of clusters or nodules of activated microglial cells, characterised by the 
expression of major histocompatability (MHC) class II molecules (De Groot et al., 
2001). These microglial nodules have also been found to be closely associated with 
stressed oligodendrocytes (van Noort et al., 2010), and express the inflammatory 
cytokines tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) (van Horssen et 
al., 2012). No evidence of leukocyte infiltration, demyelination, or axonal damage is 
evident in such areas (Allen and McKeown, 1979; De Groot et al., 2001; van Horssen et 
al., 2012). These lesions can be found in the CNS of MS patients irrespective of disease 
subtype and duration, although they tend to occur more frequently in the vicinity of 
active lesions (van Horssen et al., 2012). Due to the frequency, and characteristics of 
these lesions, it is believed that not all preactive lesions develop into demyelinating 
lesions, but rather spontaneously resolve. Thus, this lesion is thought to represent the 
earliest, and potentially reversible, stage of the formation of an MS plaque.  
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1.2.2.2 Periplaque white matter  
In a more established lesion, the periplaque white matter is the region of tissue adjacent 
to the lesion. Although myelin and oligodendrocytes remain intact, diffuse, perivascular 
inflammatory infiltrates are present, with only few lymphocytes scattered throughout 
the parenchyma in addition to generalised microglial activation, characterised by the 
expression of CD68 (Marik et al., 2007). Occasionally, dystrophic axons are seen, and 
may represent either initial axonal injury that precedes demyelination, or secondary, 
Wallerian degeneration (Evangelou et al., 2000). 
 
1.2.2.3 Initial ‘pre-phagocytic’ lesion 
Adjacent to the periplaque white matter, is the initial (Marik et al., 2007) or pre-
phagocytic (Barnett and Prineas, 2004) zone of the active lesion. Here, the largely intact 
myelinated tissue exhibits extensive oligodendrocyte apoptosis, with early microglial 
activation (Barnett and Prineas, 2004; Henderson et al., 2009), microglial NADPH 
oxidase activity (Fischer et al., 2012), and oxidised DNA and lipids (Haider et al., 
2011). This zone contains an increased number of axonal spheroids and end bulbs 
(Marik et al., 2007), that are surrounded by normal myelin sheaths. Astrocytes show an 
up-regulation of glial fibrillary acidic protein (GFAP), and appear to have, in part, lost 
their polarity (Sharma et al., 2010). In Pattern III lesions, there is a profound loss of the 
most distal myelin proteins of the oligodendrocytes; myelin-associated glycoprotein 
(MAG) and cyclic nucleotide phoshodiesterase (CNPase) (Lucchinetti et al., 2000). 
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1.2.2.4 Early active lesion 
The early active demyelinating lesion comprises large numbers of 
microglia/macrophages which contain myelin degradation products with 
immunoreactivity for all the major and minor myelin proteins (Bruck et al., 1995). This 
zone contains the highest density of axonal spheroids or end bulbs (Ferguson et al., 
1997; Trapp et al., 1998; Kornek et al., 2000), with some oligodendrocte loss. Large 
protoplasmic astrocytes are present, many of them having lost their polarity and 
expression of α-synuclein at the astrocytic end feet (Sharma et al., 2011). 
 
 1.2.2.5 Late active lesion 
The late active lesion is the zone closest to the centre of the plaque. Here, the density of 
macrophages is decreased compared to that seen in early active lesions. Myelin is 
completely lost, and any remaining macrophages contain later stages of myelin 
degradation (myelin basic protein; MBP and proteolipid protein (PLP), or contain oil 
red O-reactive lipids (Bruck et al., 1995). Axonal density is reduced, and only a few 
axonal spheroids or end bulbs remain (Lassmann, 2011). A subset of lesions, have been 
reported to contain a considerable number of oligodendrocytes (Raine et al., 1981; 
Prineas et al., 1989), which are thought to be recruited from the pool of progenitor cells, 
and is associated with the early stages of remyelination (Patrikios et al., 2006; Bramow 
et al., 2010). 
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1.2.3.0 Cortical lesions 
To date, three types of cortical lesion have been described; leukocortical lesions, which 
extend out from the white matter into the cortex, intracortical lesions, which radiate 
from microvessels, and subpial lesions, which project from the pia into the cortex (Bo et 
al., 2003a,b). In early stage MS, leukocortical lesions appear to be most common 
(Lucchinetti et al., 2011), whereas in later stage disease, subpial lesions are the most 
abundant form of cortical demyelination (Bo et al., 2003a). During the early stages of 
MS, myelin-laden macrophages are present to different extents, depending on the lesion 
subtype; leukocortical lesions contain the largest numbers, and subpial lesions, the 
lowest (Lucchinetti et al., 2011). Inflammation is also associated with cortical lesions in 
early disease (Lucchinetti et al., 2011). Leukocortical and subpial lesions, in particular, 
predominantly show severe to moderate T-cell inflammation. Occasionally, neuritic 
swelling, oligodendrocyte loss and focal neuronal injury are also evident (Lucchinetti et 
al., 2011). Cortical lesions in progressive disease are somewhat different. No T-cells or 
B-cells are evident in intracortical and subpial cortical lesions, but there can be 
profound microglial activation (Bo et al., 2003b). Actively demyelinating plaques are 
rare (Peterson et al., 2001; Bo et al., 2003a, b), however, transected neurites and 
apoptotic neurons within the demyelinated cortex have been reported (Peterson et al., 
2001). 
 
1.2.4.0 Slowly expanding lesions of progressive disease 
Classical active MS plaques are rare in progressive disease, although some focal 
demyelinated white matter lesions are still present (Lassmann et al., 2007). Some of 
these pre-existing plaques show a slow, gradual expansion of the lesions at their 
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margins (Prineas et al., 2001). Unlike classical active lesions, slowly expanding lesions 
containing macrophages with all stages of myelin degradation are rare or absent. Rather, 
these lesions are characterised by a rim of activated microglia at the lesion edge. T-cells, 
if present, are primarily found perivascularly. Ongoing myelin destruction occurs in the 
absence of any significant inflammation, but it is found in close concert with activated 
microglia and complement deposition (Prineas et al., 2001). BBB damage, assessed by 
the leakage of serum proteins, is not evident (Hochmeister et al., 2006). The centre of 
the plaque is characterised by a dense astrocytic scar accompanied by demyelination, 
which is associated with a complete loss of oligodendrocytes and a substantial decrease 
in axonal density (Mews et al., 1998).  
 
 
1.3.0.0 The pathogenesis of MS: ‘outside-in’ or ‘inside-out’? 
The classical pathological spectrum associated with MS includes BBB breakdown, 
inflammation, demyelination and degeneration. Due to the overwhelming inflammatory 
nature of the disease, it was traditionally assumed that some abnormality in the adaptive 
immune repertoire, against a CNS antigen(s), was the primary trigger for the infiltration 
of peripheral immune cells and their subsequent ‘attack’ on myelinated axons, thereby 
initiating the formation of the infamous inflammatory demyelinating MS lesion 
(McFarland and Martin, 2007). Consequently, a substantial amount of research was 
conducted, over the past several decades, to deduce the immunological mechanism(s) 
that may be involved. It was proposed that interferon-γ (IFN-γ) secreting, myelin-
reactive T-helper 1 (Th1) cells initiate the macrophage-mediated destruction of normal 
myelin. Indeed, both the Th1 cytokine profile of MS patients with active disease (Imam 
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et al., 2007), and the similarities to the T-cell mediated experimental animal model of 
the disease, uphold and support such a hypothesis. A great deal of knowledge has been 
gained from studies focusing on this ‘outside-in’ hypothesis of MS (Stys et al., 2012), 
including, but not restricted to, the elucidation that a strong genetic association with 
immune regulation exists (Sawcer et al., 2011), the illumination of mechanisms of 
immune-mediated damage to CNS components (Hertz et al., 2010), and the 
development of immune-modulating pharmacological agents (Menge et al., 2008). 
However, inconsistencies exist, and with recent observations raising a number of 
questions with regard to the exact sequence of events, the ‘outside-in’ hypothesis has 
been challenged by some. The earliest changes in the myelin begin peri-axonally, 
involving a uniform widening of the inner myelin lamellae, often in areas distant to 
inflammatory foci (Rodriguez and Scheithauer, 1994) with the outer myelin wraps still 
intact. Histological studies on early MS lesions are consistent with these observations, 
showing that the innermost myelin protein, MAG, is preferentially lost (Aboul-Enein et 
al., 2003). If damage was primarily mediated by immune cells, it is suspected that the 
outermost myelin regions would be affected first. The lack of T-cell or B-cell 
infiltration in early areas of active demyelination and oligodendrocyte loss (Barnett and 
Prineas, 2004; Henderson et al., 2009), also raises the question of whether MS is in fact 
an autoimmune disease. Neuropathalogical studies have shown that the NAWM of MS 
patients commonly exhibits pathological abnormalities, such as microglial activation 
(De Groot et al., 2001; Barnett and Prineas, 2004), oligodendrocytic stress (van Noort et 
al., 2010), myelin pallor and oligodendrocytic apoptosis (Barnett and Prineas, 2004), 
and even axonal changes (Trapp et al., 1998), in the absence of an adaptive immune 
response. These studies, therefore propose a putative ‘inside-out’ hypothesis (Stys et al., 
2012), whereby an unknown trigger initiates oligodendrocytic damage, which in turn 
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activates the innate immune system, and elicits the involvement of the adaptive immune 
system.  Indeed, stressed oligodendrocytes have been found to co-cluster with, and 
activate, microglia, within preactive lesions, the supposed earliest stage of MS lesion 
formation (van Noort et al., 2010), corroborating such a hypothesis. However, the 
primary trigger that may induce oligodendrocyte damage has yet to be discovered.  
These studies clearly raise important questions regarding the aetiology of MS, and have 
significant implications for the treatment of the disease. Nevertheless, the cause of MS 
currently remains an enigma. 
 
1.4.0.0 Mediators of dysfunction and tissue damage 
1.4.1.0 Nitric Oxide 
The inflammatory process results in the release of a number of toxic mediators, some of 
which have been found directly to affect axonal conduction and induce structural 
damage. One such mediator, nitric oxide (NO), is synthesised by the enzyme nitric 
oxide synthase (NOS), which catalyses the reaction of arginine with one molecular 
oxygen to produce citrulline and NO (Bredt, 1999). To date, three isoforms of NOS 
have been identified, the constitutively-expressed endothelial NOS and neuronal NOS, 
and the transcriptionally regulated iNOS. The former two are normally present in the 
CNS and account for nanomolar concentrations of NO in a calcium dependent manner, 
whereas the latter inducible isoform is responsible for the high concentrations of NO 
seen at sites of inflammation. Indeed, increased iNOS mRNA expression is evident in 
MS plaques (Bö et al., 1994). In vivo, NO is rapidly degraded into its metabolites nitrate 
and nitrite, and their concentrations can be a direct indication of NO levels in body 
fluids. Increased NO metabolite levels have been found in the cerebrospinal fluid (CSF) 
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of MS patients (Yamashita et al., 1997; Cross et al., 1998; Giovannoni et al., 1998), and 
appear to correlate with disease activity and course (Svenningsson et al., 1999; Rejdak 
et al., 2004). Increased iNOS and NO levels have also been found in experimental 
autoimmune encephalomyelitis (EAE) (Lin et al., 1993; Hooper et al., 1995), an 
experimental model of MS, with the former also correlating with disease severity 
(Okuda et al., 1995). The levels of iNOS have been found to be most pronounced during 
the peak of the disease, corresponding with complete hind limb paralysis, whereas they 
are absent during the recovery phase of the disease (Okuda et al., 1995).  
NO has been proven to mediate a reversible conduction block, not only in 
normal axons (Redford et al., 1997; Shrager et al., 1998), but also in demyelinated 
axons, which are particularly vulnerable (Redford et al., 1997). Thus, low levels of NO 
would selectively mediate conduction block in demyelinated axons (Smith and 
Lassmann, 2002).  Although the exact mechanism of NO-mediated conduction block is 
unclear, it is thought to involve the modulation of ion channels, including sodium (Li et 
al., 1998) and potassium (Kurenny et al., 1994) channels, which would affect 
conduction. Although calcium channels are not prominently expressed along myelinated 
axons, they are present at sites of demyelination (Kornek et al., 2001). These too can be 
affected by NO (Kurenny et al., 1994), resulting in impaired conduction. Direct 
modulation of the sodium-potassium (Na
+
/K
+
) ATPase by NO (Guzman et al., 1995) 
may result in axonal depolarisation, and a subsequent conduction block. Alternatively, 
NO may impair mitochondrial energy metabolism (Bolanos et al., 1994, 1997; Brown et 
al., 1995), and ultimately cause conduction block. Besides NO, numerous cytokines are 
also present in the inflammatory milieu. Some of these cytokines, for example tumour 
necrosis factor-α (TNF-α) and IFN-γ, exert some of their actions through the induction 
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of iNOS expression (Goodwin et al., 1995; Hu et al., 1995; Goureau et al., 1997), and 
thus NO.  
 Besides its ability to induce dysfunction, NO has also been implicated in 
structural damage, arguably due to NO-mediated mitochondrial dysfunction. As will be 
described below, mitochondrial dysfunction can have a significant impact on 
physiological function. Oligodendrocytes and axons are particularly vulnerable to NO 
exposure (Smith et al., 1999; Smith and Lassmann, 2002). Although NO induces 
conduction block in demyelinated axons (Redford et al., 1997), demyelinated axons that 
are exposed to both, NO and metabolic stress, degenerate (Smith et al., 2001). Several 
lines of evidence suggest that NO directly affects mitochondrial function (Bolanos et 
al., 1994; Brown and Cooper, 1994; Mitrovic et al., 1994; Erevinska et al., 1995). NO 
has been shown to irreversibly damage mitochondrial respiratory chain complexes II 
through to IV (Bolanos et al., 1994) and succinate dehydrogenase (Mitrovic et al., 
1994), in vitro. Moreover, NO competitively inhibits the consumption of molecular 
oxygen, at the level of complex IV (Brown and Cooper, 1994), resulting in a decrease in 
oxygen consumption and the ATP/ADP ratio (Erecinska et al., 1995). Consequently, an 
energy insufficiency ensues, the consequence of which will be discussed in further 
detail below. Thus, vulnerable cell types, such as oligodendrocytes and neurons, are 
presumably unable to withstand such an insult, and therefore respond by initiating a 
cascade of events resulting in cell death. Consistent with this notion, oligodendrocytes 
have been found to be particularly vulnerable to NO exposure in vitro (Mitrovic et al., 
1994). Accordingly, the tissue damage in the ‘hypoxia-like’ Pattern III MS lesion has 
been attributed to NO-mediated mitochondrial damage (Aboul-Enein et al., 2005) in 
vulnerable cell types. 
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 1.4.2.0 Reactive oxygen and nitrogen species  
Under physiological conditions, basal levels of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) are routinely generated by various tissues; but although 
inherently toxic they pose very little threat owing to a highly developed set of defence 
and repair mechanisms present in cells. Nevertheless, during certain events, such as 
inflammation, there is an overproduction of these toxic mediators, or a failure in the 
antioxidant mechanisms, and then damage to lipids, proteins and nucleic acids may 
ensue, ultimately leading to cell death.  
ROS/RNS include superoxide, peroxynitrite and the hydroxyl radical, all of 
which are produced as part of the inflammatory response. Superoxide is produced by a 
one-electron reduction of oxygen, and it is the precursor of most other forms of ROS. 
Aberrant superoxide production occurs under adverse conditions, particularly when 
mitochondria are damaged (Murphy, 2009), a well-recognized feature of MS lesions 
(Mahad et al., 2008). Dismutation of superoxide produces hydrogen peroxide (H2O2), 
which in turn can be fully reduced to water, or partially reduced to the notorious 
hydroxyl radical. Superoxide can also react with NO, in a reaction that is limited by the 
rate of diffusion of both radicals, to produce peroxynitrite. Superoxide can be formed in 
vivo in a number of ways, one of which is the mitochondrial respiratory chain. Some 
components of the respiratory chain e.g. ubiquinone, leak electrons directly to molecular 
oxygen. As oxygen accepts one electron at a time, superoxide is released (Halliwell and 
Gutteridge, 1985). The rate of electron leakage, and superoxide production, increases 
with the oxygen concentration (Turrens et al., 1982). Paradoxically, mitochondrial 
superoxide production is also reported to increase in response to low oxygen 
concentrations (Chandel et al., 1998; Guzy and Schumacker, 2006). Besides the 
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mitochondrial respiratory transport chain, another abundant source of superoxide is the 
respiratory burst system of activated microglia and macrophages, whereby copious 
amounts of the free radical are generated on the microglial outer membrane during 
oxygen dependent destruction of pathogens, and released into the surroundings (Gilgun 
Sherki et al., 2004).  
Superoxide itself is relatively harmless; it is in fact its reaction products such as 
peroxynitrite and hydroxyl radical that are potent mediators of damage. Peroxynitrite 
initiates DNA strand breaks, and subsequent activation of poly (ADP-ribose) synthetase 
(Szabό, 1996). This enzyme depletes local ATP stores in an attempt to repair the 
damaged DNA, which results in cell death due to metabolic failure (Szabό, 2003). 
Peroxynitrite is also thought to induce axonal damage, with characteristics similar to 
acute axonopathy (Smith et al., 1999). 
Oxidative damage has been detected biochemically (Vladimirova et al., 1998; 
Bizzozero et al., 2005; Qin et al., 2007) and immunohistochemically (Haider et al., 
2011), in the tissue of patients with MS, suggesting an important role for ROS/RNS in 
MS. Furthermore, a recent study has reported a role for free radical-mediated 
mitochondrial damage, which is followed by axonal damage prior to any demyelination, 
in murine EAE (Nikić et al., 2011).  Furthermore, elevated concentrations of 3-
nitrotyrosine (3-NT), a marker of peroxynitrite-mediated damage, has  also been found 
in MS (Cross et al., 1998; Liu et al., 2001) and EAE lesions (Cross et al., 1997). In 
acute lesions, cells of mononuclear/macrophage lineage and hypertrophied astrocytes 
express 3-NT, whereas no such expression was detected in chronic lesions (Oleszac et 
al., 1998). Due to these findings, and others, oxidative/nitrative stress is increasingly 
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recognised to play an important role in the pathogenesis of demyelination and 
neurodegeneration in MS.  
 
1.5.0.0 Energy insufficiency as a mechanism of neurological 
dysfunction and tissue damage 
Understanding the mechanisms responsible for the expression of a neurological deficit 
and tissue injury in MS represents a challenging yet active area of research. Increasing 
evidence suggests that ultimately an energy insufficiency may represent a key event in 
MS (Smith et al., 2001; Aboul-Enein et al., 2005; Mahad et al., 2008). Indeed, the 
selective vulnerability of small diameter axons in MS (Evangelou et al., 2001), supports 
such a hypothesis as smaller axons have a large surface to cytoplasmic volume ratio, 
rendering them more susceptible to damage (Aboul-Enein et al., 2005).  
ATP is a vital substrate required for a number of physiological cellular 
processes, including signal transduction, ionic balance and macromolecule synthesis 
and transport. It is therefore not surprising that ATP depletion can have devastating 
consequences on cellular function and survival. Although energy insufficiency currently 
represents one of many hypotheses of axonal degeneration in chronically demyelinated 
axons (Bechtold and Smith, 2005; Trapp and Stys, 2009), it can also account for the loss 
of function, and structural damage to vulnerable cell types. The maintenance of sodium 
ion homeostasis is paramount to ensure physiological functioning, thus a disruption to 
the ionic gradients can have a considerable impact. Essentially a decrease in the 
intracellular ATP pool results in the failure of the Na+/K+ ATPase. This ionic pump is 
exceptionally ATP consuming (Ames, 2000), and is responsible for the maintenance of 
the ionic membrane gradient. Failure of the pump therefore prevents extrusion of 
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sodium ions, resulting in sodium loading within the cell. Presumably, vulnerable cell 
types, such as oligodendrocytes and neurons, would be particularly affected by such an 
energy insufficiency.  
Sodium loading is further promoted in axons, following demyelination, due to 
the redistribution of sodium channels along the axolemma (Bostock and Sears, 1978; 
Felts et al., 1997). Once the intracellular sodium increases above its nominal 
concentration (Stys et al., 1997), the sodium-calcium exchanger (NCX), responsible for 
exchanging extracellular sodium for intracellular calcium, operates in reverse. 
Consequently, calcium accumulates within the axons, and calcium-mediated 
degenerative pathways are initiated (Trapp and Stys, 2009). Indeed, demyelinated axons 
in patients with chronic MS show signs of calcium-activated protease activity, e.g. 
fragmented neurofilaments, depolymerised microtubules, and fewer organelles (Dutta et 
al., 2006).The energy deficit needs to be quite severe before calcium-mediated 
degenerative pathways are activated, but it seems reasonable to predict that an energy 
deficit of a smaller magnitude may result in more subtle deficits, such as aberrant 
axonal conduction and, thereby, neurological dysfunction. However, the ability of an 
energy deficit to induce neurological dysfunction remains to be proven.  
 Essentially, any mechanism that impairs ATP production during inflammatory 
demyelination is likely to result in energy insufficiency. It has been proposed that a 
number of factors conspire to compromise ATP production in MS (Aboul-Enein et al., 
2005; Mahad et al., 2008), including NO, ROS/RNS, and hypoxia/ischaemia, however 
they most likely exert their toxic effects on mitochondria, as will be described in further 
detail below. 
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1.5.1.0 Mitochondrial dysfunction 
Mitochondrial dysfunction is increasingly recognised as an important mediator of 
damage in both acute (Mahad et al., 2008) and chronic (Lu et al., 2000; Dutta et al., 
2006; Mahad et al., 2009; Witte et al., 2009) MS lesions. Functional defects in the 
mitochondrial respiratory chain complex IV, in addition to COX-I, its catalytic 
component, have been described in acute, Pattern III MS lesions (Mahad et al., 2008).  
Mitochondrial complex I activity is substantially reduced in chronic MS lesions (Mahad 
et al., 2009), whilst complex I and III activity is decreased in non-lesional motor cortex 
of MS patients (Dutta et al., 2006). The decrease in complex I and III activity in non-
lesional motor cortex is accompanied by a decrease in γ-aminobutyric acid (GABA) 
mediated inhibitory input (Dutta et al., 2006). Thus, it has been proposed that the energy 
demand of demyelinated axons increases, not only due to the diffuse distribution of 
sodium channels (Craner et al., 2004; Waxman et al., 2004), but also increased firing 
due to the loss of inhibitory inputs from interneurons. The ensuing failure of the 
Na+/K+ ATPase, following inevitable sodium loading, has been attributed to a 
population of dysfunctional mitochondria that are supplied by the upper motor neuron, 
by some researchers (Dutta and Trapp, 2011).  
As mentioned briefly above, a number of different mediators are capable of 
provoking mitochondrial dysfunction in inflammatory lesions, including, but not limited 
to, NO (Bolanos et al., 1997; Brorson et al., 1999; Heales et al., 1999; Beltran et al., 
2000) and ROS/RNS (Lu et al., 2000). Despite its ability to directly affect 
mitochondrial function, NO is also a precursor for a number of ROS/RNS, one of which 
is particularly deleterious to mitochondria. As described above, the reaction between 
NO and superoxide, results in the formation of peroxynitrite. Besides its detrimental 
effects on DNA, peroxynitrite can also irreversibly damage mitochondrial respiratory 
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complexes II to IV (Bolaños et al., 1994, 1995), an event that is thought to precede cell 
death (Bolaños et al., 1995). Thus, irreversible damage mediated by peroxynitrite may 
lead to neurotoxicity, ATP depletion and ultimately cell death (Bolanos et al., 1995, 
1996).  
Evidently, unravelling the exact mechanisms of energy failure in MS during the 
different stages of disease is important and may provide the basis for the development 
of novel therapeutic strategies. 
 
 
1.6.0.0 Animal models of MS 
1.6.1.0 Experimental Autoimmune Encephalomyelitis  
EAE is an animal model of MS that dates back to the 1900s, with the discovery that 
rabbits inoculated with human spinal cord homogenate develop spinal cord 
inflammation and paralysis (Koritschoner and Schweinburg, 1925; Gold et al., 2006; 
Stromnes and Goverman, 2006). Since then, there has been much progress in inducing 
EAE, particularly through the development of a mineral oil-based adjuvant by Jules 
Freund which results in disease after a single injection of a CNS encephalitogen 
emulsified in the adjuvant (Freund et al., 1947). Encephalitogens used for the induction 
of EAE can be purified myelin proteins, recombinant proteins, synthesised peptides, or 
whole brain and spinal cord homogenates (Wallström and Olsson, 2008). Although no 
animal model can reflect the entire pathological spectrum of this insidious disease, EAE 
shows neurological signs, immunological and histopathological similarities with MS 
(Hohlfeld and Wekerle, 2001), and the disease can be induced in a number of different 
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species, through either active or passive immunisation. The former type of 
immunisation refers to the co-injection, with adjuvant, of myelin antigens, such as 
MBP, PLP and MOG, whereas the latter involves the adoptive transfer of 
encephalitogenic T-cells. Various factors, including genetic susceptibility, species, age, 
sex, the type and preparation of antigen employed, and the dose and administration 
route, influence the pathogenesis, sensitivity, clinical course of the disease, and the 
pathology of EAE (Teixeira et al., 2005). Thus, in essence, each animal species and 
type of EAE, potentially allows the study of one or more aspects of MS. Nevertheless, 
differences in the nature, size and the distribution of lesions throughout the CNS exist, 
between EAE models and the human disease (Storch et al., 1998). Furthermore, EAE is 
essentially an autoimmune disease principally mediated by T-cells (Ben Nun et al., 
1981) that enter the CNS, recruit circulating monocytes and activate resident microglia. 
These effector cells are central to the induction of inflammatory damage in EAE 
(Berger et al., 1997), but whether this is an accurate model of MS remains uncertain. In 
the majority of susceptible rodent strains, the disease presents as an ascending flaccid 
paralysis, beginning with a limp tail, followed by unilateral and subsequent bilateral 
hind limb paralysis, progressing to the forelimbs, and ultimately death. This pattern is 
entirely unlike MS, a point which is often ignored and not understood (Simmons et al., 
1984).  
In the last three decades, rats and mice have become the preferred choice of 
animal model for EAE studies (Teixeira et al., 2005; Stromnes and Goverman, 2006). 
Although it is possible to induce EAE in mice, producing a chronic-progressive or 
relapsing-remitting disease with demyelination, they are relatively resistant to EAE, 
with highly variable degrees of incidence and time of attack, and the need for an 
ancillary adjuvant to induce disease (Teixeira et al., 2005). Furthermore, in comparison 
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with susceptible rat strains, multiple injections of high doses of antigen are required, 
with the additional use of pertussis toxin as an adjuvant supplement. However, the 
discovery that MOG (or MOG peptides), a minor myelin component, can induce 
chronic paralytic EAE in mice, including the previously resistant C57BL/6 mice (Amor 
et al., 1994; Slavin et al., 1998), has facilitated the generation of numerous transgenic 
mice. MOG is a myelin encephalitogen in that it not only elicits an encephalitic T-cell 
response, but also widespread antibody-mediated CNS demyelination (Johns et al., 
1995; Gold et al., 2006), resulting in a chronic relapsing or progressive disease in both a 
homogeneous and relatively predictable manner (Storch et al., 1998). In C57BL/6 mice, 
the transgenic introduction of either myelin-specific MHC class I CD8+ antigen, or 
MHC class II CD4+ antigen, T cell receptors, into all T cells results in spontaneous 
disease (Bettelli, 2007; Johnson et al., 2010). Similarly, the introduction of myelin-
specific human T cell receptors and human MHC antigens also yields spontaneous 
disease in mice (Ellmerich et al., 2005; Friese et al., 2006). Although the humanised 
models have been suggested to provide significant improvements over the conventional 
models (Friese et al., 2006), the mice rapidly develop a monophasic, chronic disease 
course, with poor recovery (Jones et al., 2008; Soulika et al., 2009).  
MOG induced EAE in the female dark agouti (DA) rat, yields a relatively 
predictable and reliable disease course that more fully represents the pathology and 
clinical course of MS (Storch et al., 1998). At lower doses of MOG (50μg), an acute 
progressive disease course with increasing neurological deficit is observed, whereas at 
higher doses (200μg), a progressive relapsing disease course develops, with relapses 
superimposed upon a slowly increasing neurological deficit, beginning approximately 
12-14 days post injection (Papadoupoulos et al., 2006a,b). The pathology of MOG 
induced EAE in the DA rat, has been found to resemble the pathological spectrum of 
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MS, more so than the other EAE models available (Storch et al., 1998), and thus it can 
represent one of the better EAE models in which to study factors related to MS. 
 
 1.6.2.0 LPS dorsal column model of the MS Pattern III lesion 
The direct intraspinal injection of the pro-inflammatory agent lipopolysaccharide (LPS) 
into the dorsal column of Sprague Dawley rats induces a focal demyelinating lesion that 
exhibits characteristics of the human Pattern III lesion (Felts et al., 2005; Marik et al., 
2007). Within 8 hours, an inflammatory response is elicited in the dorsal columns, but 
the myelin sheaths remain intact at this time (Felts et al., 2005). Following initial 
microglial activation, a functional disturbance begins in astrocytes, namely retraction of 
foot processes, and loss of aquaporin IV and connexin proteins (Sharma et al., 2010).  
The early stages of this lesion are associated with massive precipitation of fibrin, 
particularly on the surface of activated macrophages and microglia (Marik et al., 2007). 
Preferential loss of MAG begins between 5 and 7 days, with demyelinated lesions 
persisting between 9 and 14 days once formed (Felts et al., 2005), and is accompanied 
by profound axonal degeneration (Marik et al., 2007). Interestingly, the lesions form at 
the base of the dorsal columns, rather than at the site of the injection of LPS (Felts et al., 
2005). The lesion persists indefinitely, even if is properties may change (e.g. 
remyelination), and encompasses more than 50% of the cross-sectional area of the 
dorsal columns (Felts et al., 2005). By 28 days, the lesions are largely remyelinated, 
primarily by Schwann cells (Felts et al., 2005).  
The development of tissue injury in the LPS lesion resembles that of the human 
Pattern III lesion, thus a common mechanism of damage is thought to exist (Marik et 
al., 2007). However, the exact sequence of events that leads to the formation of 
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‘hypoxia-like’ demyelination remains unclear. It is clear that focal microglial activation 
results in the production of a number of toxic mediators, including NO, that are capable 
of inducing mitochondrial dysfunction, thereby promoting ‘hypoxia-like’ injury of the 
axons and supporting cells (Marik et al., 2007).  Thus the tissue injury, is currently 
attributed largely to mitochondrial dysfunction as a consequence of oxygen and nitrogen 
radicals, such as NO (Marik et al., 2007). However, administration of the broad-
spectrum anti-inflammatory agent dexamethasone, did not reduce the extent of LPS-
induced demyelination, despite significantly reducing the number of cells expressing 
iNOS (Felts et al., 2005). Therefore, although NO likely plays an important role in the 
development of ‘hypoxia-like’ demyelination, it may not be the only factor involved. 
 
1.7.0.0 Cerebral Blood Flow, Oxygenation and Metabolism  
The brain is a highly oxidative organ that relies on an efficient supply of nutrients to 
maintain normal function and tissue viability. The dependence of cells on a constant and 
plentiful supply of ATP requires an adequate provision of oxygen, which essentially 
depends on the vasculature. Values for cerebral blood flow (CBF) and oxygen 
consumption (CMRO2) are species-specific, with larger values being associated with 
smaller animals (Siesjo, 1978). In rat, the CBF has been reported to be 0.8–1.1 ml/min 
per gram wet weight of tissue, and the reported whole brain CMRO2 rate 3.4–4.6 
µmol/min per gram wet weight (Erecińska and Silver, 2001). 
Increases in CBF have been reported to occur in areas that are expected to be 
activated by a specific stimulus, for example, in the visual cortex in response to a visual 
input (Ances et al., 1999; Colebatch et al., 1991; Lassen and Friberg, 1988; Lu et al., 
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2004), or in the motor cortex during finger movement (Allison et al., 2001). Although it 
is relatively established that under basal conditions in the rodent brain, oxygen and 
glucose consumption, and blood flow are coupled to local brain function (Yarowski and 
Ingvar, 1981; Fox and Raichle, 1986; Fox et al., 1988 Clarke and Sokoloff, 1999), there 
were controversies as to whether such a coupling exists between these parameters 
during physiological activation. Some groups reported a good correlation between CBF, 
and oxygen uptake and glucose utilisation (Yarowski and Ingvar, 1981; Di Rocco et al., 
1989; Clarke and Sokoloff, 1999), whereas others reported that, during activation, the 
CBF and glucose utilisation increased by 53–55%, while oxygen consumption increased 
only by 5% (Fox and Raichle, 1986; Fox et al., 1988). Fox and colleagues proposed that 
this uncoupling of CBF and CMRO2 suggested that the metabolic needs of the tissue 
are met, in part, by non-oxidative metabolism (i.e. glycolysis). Indeed, such a notion 
was supported years later by studies showing activity-induced increases in lactate 
concentration in different brain areas (Figley and Stroman, 2011). It is now generally 
accepted that following physiological activation, (1) CBF increases with metabolic 
demand, (2) CBF and glucose utilisation increase more than oxygen utilisation, and (3) 
oxidative and glycolytic pathways are involved in satisfying the increased metabolic 
demand (Figley and Stroman, 2011). 
More than 90% of the oxygen consumed by the brain is used by mitochondria 
during the oxidation of glucose, to produce energy in the form of ATP (Schiamanna and 
Lee, 1993). The consumption of oxygen and glucose is adjusted to meet regional 
metabolic demand (Sokoloff, 1981; Yarowski and Ingvar, 1981; Fox and Raichle, 1986; 
Fox et al., 1988; Clarke and Sokoloff, 1999). Since glycogen stores are limited in the 
brain, a permanent supply of glucose is essential to maintain brain function. 
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Accordingly, a cessation of oxygen and glucose supply leads to unconsciousness and 
coma within less than 10 sec (Clarke and Sokoloff, 1999).  
Metabolism in the brain is highly compartmentalized, in that, within a given cell, 
there is more than one pool of a given metabolite (Siegel et al., 2006). This 
compartmentalisation is due to the specialised cellular and subcellular localisation of 
transporters, enzymes and metabolic pathways, allowing brain cells to carry out specific 
functions and remain independent (Siegel et al., 2006). Cerebral metabolism is thus a 
complex process, where continuous interactions between neurons and glial cells are 
crucial for correct functioning of the brain (Hertz et al., 1999).  
The traditional view of cerebral energy metabolism was that aerobic respiration 
of glucose was solely responsible for yielding energy in neurons and glia. However, 
each cell type preferentially uses different metabolic substrates and pathways for the 
production of ATP under physiological conditions. Besides glucose, neurons and glial 
cells can additionally utilise lactate, pyruvate, glutamate and glutamine as metabolic 
substrates (Zielke et al., 2009). Among these substrates, lactate is increasingly emerging 
as an important energy source for the brain (Schurr et al., 1999; Gallagher et al., 2009; 
Smith et al., 2003; Boumezbeur et al., 2010; Belanger et al., 2011). Recent evidence 
also suggests that lactate is an important product of glycolysis, in addition to pyruvate 
(Schurr and Payne, 2007). Moreover, a putative mitochondrial lactate oxidation 
complex, which allows entry and oxidation within mitochondria, has been described to 
exist in neurons (Hashimoto et al., 2008). Interestingly, growing evidence suggests that 
neurons can use lactate as an energy source (Schurr et al., 1997; Bouzier et al., 2000; Qu 
et al., 2000; Serres et al., 2005; Boumezbeur et al., 2010; Bellanger et al., 2011), and 
even show a preference for lactate, over glucose when both are available (Itoh et al., 
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2003; Bouzier-Sore et al., 2006; Bellanger et al.. 2011). Accordingly, increasing 
evidence suggests that neurons and astrocytes may share some sort of “coupled lactate 
metabolism”, a mechanism by which astrocytes glycolytically convert glucose to 
lactate, and release it into the extracellular space, where it can be taken up into 
neighbouring neurons to be utilised as a metabolic substrate for oxidative 
phosphorylation (Vibulsreth et al., 1987; Walz and Mukerji, 1988; Magistretti et al., 
1999). More recently, oligodendrocytes have been found to be vital suppliers of lactate 
to axons (Fünfschilling et al., 2012; Lee et al., 2012), via the lactate transporter MCT-1 
(Lee et al., 2012).The process of oxidative phosphorylation yields 38 moles of ATP 
from just one mole of glucose compared to a meagre two moles of ATP for every mole 
of glucose via glycolysis. Therefore, it is understandable why oxygen is essential to 
ensure an efficient rate of energy metabolism, particularly in metabolically demanding 
cells such as neurons and oligodendrocytes. 
Most of the energy consumed by the brain is used for the restoration of the 
membrane resting potential, following neuronal depolarisation, which is accomplished 
by the Na
+
/K
+
 ATPase (Attwell and Laughlin, 2001). Neuronal activity is reported to 
account for almost 80% of the energy consumed by the brain (Sibson et al. 1998; 
Rothman et al. 1999), whereas, neurotransmitter recycling utilises 3–5% of the total 
energy used by the brain (Magistretti and Pellerin, 1996; Sibson et al., 1998; 
Magistretti, 1999; Ames, 2000; Attwell and Laughlin, 2001). Therefore, an impairment 
of energy metabolism can have significant consequences on CNS function. 
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1.8.0.0 Hypoxia and the CNS 
1.8.1.0 The inherent vulnerability of the CNS to hypoxia 
The structural organisation and intrinsic characteristics of the CNS render it particularly 
vulnerable to hypoxia/ischaemia-induced damage. The brain’s substantial energy 
requirements, its limited capacity to store excess glucose, and its poor vascular supply, 
all contribute to the process of hypoxic tissue damage. 
The brain and spinal cord rely on a continuous, rich blood supply to sustain 
ongoing activity. If blood flow is arrested, unconsciousness ensues within 6-7s (Kabat 
and Anderson, 1943; Hansen et al., 1985) and irreversible brain damage occurs within 
minutes. Although the brain comprises only 2% of the body weight, it is estimated to 
receive 15% of the cardiac output, and, 20% and 10% of the oxygen (Afifi and 
Bergman, 2005) and glucose (McKenna et al., 2006) consumed by the entire body, 
respectively. Thus, the brain is a very metabolically expensive organ. This high demand 
for metabolic energy has important implications for the evolution of the brain and its 
function. In fact, the availability of energy essentially limits brain size (Aiello and 
Wheeler, 1995), and determines the circuitry and activity patterns (Mitchison, 1992; 
Koulakov and Chklovskii, 2001) and neural codes (Levy and Baxter, 1996; Baddeley et 
al., 1997; Balasubramanian et al., 2001). Moreover, the energy supplied to the CNS is in 
the form of oxygen and glucose, and the rate of their consumption and utilisation, 
respectively, is high. Despite the considerable reliance on these substrates for energy, 
the CNS has very little in the form of glycogen stores to sustain energy metabolism at 
times of high demand, compared with other tissues such as liver and muscle.. 
Astrocytes are the principal storage sites of glycogen in the CNS (Cataldo and 
Broadwell, 1986), although it is not known whether all astrocytes store glycogen, and if 
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they store glycogen at the same concentration. Indeed, the greatest accumulation of 
glycogen occurs in areas of high synaptic density (Phelps, 1972; Brown and Ransom, 
2007), and the utilization of such stores has been found to sustain neuronal activity 
during periods of hypoglycaemia (Suh et al., 2007). Nevertheless, during periods of 
ischaemia in vivo, the glycogen stores are rapidly depleted, concurrently with ATP 
(Swanson et al., 1989). Thus, despite the presence of these stores, and their role in 
providing energy substrates when the blood-borne glucose is insufficient to meet the 
demand (Brown et al., 2003; Choi et al., 2003), they are relatively inadequate. The 
stores are essentially there to supplement the glucose available to maintain energy 
metabolism, not to be the main or sole source of substrate. Therefore, during 
hypoxic/ischaemic insults, it is not surprising that the glycogen stores are unable to 
maintain substrate delivery.     
Through evolution, the brain has developed a thick parenchyma, which is 
disproportional to its vasculature. The major arteries that enter at the cranial vault at the 
base of the brain are distributed to bifurcate and anastomose on the cortical surface, 
giving off smaller nutrient arteries that penetrate the parenchyma. These small diameter 
penetrating arteries only have a capillary network to provide collateral flow (Moody et 
al., 1990), with each penetrating artery supplying the given surrounding area of tissue 
(Nishimura et al., 2007). Particular areas of the brain, including the cortex, centrum, 
basal ganglia, and thalamus, are supplied by a single penetrating artery (Moody et al., 
1990), rendering them particularly vulnerable to hypoperfusion. Similarly areas that lie 
between two major arterial supplies, known as watershed zones, are also vulnerable to 
hypoperfusion. The best known watershed zones in the brain lie between the anterior 
and middle cerebral circulations, and the middle and posterior cerebral circulations. 
Another watershed zone also exists in the tegmentum of the brain stem.  
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Similar to the brain, the spinal cord also has a vascular architecture which 
renders it vulnerable to hypoxia, whereby major arteries, the ventral and the two dorsal 
spinal arteries supply the cord, promoting segmental vulnerabilities. The ventral spinal 
artery, supplying the ventral and central portions, and the grey matter core, gives off 
smaller end-arteries that penetrate the ventral spinal cord parenchyma.  The dorsal 
spinal arteries, however, descend on the dorsal surface of the spinal cord, and are fed by 
dorsal feeding arteries. The dorsal spinal arteries supply the periphery through the 
circumferential pial network, a rich anastamotic network on the surface of the spinal 
cord that sends penetrating branches into the white matter at all levels of the spinal cord 
(Tveten, 1976; Hayashi et al., 1983). Both the ventral spinal artery and the dorsal spinal 
arteries are dependent on segmental contributions from feeding arteries, along the length 
of the cord. The number of feeding vessels that contribute to each, however, has been 
found to be variable; the average number of arteries contributing to the ventral spinal 
artery is 7, whereas the average number of arteries contributing to the dorsal spinal 
arteries is 25 (Tveten, 1976).  For the ventral spinal artery, these feeding arteries were 
more frequent at C5 and C6, and from T11 to L1, and less frequent at C1-C3, T1-T3 
and caudal to L2 (Tveten, 1976). The presence of one dominant feeding vessel of the 
lumbar segment has been previously reported in the rat (Tveten, 1976), similar to the 
human artery of Adamkeiwicz. However, later studies have suggested that there are in 
fact three to five such vessels between T11 and L4 vertebral segments (Schievink et al., 
1988). The vascular architecture of the brain and spinal cord does not appear to be 
optimal, with particular intrinsic characteristics rendering the CNS vulnerable to 
hypoxic damage, rather than preventing it.  
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1.8.2.0 Effects of hypoxia on the CNS 
Multiple intrinsic and extrinsic mechanisms exist within the CNS to maintain a suitable 
level of oxygen availability. Hypoxia refers to a decrease in the availability of oxygen, 
or a decrease in the partial pressure of oxygen (pO2; LaManna, 2007). At physiological 
partial pressures, haemoglobin is saturated with oxygen, and even a slight decrease in 
the ambient oxygen does not influence the haemoglobin saturation, and tissue oxygen 
availability remains the same (LaManna, 2007). When the arterial pO2 falls below 12 
kPa, a condition known as hypoxaemia (lower blood oxygen) ensues. Successful long-
term adaptation is possible when the hypoxic exposure is mild (below 12 kPa but above 
6 kPa), and it is these adaptations that allow mammals to live at high altitudes 
(LaManna et al., 2004). Mild hypoxia does not usually lead to any tissue damage; 
therefore, there are no problems for humans up to an altitude of 3000 m (LaManna, 
2007). However, between 4 and 6 kPa, there is a good chance of permanent damage and 
with longer exposure below 4 kPa, the hypoxia is severe and results in loss of 
consciousness and neurodegeneration (LaManna, 2007). Indeed, mountain climbers 
often ascend to higher altitudes than 3000 m, and although high altitude illness is the 
most common disturbance reported, neurological conditions such as mental 
disturbances (Ryn, 1988), focal neurological deficits (Song et al., 1986) and transient 
global amnesia (Litch and Bishop, 2000) have also been reported. Cortical atrophy has 
been found on MRI in 92% of Everest (8848 m) climbers, and subcortical lesions were 
found on MRI of inexperienced climbers who were not adequately acclimatized (Fayed 
et al., 2006). Furthermore, such high altitude exposures have been found to provoke 
subtle white and grey matter changes that mainly affect the brain regions that are 
associated with motor activity (Paola et al., 2008). 
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 Systemic compensatory changes that occur in response to mild hypoxia include 
increased ventilation, increased haematocrit, decreased core temperature, weight loss 
and bicarbonate ion excretion (LaManna et al., 2004). For instance, exposure of rats to 
hypobaric hypoxia for a week or more, more than doubles their ventilatory rates 
(LaManna et al., 2004). This increased ventilation results in a decrease in the arterial 
partial pressure of carbon dioxide and subsequent bicarbonate ion excretion by the 
kidney to reduce the blood alkalosis. A fall in core body temperature has also been 
described following exposure to mild hypoxia (Wood, 1991; Mortola, 1993; Mortola et 
al., 1994; Wood and Gonzales, 1996). The drop in temperature is a transient 
phenomenon, lasting only for a few days before returning to basal levels, and may 
suggest decreased metabolism. Furthermore, studies in humans have reported appetite 
suppression and subsequent body weight loss at high altitudes due to hypoxic conditions 
(Westerterp et al., 1994; Westerterp et al., 1999; Shulka et al., 2005). 
 In contrast to the systemic changes, organ specific adaptations are primarily 
found in the capillary bed and the components involved in metabolism (LaManna et al., 
2004), and the brain is no different. Physiologically, the tissue pO2 varies spatially and 
temporally, with the mean tissue pO2 lower than the venous pO2, and there are many 
low values (Sick et al., 1982; LaManna et al., 2004). The CNS undergoes significant 
adaptations in order to preserve tissue oxygen and the energy supply required to support 
cellular functions. One such adaptation is an increase in CBF. An increase in CBF in 
response to hypoxia was previously described, when Kety and Schmidt (1948) recorded 
an average CBF increase of 137 ± 9% in seven young men, whilst breathing 10% 
oxygen. Similarly, Severinghaus and colleagues (1966) reported a mean CBF increase 
from 42 ± 2 ml/100g of brain tissue per minute to 51 ± 4 ml/100g of brain tissue per 
minute after 6-12 hours at altitude, and a subsequent decrease to 47 ± 3 ml/100g of 
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brain tissue per minute. A possible reason as to why the CBF re-normalises could be 
due to the increase in haematocrit, or packed red blood cell volume (Lefant and 
Sullivan, 1971; Xu and LaManna, 2006), by day 3 of exposure to mild hypoxia (Xu et 
al., 2004). Increase in haematocrit level allows an increase in the oxygen content of the 
circulating blood, and restoration of oxygen delivery at the pre-hypoxic rate of blood 
flow rate. An increase in cerebral blood volume, which also occurs in response to acute 
hypoxia (Shockley and LaManna, 1988; Julien-Dolbec et al., 2002), is associated with 
an increase in the capillary mean transit time (Shockley and LaManna, 1988), that is the 
average time it takes for any unit of blood to travel from the arterial end of the capillary 
to the venous end (Xu and LaManna, 2006). An increase in capillary transit time 
increases the time available for the unloading of vital nutrients such as oxygen and 
glucose. This increase in glucose influx across the BBB is seen as an adaptation to 
chronic exposure to mild hypoxia (Harik et al., 1994). There is also an increase in 
capillary density, by week 1 of exposure to prolonged hypoxia, which results in a 
decrease in the inter-capillary distance, and thus decreased diffusion distance (LaManna 
et al., 2004).  In the rat brain, the capillary density almost doubles, thereby decreasing 
the inter-capillary distance from approximately 50 to 40 µm (Lauro and LaManna, 
1997). Not only is there an increase in capillary density, there is also an increase in 
glucose transporter 1 (GLUT-1), as measured by molecules per milligram of 
microvessel (Xu and LaManna, 2006). Interestingly, endothelial cell activation was 
reported in response to prolonged hypobaric hypoxia (Dore-Duffy et al., 1999). 
Exposure to hypoxia resulted in the expression of specific markers associated with 
endothelial cell activation, such as cell surface adhesion molecules, whose expression 
increased in a time dependent manner from 0 to 2 weeks. Induction of endothelial MHC 
class II molecules in addition to increased constitutive expression of GLUT-1 was 
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observed within 24 hours of exposure, and an increase in constitutive expression of 
MHC class I by 48 hours (Dore-Duffy et al., 1999). By 3 weeks of exposure to hypoxia, 
the endothelial cells returned to their quiescent state (Dore-Duffy et al., 1999). 
 
1.8.0.0 Hypoxia and MS 
Increasing evidence from neuropathological, microarray and imaging studies suggest 
that hypoxic conditions may exist within MS lesions. Firstly, the demyelination in 
Pattern III MS lesions has been described to occur by a ‘hypoxia-like’ mechanism, due 
to the pathological similarities this lesion shares with acute white matter stroke lesions 
(Aboul-Enein et al., 2003). As described above, the characteristic feature of Pattern III 
lesions is the striking, preferential loss of MAG (Lucchinetti et al., 2000), a myelin 
protein concentrated in periaxonal regions of the myelin sheath, most distal to the 
oligodendrocyte cell body (Trapp and Quarles, 1984), and a common feature of acute 
white matter stroke lesions. Other myelin proteins, PLP and MBP, which are located in 
compact myelin, and MOG, which is expressed on the surface of oligodendrocytes and 
their processes, initially remain well preserved in this lesion subtype (Lucchinetti et al., 
2000; Lassmann, 2003). In these lesions, areas of MAG loss are associated with 
increased expression of hypoxia-inducible transcription factor-1α (HIF-1α), 
predominantly in oligodendrocytes, astrocytes and some endothelial cells (Aboul-Enein 
et al., 2003). Although the expression of HIF-1α can be induced by hypoxia-
independent factors, its presence in the ‘hypoxia-like’ MS lesion is suggestive that 
oxygen concentrations within the lesion may actually be low. Secondly, microarray 
studies of the NAWM have revealed an up-regulation of a number of genes involved in 
hypoxic pre-conditioning (Graumann et al., 2003). However, these studies have 
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attributed the findings to an energy insufficiency, consequent to NO-mediated 
mitochondrial dysfunction, rather than to hypoxia per se.  
  Vascular disturbances could easily lead to tissue hypoxia, and indeed such 
abnormalities have been described in MS patients. Cerebral hypoperfusion has been 
reported in MS patients since 1983 (Swank et al., 1983; Brooks et al., 1984; Lycke et 
al., 1993; Sun et al., 1998), however, it was not until the development of dynamic 
susceptibility MRI that this phenomenon regained interest (Law et al., 2004; Adhya et 
al., 2006). Law et al (2004), described a decrease in CBF and an increase in mean 
transit time throughout the NAWM of patients with RRMS, compared with that of 
control subjects. Similarly, Adhya et al (2006) found a significant reduction in both the 
CBF and CBV in patients with RRMS and patients with PPMS in comparison to 
controls. Interestingly, more recently, a profound decrease in CBF in the NAWM was 
found in patients with early RRMS, precisely within the first five years of symptoms 
(Varga et al., 2009), suggesting that perfusion abnormalities are present, even in the 
very early stages of disease.  It seems reasonable that these perfusion abnormalities have 
a considerable effect on tissue oxygenation, particularly given that atrophy would not be 
expected at this stage of the disease, and would therefore not account for the decrease in 
CBF. However, increases in CBF and CBV have also been described in a longitudinal 
study, as early as three weeks prior to, and at the time of Gd-DTPA enhancement in 
patients with early RRMS, and mean disease duration of 30.9 months (Wuerfel et al., 
2004). Besides this pattern of perfusion, Wuerfel and colleagues (2004) also described 
decreases in CBF and CBV, and an increase in the mean transit time, in the T1-
hypointense region of lesions that developed ring enhancements, which is consistent 
with previous studies (Haselhorst et al., 2000). Such lesions, are typically focal, and 
exhibit a hyperintense ring at the lesion margin on un-enhanced T1-weighted images, 
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and are thought to persist for long periods of time (Guttmann et al., 1995). The 
perfusion changes associated with the T1-hypointense region has therefore been 
proposed to play a part in the development of a subcategory of focal MS lesions 
(D'haeseleer et al., 2011). 
 More recently, MS has controversially been associated with a reduced CNS 
venous blood drainage, referred to as chronic cerebrospinal venous insufficiency 
(CCSVI) (Zamboni et al., 2009; Al-Omari and Rousan, 2010; Simka et al., 2010). 
CCSVI is characterised by obstruction at different levels of the internal jugular veins, 
vertebral veins, azygous system, and the lumbar venous plexus (Zamboni et al., 2009). 
It is hypothesised that CCSVI stretches the venous walls, which leads to the 
extravasation and degradation of erythrocytes, and subsequent peri-venular iron deposits 
(Singh and Zamboni, 2009). These iron deposits in turn initiate inflammation and 
plaque generation. Indeed, such an abnormality would also be expected to have a 
considerable effect on tissue oxygenation.  However, CCSVI remains a particularly 
controversial topic among the MS community, with other groups unable to reproduce 
the original findings (Doepp et al., 2010; Baracchini et al., 2011; Mayer et al., 2011). 
 
1.9.0.0 Detection of Tissue hypoxia 
Hypoxia is a feature of a number of pathological conditions, yet it represents a 
phenomenon that has not been routinely measured in vivo. This, in part, could be due to 
the limitations associated with traditional invasive methods, such as oxygen 
microelectrodes, and non-specific extrinsic hypoxia markers. However, there have been 
significant improvements in the techniques available to measure CNS oxygen tension in 
vivo.  Such techniques exploit the chemical and physical properties of oxygen in order 
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to acquire a relatively accurate measurement. Such methods include polarography, 
optical probes, electron paramagnetic resonance, nuclear magnetic resonance, positron 
emission tomography and mass spectrometry (Ndubuiza and LaManna, 2007). 
Alternatively, indirect measurements of oxygen concentration, such as haemoglobin 
saturation, cytochrome oxidase redox state, and NADH redox state, also give an 
indication of tissue oxygen concentration. Although, these techniques may differ with 
regard to their sensitivity, accuracy, and ability to measure repetitively (Swartz, 2007), 
no one technique is able to map the oxygen distribution of the brain in vivo.  
The expression of a number of genes is altered in response to hypoxia (Leonard 
et al., 2003; Manalo et al., 2005; Xia et al., 2009). This response to hypoxia is mediated 
by the transcription factor HIF-1α, and, therefore, its presence within tissue is often 
used as an indicator of hypoxia. Pimonidazole, a chemically stable, water soluble drug 
that can cross the BBB and is routinely used in tumour studies, represents another 
means to detect tissue hypoxia. This drug is thought to facilitate the measurement of 
oxygen gradients at the cell level. The mechanisms of action of HIF-1α, pimonidazole, 
and fibre-optic oxygen probes, will be discussed in further detail below. 
 
1.9.1.0 Hypoxia inducible factor (HIF-1α) 
HIF is a heterodimer comprising a constitutively expressed stable β-subunit and an 
oxygen-sensitive α-subunit (Wang et al., 1995; Semenza, 2000). Both HIF-α and HIF-β 
are continuously transcribed and translated, however the HIF-α subunit is subject to 
oxygen-dependent post-translational modifications. Under normoxic conditions, 
conserved proline residues in the oxygen degradation domain, Pro
402
 and Pro
564
 in HIF-
1α (Schofield and Ratcliffe, 2004; Coleman and Ratcliffe, 2007), are hydroxylated by 
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prolyl hydroxylate enzymes (PHDs) (Bruick and McKnight, 2001). In order to 
hydroxylate proline residues on HIF-1α, the PHDs require iron and 2-oxoglutarate as 
substrates in addition to oxygen (Schofield and Zhang, 1999). The hydroxylation of 
either proline residue creates a recognition and binding site for an E3 ubiquitin ligase, 
von Hippel-Lindau protein (VHL), which rapidly targets HIF-1α for proteasomal 
degradation (Maxwell et al., 1999; Ivan et al., 2001; Jaakkola et al., 2001; Kilmova and 
Chandel, 2008). A second oxygen-sensitive control of HIF activity is mediated by the c-
terminus, which contains the c-terminal transactivation domain (CAD; Coleman and 
Ratcliffe, 2007). The HIF-1α CAD is responsible for recruiting the transcriptional co-
activators p300 and CREB-binding protein (CBP; Coleman and Ratcliffe, 2007; 
Kilmova and Chandel, 2008). Under normoxic conditions, HIF-1α CAD activity is 
suppressed by the hydroxylation of a conserved asparagine residue, Asn
803
, by factor 
inhibiting HIF (FIH), which, like the PHDs, requires iron and 2-oxoglutarate as 
substrates in addition to oxygen (Schofield and Ratcliffe, 2004). 
 Under hypoxic conditions, HIF-α is not hydroxylated by either PHDs or FIH, 
allowing it to translocate into the nucleus, dimerise with HIF-β and bind to specific 
hypoxia-responsive elements (HRE) in promoter regions of its target genes (Kilmaova 
and Chandel, 2008). It has been estimated, at least in vitro, that more than 50% of the 
genes that respond to hypoxia are regulated directly or indirectly by HIF (Elvidge et al., 
2006). 
 The cellular responses mediated by hypoxic stabilisation of HIF-α include 
changes in energy metabolism, cell growth, survival and migration (Coleman and 
Ratcliffe, 2007). For instance, HIF promotes the delivery of oxygen to hypoxic areas via 
the up-regulation of growth factors involved in angiogenesis, such as vascular 
endothelial growth factor (VEGF), and can promote the delivery of glucose via the up-
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regulation of glucose transporters, such as GLUT-1. Thus, it is no wonder that HIF is 
sometimes considered the master regulator of hypoxia. 
 
1.9.2.0 Pimonidazole 
Pimonidazole is a chemical compound that allows the detection of hypoxia during life. 
It is often used as a marker of hypoxia in tumour studies (Raleigh et al., 1998; Wykoff 
et al., 2000; Janssen et al., 2002; Airley et al., 2003; Hoskin et al., 2003; Hutchison et 
al., 2004; van Laarhoven et al., 2006), and currently represents one of the best ways in 
which to detect cellular hypoxia. Following administration, pimonidazole is metabolised 
as depicted in Figure 1.9.2.0. Briefly, in the presence of adequate oxygen, pimonidazole 
is subject to oxidative metabolism to an amine oxide, or conjugation to sulfotransferase 
or glucuronyl transferase all of which are readily excreted (Arteel at al., 1998). 
Pimonidazole is also subject to a series of reduction steps, whereby nitroreductases such 
as NADPH and NADH transfer electrons to the parent compound. Oxygen, is the rate 
limiting factor, and competes for the transfer of the first electron to pimonidazole, 
reoxidising the nitro-intermediate pimonidazole, thereby preventing further reduction of 
pimonidazole by nitroreductases (Arteel et al., 1998). In the absence of oxygen, the 
nitro-intermediate pimonidazole is further reduced, and can bind to thiol containing 
molecules such as glutathione and proteins to form pimonidazole adducts. The location 
of these adducts can then be determined by immunohistochemistry using antibodies 
directed against the bound pimonidazole.  
 In addition to hypoxic labelling, pimonidazole has been found to label normoxic 
tissues, raising the suspicion that its ability to bind may not be oxygen dependent in all 
cases, and may in fact also depend on the presence of specialised nitroreductases (Cobb 
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et al., 1990). However, neither the distribution of nitroreductases (Arteel et al., 1995), 
nor the redox state of nitroreductases (Arteel et al., 1998), influences the binding ability 
of pimonidazole.  
 Correlations between pimonidazole binding and other endogenous hypoxia 
markers have been carried out in a number of tumour studies (Raleigh et al., 1998; 
Wykoff et al., 2000; Janssen et al., 2002; Airley et al., 2003; Hoskin et al., 2003; 
Hutchinson et al., 2004; van Laarhoven et al., 2006)). In cervical carcinomas, a mild, 
yet statistically significant correlation between pimonidazole binding and HIF-α, and 
GLUT-1 was found (Airley et al., 2003; Hutchinson et al., 2004), whereas no 
correlation between pimonidazole labelling and VEGF was found (Raleigh et al., 1998). 
Pimonidazole binding was found to correlate with GLUT-1 in bladder carcinoma 
(Wykoff et al., 2000; Hoskin et al., 2000). It appears that the correlation between 
pimonidazole binding and other endogenous markers, is not absolute, and may 
sometimes depend on the model being examined. Nevertheless, pimonidazole represents 
an alternative yet novel way of labelling the CNS for hypoxia during life. 
 
 
 
 
41 
 
 
 
Figure 1.9.2.0:  Metabolism of pimonidazole in vivo 
(a) In vivo, under normoxic conditions, pimonidazole is rapidly metabolised and eliminated from the 
body, by oxidation or conjugation. (b) In the absence of oxygen pimonidazole is reduced by 
nitroreductases to a nitro-intermediate; however, oxygen is the rate limiting factor at this point, and can 
oxidise the nitro-intermediate back to pimonidazole (c). In hypoxic cells, the nitro intermediate is subject 
to a series of reductions (d), until reduced pimonidazole can bind to thiol (SH-) containing molecules 
resulting in the formation of pimonidazole adducts (e). Adapted from Arteel et al., 1998. 
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1.9.3.0 Fibre optic oxygen sensitive probes 
Optical oxygen probes are based on the ability of oxygen to act as a fluorescence 
quencher, thereby decreasing the lifetime of an excited, immobilised lumniphore 
(Kautsky, 1939; Klimant et al., 1995). Specially formulated dyes, designed for their 
highly efficient oxygen quenching capabilities, have facilitated oxygen measurement in 
vivo. In essence, collision between the lumniphore and molecular oxygen results in a 
change in energy state, and thus, deactivation of the luminescent indicator molecule. 
Accordingly, an inverse relationship between the oxygen concentration and luminescent 
decay time exists, whereby a low oxygen concentration is associated with a long decay 
time. The advantage these probes provide over traditional electrodes is that they do not 
consume oxygen and so reach equilibrium. Moreover, they offer relatively high spatial 
and temporal resolution. 
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CHAPTER TWO 
 
HYPOXIA AND DYSFUNCTION 
 
2.1.0.0 INTRODUCTION 
The mechanisms through which neuroinflammation can cause neurological dysfunction 
remain unclear. Traditionally, neurological dysfunction in MS has been attributed to 
demyelination, and axonal degeneration. However, increasing evidence suggests that 
inflammation, in the absence of demyelination, is also capable of causing significant 
clinical deficits (Youl et al., 1991; Moreau et al., 1996; Bitsch et al., 1999). Alterations 
in the conduction properties of axons are thought to underlie a number of symptoms, 
particularly during the relapse-remitting stage of the disease (Smith and McDonald, 
1999). Negative symptoms during relapse (e.g. blindness, numbness, paralysis), have 
been attributed to conduction block, whereas axonal hyperexcitability is thought to 
cause positive symptoms (e.g. tingling sensations). Demyelinated axons are particularly 
susceptible to such changes in electrical activity; however, myelinated axons can also be 
affected.  NO, a toxic mediator found to be elevated in MS (Bo et al., 1994), has 
emerged as a key mediator of such electrical disturbances. NO can induce reversible 
conduction block in normal axons (Redford et al., 1997; Shrager et al., 1998), through 
mechanisms such as ion channel modulation (Kurenny et al., 1994; Li et al., 1998; 
Smith and Lassmann, 2002), inhibition of mitochondrial energy metabolism (Bolanos et 
al., 1994; Brown et al., 1995), and the disruption of synaptic transmission (Kilbinger et 
al., 1996; Holscher et al., 1997; Kara and Friedlander, 1998; Smith and McDonald, 
1999). However, besides the release of toxic mediators, inflammation might also 
promote a hypoxic environment within the tissue. Indeed, a ‘hypoxia-like’ mechanism 
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of tissue injury is suggested to occur in Pattern III MS lesions (Aboul-Enein et al., 
2003), and genes associated with hypoxic pre-conditioning have been found to be up-
regulated in NAWM (Graumann et al., 2003). Hypoxia can directly impair neuronal 
function, and therefore, if present in MS, may not only induce tissue damage, but may 
also play a role in the expression and progression of a neurological deficit. We therefore 
examined the rMOG EAE model of MS for evidence of hypoxia. 
 
2.1.1.0 Aims 
1. To determine whether the spinal cord inflamed by EAE is hypoxic 
2. To determine the role of hypoxia in causing neurological deficits rMOG 
EAE. 
3. To determine the efficacy of acute normobaric hyperoxia on function in 
rMOG EAE 
 
4. To establish the effects of combination therapy (iNOS inhibition, 
antioxidant, and oxygen) on the disease course of rMOG EAE 
 
2.1.2.0 Hypothesis 
Hypoxia mediates neurological dysfunction in the first peak of rMOG EAE. 
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2.2.0.0 MATERIALS AND METHODS 
2.2.1.0 Induction of rMOG-EAE 
All animals were randomized into cages and treatment groups, prior to the experiments, 
and left to acclimatise for at least 7 days. The N-terminal sequence (aa 1-125) of rat 
recombinant MOG (rMOG; a gift from C. Linington, University of Aberdeen, UK) was 
used to induce EAE in adult female DA rats (Harlan, UK; 150g- 190g). Animals (n = 
191) were injected subcutaneously in the rear flank near the base of the tail, with 0.2 ml 
of a hard emulsion comprising 0.100 ml rMOG in 0.100 ml incomplete Freund’s 
adjuvant (IFA; Sigma-Aldrich, USA), under general anaesthesia (2% isoflurane in room 
air). Control animals received 0.2 ml injections of an emulsion of IFA and saline (n = 
19), or saline (n = 19) alone. 
 
2.2.2.0 Neurological Evaluation  
Rats were daily weighed and examined blindly throughout the course of the 
experiments to determine the degree of neurological deficit using a 10-point scoring 
system (Table 2.2.2.0). Briefly, neurological scores were assigned on a scale of 0 to 10, 
whereby the final score represented the total of all the individual scores. The 
neurological assessment comprised examination of tail and bilateral hind limb muscle 
strength (normal, weak, paralysed). The scores corresponded to the following clinical 
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deficit: 0 = normal muscle strength; 1 = muscle weakness; 2 = complete muscle 
paralysis.  
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Neurological Deficit 
Tail tip weakness 
Tail weakness 
Tail paralysis 
Abnormal gait 
Abnormal toe spreading 
Unilateral hind limb weakness 
Bilateral hind limb weakness 
Unilateral hind limb paralysis 
Bilateral hind limb paralysis 
Moribund 
 
 
Table 2.2.2.0: Conventional scoring scale for evaluating neurological deficit 
Table showing the criteria used to evaluate the extent of neurological deficit in animals immunised with 
rMOG. A score of one was given for each of the deficits outlined in the table to give a total score out of 
ten. 
 
 
 
 
 
 
 
 
 
 
48 
 
2.2.3.0 Selection of animals  
2.2.3.1 rMOG EAE disease time course 
During various stages of the disease (asymptomatic (prior to deficit), first peak (within 
3 days of onset of deficit), remission (at least two days of functional improvement 
following an initial deficit), and relapse (at least two days of increasing severity of 
deficit following the remission period)), animals were grouped into cohorts of eight 
animals comprised of an IFA control (n=15 in total), a saline control (n=15 in total), and 
6 animals displaying a range of neurological deficit scores (n=75 in total). 
 
2.2.3.2 One hour oxygen therapy in rMOG EAE 
At the onset of neurological deficit, rMOG animals were placed in pairs based on the 
similarity and timing of their neurological deficit as dictated by their 10-point 
neurological score, and each animal of the pair was randomly assigned to receive either 
room air (n=12) or normobaric hyperoxia (~98%, n=12). IFA (n=2 per treatment) and 
saline (n=2 per treatment) controls were also included. Animals were housed in a 
purpose-built chamber (BioSpherix, USA), for the duration of the treatment (1 hour), 
and temperature, oxygen concentration, and carbon dioxide concentration were 
monitored and controlled throughout. Prior to, and following treatment, animals were 
subjected to a more rigorous neurological assessment using a 25-point scale (Table 
2.2.3.2). Thus each hind limb was assessed for stretch withdrawal, pinch withdrawal, 
toe spreading, spasticity, and plantar placement with a maximum of two points awarded 
for each measure (ten points per hind limb), with a score of zero indicating normal 
 
 
49 
 
function.  Tail function (0-3 points) and hip flexion (0-2 points) were also assessed, for 
a total maximum score of 25 points.   
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Neurological Deficit Score 
Hind limbs 
 Stretch Withdrawal 
  Delayed, Weak, Partial 1 
  No Response 1 
 Pinch Withdrawal 
  Delayed, Weak, Partial 1 
  No Response 1 
 Toe Spreading 
  Incomplete, Asymmetrical Foot 
Splaying or Toe Spreading 
1 
  No Response 1 
 Spasticity 
  Partial rigidity or immobilization, 
some residual movement 
1 
  Complete rigid spasticity 1 
 Plantar Placement 
  Attempted but unsuccessful or 
incomplete plantar placement during 
walking 
1 
  No attempted plantar placement 
during walking 
1 
Tail 
  Tail tip weakness 1 
  Tail weakness 1 
  Complete tail paralysis 1 
Hip 
  Asymmetrical, some flexion 1 
  Complete Absence of flexion, or 
dragging 
1 
 
 
Table 2.2.3.2: Enhanced scoring scale for the evaluation of neurological deficit  
Table outlining the criteria used to evaluate the extent of neurological dysfunction in animals immunised 
with rMOG, prior to and following treatment with one hour of oxygen. A score of one was given for each 
deficit, resulting in a total score out of 25. 
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2.2.3.3 7-day combination therapy 
To assess the relative contributions of oxygen, NO and superoxide to functional 
impairment in EAE, the effects of prolonged normobaric hyperoxia (~75% oxygen), 
iNOS inhibition (1400W; Enzo Life Sciences Ltd, UK), mitochondrially targeted 
antioxidant therapy (MitoQ, a kind gift from M. Murphy), and a combination of all the 
therapies, was investigated. Animals (n = 85) were randomly assigned to one of five 
treatment groups; oxygen (n=17), 1400W (iNOS inhibitor; n = 17), MitoQ (antioxidant; 
n = 17), All (n = 17) and controls (n = 17), at least 7 days prior to immunisation. Oral 
administration of MitoQ (500 μM), via the drinking water, began on the day of 
immunisation, and was monitored daily. All other treatments began on the day of 
disease onset. 1400W (10 mg/ml in sterile saline) was administered daily 
intraperitoneally, to animals in the 1400W and All, treatment groups, from disease 
onset. The remaining animals were daily administered intraperitoneal injections of 
saline alone, from disease onset. Treatment was continued for 7 days post-disease onset. 
Daily monitoring and assessment of neurological deficit was performed by a blind 
assessor.  
 
2.2.4.0 Intravenous and tissue probes 
Four hours prior to perfusion, intravenous injections of pimonidazole (60mg/kg in 
sterile saline; HPI Inc, USA), and dihydroethidium (DHE) (1μg/ml in DMSO, Sigma 
Aldrich, UK) were administered into each of the saphenous veins, under light 
anaesthesia (2% isoflurane in room air, or oxygen, as appropriate). Animals that were 
part of the acute oxygen therapy study were maintained in their respective treatment 
condition, from the beginning of treatment, until perfusion. Prior to perfusion, a 
laminectomy was performed at the T13/L1 vertebral level, under general anaesthesia 
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(2% isoflurane in room air, or oxygen, as appropriate), so as to expose the cord. A small 
hole was made in the dura, approximately 700 μm lateral to the midline, and the 
neighbouring dorsal spinous process stabilised using a secure haemostat. A tapered-tip 
(<50 μm) oxygen-sensitive optical probe (OxyMicro, WPI inc, USA) was then inserted 
at an angle of 12 degrees from vertical into the grey matter, through the hole in the dura, 
to a depth of 1100 μm and then retracted 100 μm.  Subsequent oxygen and temperature 
measurements were recorded continuously (1 Hz) using OxyMicro software (WPI inc, 
USA) for at least five minutes following stabilization of the recording.  The oxygen 
probe was calibrated prior to use on a daily basis.  
 
All protocols for animal research were carried out in accordance with UK Home Office 
scientific procedures act and an appropriate project license.  
 
2.2.5.0 Tissue Processing 
Animals were perfused transcardially with phosphate-buffered saline (PBS; Sigma-
Aldrich, USA), followed by 4% paraformaldehyde (PFA) for fixation, under general 
anaesthesia (2% isoflurane in room air, or oxygen, as appropriate). Spinal cord tissue 
was harvested and post-fixed in 4% PFA overnight, with subsequent cryoprotection in 
30% sucrose (BDH International, UK) in PBS. The spinal cords were cut into 5 
segments comprising the sacral, lumbar, upper lumbar, lower thoracic and mid-thoracic 
regions of cord, and embedded in cryomoulds containing OCT medium (Leica, UK). 
The tissue was frozen by immersion in pre-cooled isopentane (VWR International, UK) 
in liquid nitrogen. Sections were cut to a thickness of 12 µm with a cryostat (Leica 
Microsystems, Germany) at -20
0
C, and thaw-mounted onto glass slides. The sections 
were stored frozen at -20
0
C until use. 
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 2.2.6.0 Histology 
 2.2.6.1 Immunohistochemistry/Immunofluorescence (IHC/IF) 
The cryosections were air dried for at least two hours prior to any histology.  First, 
sections were washed in 0.1M PBS and pretreated with 0.3% hydrogen peroxide (Sigma 
Aldrich) in neat methanol (VWR International, UK), or methanol alone, for 
immunofluorescence, for 15 minutes, to quench endogenous peroxidase activity, 
followed by PBS washes. Where necessary, sections were additionally pre-treated with 
1mg/ml sodium borohydride (NaBH4; Sigma Aldrich) in PBS, twice, for 5 minutes each 
(Table 2.2.6.1). For 8-hydroxydeoxyguanosine immunohistochemistry, tissue was 
additionally pre-treated with a buffer containing 100µg/ml RNase A (Sigma Aldrich), 
150mM sodium chloride and 15mM sodium citrate, for 1 hour at 37
o
C, followed by 2N 
hydrochloric acid, and 1M Tris-base, for 5 minutes each. Non-specific binding was 
blocked with the appropriate blocking buffer (Table 2.2.6.1), for 30 minutes. Tissue was 
then incubated overnight at 4
o
C with the primary antibody. Negative controls were 
incubated with blocking buffer alone.  
Primary antibodies were detected with either, horse anti-mouse, or goat anti-
rabbit biotinylated secondary antibodies (1:200, Vector Laboratories Inc, UK), followed 
by visualisation using an avidin-biotin complex horseradish peroxidise kit (Vectastain 
Elite ABC kit, Vector Laboratories), with diaminobenzidine (DAB) (Vector 
Laboratories) as the chromogen. Sections were finally dehydrated in graded alcohol to 
xylene, and coversliped in DPX mounting medium (BDH). PBS washes were carried 
out between all steps. 
For immunofluorescence, mouse primary antibodies were detected with a horse 
anti-mouse biotinylated secondary antibody (1:200, Vector), followed by a streptavidin-
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FITC (Fluorescein isothiocyanate) conjugated antibody (1:200, Invitrogen, UK), and 
rabbit primary antibodies were detected with a goat anti-rabbit Cy3 conjugated 
secondary antibody (1:200, Invitrogen). Sections were then coversliped with vectashield 
aqueous mounting medium (Vector). PBS washes were carried out between all steps. 
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Table 2.2.6.1: Antibody details for IHC/IF 
Antibody Target Isotype 
Pre-
Treatment 
Blocking 
Buffer 
Dilution Source 
Mouse Anti-
Rat ED1 
Activated 
macrophages/ 
microglia 
Mouse 
IgG1 
None 
 
5% horse serum 
(NHS; Vector 
Labs) 
in 0.01% PBS-
triton 
 
1:200 AbD Serotec 
Mouse Anti-
P47phox 
NADPH oxidase subunit 
Mouse 
IgG1 
None 
 
5% NHS 
in 0.01% PBS-
triton 
 
1:50 
Santa Cruz 
Biotechnology 
Mouse 
Hydroxyprobe-
1-Mab anti-
pimonidazole 
Pimonidazole adducts 
Mouse 
IgG1 
1mg/ml 
NaBH4 
 
0.25% casein 
(VWR) 
 in 0.1% PBS-
triton 
 
1:500 HPI Inc 
Mouse Anti-
RECA-1 
Rat endothelial cells 
Mouse 
IgG1 
None 
 
5% NHS 
in 0.01% PBS-
triton 
 
1:200 Abcam 
Mouse Anti- 
8-oxo-dG 
Oxidative DNA damage 
Mouse 
IgG2b 
RNase buffer, 
2N HCl, 
1M Tris base 
 
5% NHS 
in 0.01% PBS-
triton 
 
1:500 Trevigen 
Mouse Anti- 
Β-tubulin III 
Neurons Mouse 
IgG2b 
1mg/ml 
NaBH4 
 
5% NHS 
in 0.01% PBS-
triton 
 
1:200 Sigma 
Rabbit Anti-
Pimonidazole 
Pimonidazole adducts 
Rabbit  
IgG 
1mg/ml 
NaBH4 
 
5% goat serum  
(NGS; Vector 
Labs)  
in 0.01% PBS-
triton 
 
1:200 HPI Inc 
Rabbit Anti-
iNOS 
Inducible nitric oxide 
synthase 
Rabbit 
IgG 
None 
 
5% NGS 
 in 0.01% PBS-
triton 
 
1:200 
BD Transductions 
Ltd 
Rabbit Anti-
GFAP 
Astrocytes 
Rabbit 
IgG 
1mg/ml 
NaBH4 
 
5% NGS 
 in 0.01% PBS-
triton 
 
1:500 Dako 
Rabbit Anti-
HIF-1α 
Hypoxia inducible 
factor-1 α 
Rabbit 
IgG 
1mg/ml 
NaBH4 
 
5% NGS 
 in 0.01% PBS-
triton 
 
1:500 Millipore 
Rabbit Anti-
IBA 
Macrophages/microglia 
Rabbit 
IgG 
1mg/ml 
NaBH4 
 
5% NGS 
 in 0.01% PBS-
triton 
 
1:200 Wako Chemicals 
Rabbit Anti-
P22phox 
NADPH oxidase subunit 
Rabbit 
IgG 
None 
 
5% NGS 
 in 0.01% PBS-
triton 
 
1:100 
Santa Cruz 
Biotechnology 
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2.2.6.2 Myelin chemical stain 
Sections were stained with luxol fast blue (LFB)/periodic acid Schiff 
(PAS)/haematoxylin to assess demyelination. Sections were taken to 100% ethanol 
(VWR) with gentle shaking in 70% ethanol, followed by 90% ethanol for 5 minutes 
each. The sections were then incubated overnight at 50
0
C with LFB solution: 0.1% LFB 
(BDH) in acidified 95% ethanol (1.0g LFB, 1000ml 95% ethanol, 0.5ml glacial acetic 
acid). The following day the sections were removed from the LFB solution, and washed 
well in running tap water. Subsequently, the sections were differentiated by cycling 
through saturated lithium carbonate (Merck, Germany) for 30 seconds, followed by 
70% ethanol, washing with running tap water in between each step. This was continued 
until the stain was removed from non-myelinated tissue. Next, the sections were 
initially oxidised in 1% periodic acid (VWR) for 20 minutes at room temperature (RT), 
and then incubated in neat Schiff’s reagent (VWR) for 20 minutes at RT, once again 
washing in running tap water after each step. Finally, the sections were counterstained 
in neat Harris haematoxylin (VWR) for 2 minutes, washed in running tap water, 
differentiated until clear in 1% acid alcohol, and then washed well in running tap water. 
Dehydration through graded alcohol was performed by 5 minute incubations in 70% 
and 90%, followed by two x2 minute incubations in 100% ethanol, and then two 
incubations in 100% xylene for more than 2 minutes. The slides were then mounted 
using DPX mounting medium (VWR). 
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2.2.7.0 Microscopy 
2.2.7.1 Light Microscopy and Quantification 
Tissue developed using the peroxidase development system (DAB) was viewed with an 
Axiophot light microscope (Zeiss, Germany), and photographed with a Nikon D300 
camera (Nikon, USA). The illumination was kept consistent throughout image 
acquisition. Captured images were imported into Image J (NIH, Bethesda, MD) and 
converted from RGB 24 bits per pixel (bpp) to grey scale 8 bpp images.  Analysis of the 
intensity of the labelling with pimonidazole was carried out by manually demarcating 
the spinal white and grey matter, and measuring the pixel intensity above a set 
threshold.  Quantification of ED1 and iNOS immunoreactivity was performed by 
counting the number of pixels above a set threshold, and expressed as the percentage of 
cross-sectional area coverage.  Quantification of vessel count and size was performed 
using the automated ‘analyse particles’ tool, on binary images, and subsequently filtered 
for size and circularity.  All the quantification was performed blind. 
  
 
2.2.7.2 Confocal Laser Microscopy 
Fluorescent images were obtained using a Zeiss LSM5 Pascal confocal microscope, 
with a x40 objective. Excitation wavelengths of 488 nm and 543 nm were provided by 
argon and helium-neon gas lasers, respectively. Emission filters BP505-570, BP505-
530, and LP560 were used to obtain the images. 
 
 2.2.8.0 Disease parameters 
The change in neurological deficit score on the last day, the total cumulative score, and 
the score on the day of perfusion, were used to indicate disease severity. Thus, these 
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parameters were taken into consideration when assessing the contribution of various 
pathological markers to the expression of a neurological deficit.  
 
2.2.9.0 Statistical Analysis 
Pearson correlation coefficients were used to assess association between variables 
where indicated.  
A one-way analysis of variance (ANOVA) with a Bonferroni correction was used to 
compare pimonidazole labelling, oxygen probe measurements, blood vessel diameter, 
and blood vessel number between groups as indicated.  A single sample t-test was used 
to assess the difference between one hour of treatment with oxygen, or room air, using 
the difference in score change between paired animals. An independent t-test was used 
to assess differences in neurological deficit score between the control group and each 
treatment group respectively (1400W, MitoQ, oxygen, and ALL). A one-tailed 
significance is stated for the acute oxygen and long term therapy studies, based on the a 
priori hypothesis that treatment would reduce the observed neurological deficit. Q-Q 
plots were used to assess whether the data were normally distributed.   
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2.3.0.0 RESULTS 
  
2.3.1.0 Clinical course of rMOG EAE 
Subcutaneous injection of 100 μg rMOG in female DA rats induced a relapsing disease 
(Figure: 2.3.1.0 A), characterised by ascending motor paralysis, with a typical disease 
onset of 9 days post-induction (PI) and an incidence of 96%. The onset of disease was 
coupled with a loss in body weight. Within this first peak of disease, disease severity 
varied from tail weakness to a complete flaccid paralysis of the lower limb extremities. 
The first peak of the disease was characterised histopathologically by the infiltration of 
large numbers of inflammatory cells, particularly near the root entry zones and subpial 
white matter, in the absence of any obvious demyelination (Figure: 2.3.1.0 B). This first 
peak of disease was followed by a remission phase (13-17 days PI), at which point some 
evidence of demyelination, indicated by the loss of LFB staining, was observed. The 
remission phase was followed by an aggressive relapse phase (18 days PI), during 
which the demyelination was extensive (Figure: 2.3.1.0 B), and a spastic, rather than 
flaccid, paralysis was dominant. Neither asymptomatic nor control animals displayed 
any evidence of neurological disability, or a loss in body weight. 
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Figure 2.3.1.0: EAE time course: Inflammatory and demyelinating aspects 
(A) Graph showing the average scores for neurological deficit over the course of rMOG EAE in DA rats. 
Values are mean ± S.D. The two peaks in neurological deficit appear to be caused by different 
mechanisms. Dysfunction in the first peak is thought, partly from current observations, to occur via a 
mechanism that arises primarily from inflammation, whereas dysfunction in relapse (second peak) 
appears to be due primarily to demyelination. (B) Transverse spinal cord sections stained with LFB/PAS, 
and counterstained with hematoxylin (B-top, scale bar 500 µm), and high magnification of the top of the 
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dorsal column (DC) (B-bottom, scale bar 25 µm). Demyelination, revealed by the loss of LFB staining 
(blue) is absent during the first peak, which is characterised by massive infiltration of inflammatory cells 
(*). Loss of LBF staining is particularly visible in the spinal cord of animals in relapse (arrow), and 
remission (arrow), although to a lesser extent.  All micrographs are representative. 
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 2.3.2.0 Inflammation over the time course of rMOG EAE 
 2.3.2.1 ED1 labelling as a correlate of disease severity 
Microscopically, symptomatic rMOG animals exhibited varying amounts of spinal 
inflammation, characterised by ED1 immunoreactivity, which was largely absent from 
asymptomatic, and control animals (Figure: 2.3.2.1). At the early stages of disease 
(neurological deficit score 3), ED1 positive cells were predominantly found near the 
root entry zones, and subpial areas in the white matter (Figure: 2.3.2.1 Ai), however, as 
the disease progressed towards the peak of neurological deficit (neurological deficit 
score 7-9) the inflammatory cells were found to penetrate deeper into the parenchyma. 
At this stage of disease, perivascular cuffing was common. The extent of inflammation 
eased during remission, however, ED1 immunoreactivity during relapse was profound 
(Figure: 2.3.2.1 Ai).  At this stage of disease, the inflammation was not restricted to the 
subpial white matter, but, rather involved the entire white matter, and grey matter, 
although to a much lesser extent. These areas in which ED1 immunoreactivity was 
profound commonly appeared oedematous.  
 Throughout the time course of rMOG EAE, there was a notable change in ED1 
cell morphology. At first peak, the cells displayed the characteristic activated, amoeboid 
morphology, however during remission and relapse stages of disease, the cells displayed 
a ‘foamy’ debris-engulfing morphology (Figure: 2.3.2.1 Aii). 
 The extent of inflammation progressively increased within the first three days of 
disease, but varied considerably thereafter (Figure: 2.3.2.1 Bi). The extent of 
inflammation was directly related to the neurological deficit score at perfusion (p< 
0.001, r
2
=0.792, n=71, Figure: 2.3.2.1 Bii). Thus, the spinal cords of animals with a 
higher neurological deficit score were more inflamed than those of animals with a lower 
neurological deficit score. During the first peak of disease, the inflammation followed 
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the ascending nature of the disease: most extensive in the caudal portions of spinal cord, 
and decreasing more rostrally (Figure: 2.3.2.1 Biii). Similarly, in remission and relapse 
stages of disease, the extent of inflammation was largest most caudally, but decreased in 
the lumbar cord, before increasing in the rostral portions of the cord (Figure: 2.3.2.1 
Biii). No such labelling was evident in control animals. 
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Figure 2.3.2.1: ED1 labelling in rMOG EAE  
(Ai) Transverse spinal cord sections labelled with ED1, a marker of activated macrophages/microglia, at 
different stages of rMOG EAE. At the early stages of the disease, during the first peak (score 3), activated 
macrophages/microglia are present sub-pially, however, as the disease progresses (scores 7 and 9), 
activated cells begin to penetrate deeper into the parenchyma, and numerous perivascular cuffs can be 
seen (arrows). Scale bar 500 µm. Examination of these ED1 cells at high magnification (Aii) shows a 
change in morphology from an amoeboid phenotype, in the first peak, to a foamy debris-engulfing 
macrophage phenotype, during remission and relapse. Scale bar 25 µm. (Bi) Scatter plot showing the 
relationship between the extent of ED1 labelling and the number of days from first symptoms. (Bii) 
Scatter plot showing that ED1 labelling increases with the severity of the disease. (Biii) Graph showing 
the rostro-caudal extent of ED1 labelling at different stages of the disease (mean ± S.E.M). All 
micrographs are representative (Contols n=20; asymptomatics n=7; first symptoms n=29; remission n=7; 
relapse n=7).   
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 2.3.2.2 iNOS expression occurs in the first 3 days following onset of the 
disease 
In rMOG EAE, iNOS expression, although negligible, was only evident in symptomatic 
animals during the first peak of disease (Figure: 2.3.2.2). iNOS immunoreactivity was 
largely found in the root entry and exit zones, at the early stages of disease (neurological 
deficit score 3), but was also found in perivascular cuffs at the peak of disease (Figure: 
2.3.2.2 A). iNOS was largely expressed in the first three days following disease onset 
(Figure: 2.3.2.2 Bi), and therefore, did not correlate well with the neurological deficit 
score at perfusion (Figure: 2.3.2.2 Bii). Thus, an animal terminated with a neurological 
deficit score of 9 on day 5 following the onset of disease, would generally have less 
iNOS than an animal terminated with a neurological deficit score of 7 on day 3 
following the onset of disease. The rostro-caudal gradient of labelling was similar to 
ED1, with iNOS expression greatest most caudally (Figure: 2.3.2.2 Biii). iNOS was 
absent from asymptomatic animals, and those that were in remission or relapse, and 
control animals.   
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Figure 2.3.2.2: iNOS expression in rMOG EAE 
(A) Transverse spinal cord sections labelled with an anti-iNOS antibody. iNOS expression is only evident 
in the first peak of disease, specifically in the first three days following onset in rMOG animals (n=29) 
(A; Bi). Scale bar 500 µm. Labelling for iNOS is absent in IFA controls (n=20), asymptomatic controls 
(n=7) and rMOG animals in remission (n=7) and relapse (n=7) (A; B). (Bii) Scatter plot showing the 
correlation between the extent of iNOS labelling and the score at perfusion. Although iNOS expression is 
increased in symptomatic animals, there does not appear to be any obvious correlation with disease 
severity. (Biii) Graph showing labelling for iNOS along the length of the spinal cord, at different stages of 
disease (mean ± S.E.M). All micrographs are representative. 
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2.3.3.0 Hypoxia is a feature of rMOG EAE 
 2.3.3.1 rMOG EAE Spinal tissue labels positive for hypoxia 
Pimonidazole, an intravenous probe that allows the detection of low tissue oxygen 
concentrations during wakefulness, ostensibly, was administered to all animals prior to 
perfusion, and the bound drug subsequently detected immunohistochemically. During 
the first peak of disease, spinal tissue from symptomatic rMOG animals labelled 
positive for pimonidaozle (Figure: 2.3.3.1). The labelling was most obvious in the 
spinal grey matter, although punctuate cellular labelling was also observed in the white 
matter, particularly in perivascular cuffs, extending out of the grey matter (Figure: 
2.3.3.1 Ai, Aii). Immunohistochemistry with an antibody against HIF-1α, an alternative 
marker of hypoxia, yielded a similar pattern of labelling within the grey and white 
matter.  Neuronal labelling for pimonidazole and HIF-1α was especially prominent, 
with the intensity of labelling increasing with neurological deficit (Figure: 2.3.3.1 Aii, 
Aiii). At remission, the grey matter labelling for both pimonidazole and HIF-1α 
disappeared, however, by relapse, some grey matter labelling returned, but intense 
pimonidazole labelling of foci in the white matter was also observed (Figure: 2.3.3.1 A). 
No such labelling was evident in asymptomatic, or control animals.  
 The grey matter pimonidazole labelling correlated temporally with the onset of 
neurological deficit (Figure: 2.3.3.1 Bi). That is, labelling for pimonidazole was most 
prominent in the first three days following disease onset, and thus, during the first peak 
of disease expression. Similarly, the extent of grey matter pimonidazole labelling 
increased with the magnitude of the neurological deficit (p = 0.029, r
2 
= 0.405, n = 29, 
Figure: 2.3.3.1 Bii). Spatially, labelling for pimonidazole precisely followed the 
ascending nature of the disease (Figure: 2.3.3.1 Biii). The labelling was most intense in 
the most caudal regions of the cord (lumbar p< 0.001, n = 70; sacral p = 0.043, n = 67, 
 
 
72 
 
serving the paralysed hind limbs and tail respectively), and decreased rostrally. 
Pimonidazole labelling positively correlated with HIF-1α labelling (p = 0.05, r2 = 
0.343, n = 65).  
 To determine whether this tissue hypoxia was cell specific, or a general 
phenomenon, double label immunofluorescence was conducted with a range of cell 
specific markers. Interestingly, astrocytes, neurons and in particular oligodendrocytes, 
labelled positive for pimonidazole (Figure: 2.3.3.1 C). Macrophages/microglia generally 
did not label positively for pimonidazole, although there were a few exceptions (Figure: 
2.3.3.1 C). 
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Figure 2.3.3.1: Labelling for tissue hypoxia in rMOG EAE 
(A) Transverse lumbar spinal cord sections labelled with anti-pimonidazole, at different stages of disease 
progression. Positive pimonidazole labelling is virtually absent in IFA control animals, but is increased in 
the grey matter of first peak (scores 3-9) rMOG EAE animals (Ai, scale bar 500 µm; Aii, scale bar 25 
Pimo/IBA 
Pimo/IBA 
Pimo/GFAP 
Pimo/GFAP 
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µm). Similarly, labelling for HIFα, an independent marker of hypoxia, is increased in the ventral motor 
neurons of symptomatic animals (Aiii, scale bar 25 µm).  The pimonidazole grey matter labelling is 
increased during the first three days of disease (Bi), and also increases with disease severity (Bii). 
Although, animals in remission and relapse showed decreased grey matter labelling (A; Bi), animals in 
the relapse had intense foci of pimonidazole labelling in the white matter (Ai). (Biii) Graph showing the 
intensity of pimonidazole labelling along the length of the cord, for animals with differing severity of 
neurological deficit (Mean ± S.E.M), showing a gradient of labelling which follows the ascending nature 
of the disease (contols n=20; asymptomatics n=7; first symptoms n=29; remission n=7; relapse n=7). (C) 
Scatter plot showing the correlation between pimonidazole and HIF-1α labelling. (D) Confocal laser 
microscopy of transverse spinal cord sections labelled with anti-pimonidazole, and anti-IBA (microglia), 
anti-GFAP (astrocytes), anti-β-tubulin (neurons), and anti-CA2 (oligodendrocytes) antibodies. Co-
localisation of these cell specific markers (arrows) with pimonidazole suggests a generalised tissue 
hypoxia. Scale bar =100 µm. All micrographs are representative.  
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2.3.3.2 The oxygen concentration of spinal cord tissue is low in rMOG EAE 
Measurements of spinal oxygen concentration, taken using an oxygen-sensitive probe 
revealed that rMOG animals expressing a neurological deficit consistently had lower 
spinal oxygen concentrations than control animals (first peak p = 0.007, relapse p = 
0.029, Figure: 2.3.3.2 A). The average spinal cord oxygen concentration of control 
animals was 34.99 ± 2.7 mmHg (mean ± S.E.M), whereas for rMOG animals with a 
neurological deficit score of nine was 20.06 ± 3.9 mmHg (mean ± S.E.M). Moreover, 
the oxygen concentration varied inversely with the magnitude of the deficit (p< 0.001, r
2 
= 0.619, n = 71, Figure: 2.3.3.2 A, B) and with the severity of the disease represented by 
the change in neurological deficit score on the day of perfusion (Figure: 2.3.3.2 C). The 
spinal oxygen concentration was found to only mildly correlate inversely with the 
pimonidazole labelling (p = 0.06, r
2
 = -0.331, n = 68, Figure: 2.3.3.2 D). 
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Figure 2.3.3.2: Spinal oxygen probe measurements in rMOG EAE 
 (A) Representative records from animals during different stages of rMOG EAE. The records show 
readings at first in air, then the lower oxygen concentration when the probe is inserted into the spinal grey 
matter, and finally the reading in air upon withdrawal.  The spinal oxygen concentration is lower in 
rMOG animals compared to IFA controls. Furthermore, the animals in the first peak of disease exhibiting 
a more severe neurological deficit, and animals with relapse disease, had significantly lower (*p<0.05, 
ANOVA with Bonferoni correction) spinal oxygen concentrations than IFA controls (B; mean ± S.E.M).  
(C) A scatter plot showing the correlation between the spinal oxygen concentration and the score change 
on the day of perfusion. Animals with increasing severity of disease at the time of termination (first peak 
animals), generally had lower spinal oxygen concentrations. (D) A scatter plot showing the correlation 
between pimonidazole (immunohistochemical marker) labelling, and spinal tissue oxygen concentration 
(contols n=20; asymptomatics n=7; first symptoms n=29; remission n=7; relapse n=7). 
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2.3.4.0 Vascular changes over the time course of rMOG EAE 
 
Hypoxia is known to induce many downstream changes, one of which is alterations in 
the vascular architecture. Therefore, evidence of such changes was sought over the time 
course of rMOG EAE. During the first peak of disease, increases in vessel size probably 
representing vasodilation, were observed in asymptomatic and symptomatic rMOG 
animals (p = 0.001) along the length of the cord (Figure: 2.3.4.0 A, Bi), compared to 
those of control animals. The average vessel size in the spinal cord of animals in 
remission and relapse was smaller than controls (Figure: 2.3.4.0 Bi). However, at these 
later stages of disease (relapse), the total number of vessels was increased in the caudal 
segments of the spinal cord, but particularly in the lumbar and sacral segments (Figure: 
2.3.4.0 Bii), compared to control animals (p=0.003). Furthermore, many of these vessels 
had a fenestrated appearance, particularly in the white matter. Symptomatic animals at 
the first peak of disease also displayed a moderate increase in vascular density 
compared to control animals. The longer term vascular changes were associated with a 
concomitant increase in cross-sectional area of the whole spinal cord, a measure of 
oedema (Figure: 2.3.4.0 Biii). 
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Figure 2.3.4.0: Vascular changes during the course of rMOG EAE 
(A) Spinal grey matter labelling with anti-RECA1. At the acute stage of the disease (first peak), vessel 
size is increased, relative to IFA controls, and rMOG animals in remission and relapse. As the disease 
progresses, the vascular density increases, particularly in animals in relapse. (Bi) Graph showing the 
average vessel size along the length of the cord in animals at the different stages of disease (mean ± SEM. 
(Bii) Graph showing the vascular density, along the length of the cord in animals at different stages of 
disease (mean ± S.E.M). (Biii) Graph showing that the cross-sectional area of the whole spinal cord (a 
measure of oedema) was greater over time in animals with EAE when compared with controls (mean ± 
S.E.M) (contols n=20; asymptomatics n=7; first symptoms n=29; remission n=7; relapse n=7). 
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2.3.5.0 NADPH oxidase subunit expression during the first peak of disease 
 
NADPH oxidase is a major consumer of molecular oxygen during the respiratory burst, 
generating large amounts of superoxide. Thus multi-label immunofluorescence using 
antibodies against NADPH oxidase subunits p22
phox
 and p47
phox
 was performed. In 
control animals, labelling for p22
phox
 was observed, however no labelling for p47
phox
 
was evident (Figure 2.3.5.0). In the first peak of disease, animals with moderate 
neurological deficit (neurological deficit score of five) displayed increases in p22
phox
 
and p47
phox
 labelling, particularly surrounding inflamed vessels (Figure: 2.3.5.0). As the 
magnitude of the deficit increased, the extent of labelling and co-expression of these 
markers also increased (Figure: 2.3.5.0). 
 
 
 
 
 
 
 
85 
 
 
 
 
86 
 
 
 
 
 
 
 
 
Figure 2.3.5.0: NADPH Oxidase subunit labelling in first peak EAE 
Confocal laser microscopy of transverse spinal cord sections labelled with NADPH oxidase subunits 
p22phox (red) and p47phox (green). Labelling for p22phox is evident in the spinal cord of all animals, but 
the extent of labelling is increased in rMOG animals exhibiting a neurological deficit. Labelling for 
P47phox is absent in IFA control animals, however perivascular expression of p47phox is observed in 
rMOG animals expressing a neurological deficit. In animals with more severe disease (score 9), 
perivascular co-expression of the subunits is evident (arrow). 
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2.3.6.0 Histopathology of the white matter foci of pimonidazole labelling in 
relapse animals 
 
As mentioned previously, intense foci of pimonidazole labelling were observed in the 
white matter of animals in relapse (Figure 2.3.6.0 A). These foci were found at various 
places in the white matter, but predominantly in the oedematous region of the spinal 
cord. At high magnification, reactive swollen astrocytes, was seen amongst 
phagocytosing inflammatory cells (Figure 2.3.6.0 Aii). These regions were commonly 
found to be sparse in vasculature, abundant in ED1 positive cells, and largely 
demyelinated (Figure 2.3.6.0 B). 
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Figure 2.3.6.0: Intense pimonidazole foci in the white matter of relapse animals 
(Ai) Light micrograph of a lumbar spinal cord section from an rMOG animal in relapse, labelled for 
pimonidazole. Intense pimonidazole-positive foci are evident in the white matter of relapse animals. Scale 
bar 500 µm. (Aii) High magnification of pimonidazole-positive foci, showing labelling of cells tentatively 
identified as hypertrophied astrocytes (arrow), in addition to other cells. Scale bar 25 µm.  (B) Adjacent 
sections labelled for pimonidazole (i), ED1 (ii), and RECA-1 (iii), or stained with LFB (iv).  The 
observed foci of intense pimonidazole labelling correspond with areas of extensive ED1-positive cell 
infiltration, comparatively sparse vascular supply, and demyelination. Scale bars 100 m.  All 
micrographs are representative. 
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2.3.7.0 Normobaric oxygen therapy in rMOG EAE  
 2.3.7.1 One hour of normobaric hyperoxia partially restores function 
Given that hypoxia is an early feature of rMOG EAE that correlates quantitatively, 
temporally and spatially with the first peak of disease, pairs of rMOG symptomatic 
animals (matched for neurological deficit) were treated with one hour of normobaric 
hyperoxia, or room air as a control, to determine whether acute oxygen therapy could 
restore lost function. Treatment with only one hour of 100% oxygen resulted in partial 
restoration of function, with increased sensation and restoration of the hindlimb stretch 
and pinch withdrawal reflexes being the most common changes observed.  
Most rMOG animals exposed to 100% oxygen showed an improvement in 
neurological deficit score on the 25-point scale following treatment, relative to their 
counterparts treated with room air (Figure: 2.3.7.1 A). In some instances, there was no 
change, or a worsening, in neurological deficit score, following hyperoxic treatment, 
compared to the room air counterpart. However, on average, the cohort of animals 
exposed to 100% oxygen showed a statistically significant improvement in score (p = 
0.014, n = 24), compared to the cohort of animals exposed to one hour of room air 
(Figure: 2.3.7.1 B).  
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Figure 2.3.7.1: The effects of one hour of normobaric oxygen therapy on rMOG 
EAE 
(A) Plot showing the change in score rMOG EAE animals, following one hour of therapy (normobaric 
100% oxygen n=12, or room air n=12), using the 25-point scale. A negative change in score indicates a 
functional improvement. (B) Bar graph showing the average (+/- S.E.M.) neurological deficit score, 
before and after breathing room air (control) or 100% oxygen.  (*p<0.05, repeated measures ANOVA, 
n=24).  
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2.3.7.2 Labelling for hypoxia decreases following one hour of oxygen therapy 
Histological evaluation of spinal cord tissue from animals exposed to one hour of 
normobaric oxygen, revealed a decrease in labelling for hypoxia (Figure: 2.3.7.2). The 
extent of pimonidazole labelling in IFA control animals did not change following 
exposure to 100% oxygen, with some faint neuronal, and grey matter labelling still 
evident at high magnification (Figure: 2.3.7.2 A). Spinal cord tissue from rMOG 
animals exposed to room air, labelled positive for hypoxia, indicated by the intense 
pimonidazole immunoreativity. However the spinal cords from animals exposed to 
100% oxygen showed no evidence of pimonidazole labelling, and thus hypoxia. Rather, 
the labelling was less than that observed in IFA control animals. The lack of neuronal 
labelling, in particular, was surprising (Figure: 2.3.7.2 A). Similarly, in IFA control 
animals, labelling for HIF-1α did not change following 100% oxygen therapy, but 
neuronal HIF-1α was completely lost in rMOG animals exposed to 100% oxygen 
(Figure: 2.3.7.2 B). 
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Figure 2.3.7.2: Labelling for hypoxia following acute normobaric oxygen therapy 
Micrographs of the spinal ventral grey matter of animals from the acute oxygen therapy study, showing 
labelling for pimonidazole (A) and HIF-1α (B). In IFA controls, pimonidazole labelling does not appear 
to change following exposure to 100% oxygen, however, in symptomatic rMOG animals, pimonidazole 
labelling is decreased substantially (A). Exposure to 100% oxygen does not affect the extent of HIF-1α 
labelling in IFA controls, however, in symptomatic rMOG animals, the extent of labelling is decreased 
considerably (B). The lack of any neuronal pimonidazole or HIF-1α labelling, following 100% oxygen in 
symptomatic animals is striking. Scale bar 25 µm. All micrographs are representative. 
S
co
re
 7
 
IF
A
 
Room Air Oxygen 
H
IF
-1
α
 
S
co
re
 7
 
IF
A
 
Room Air Oxygen 
P
im
o
n
id
a
zo
le
 
A 
B 
 
 
96 
 
 2.3.7.3 One hour hyperoxia does not increase oxidative damage 
  Oxygen therapy can be associated with increased oxidative damage, so the tissue was 
examined to determine the magnitude of such damage. Oxidative DNA damage, as 
indicated by 8-Oxo-2’-deoxyguanosine (8-Oxo-dG) labelling, was not a common 
feature of rMOG EAE. Clusters of 8-Oxo-dG positive cells, when observed, were 
located predominantly surrounding vessels in the white matter, co-localising with DHE 
(Figure: 2.3.7.3 A). Animals treated with 100% oxygen generally displayed a decrease 
in the size, and fluorescent intensity of these white matter clusters (Figure: 2.3.7.3 A). 
The uncanny co-localisation of 8-Oxo-dG and DHE raised the potential problem of 
fluorescence bleed through, however, these clusters were also observed in DAB labelled 
tissue (Figure: 2.3.7.3 B), and sections with DHE-induced fluorescence alone, thereby 
ruling out fluorescence bleed through. 
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Figure 2.3.7.3: ROS labelling following acute normobaric oxygen therapy 
(A) Light micrographs of ventral horn grey matter in lumbar spinal cord cross-sections labelled with 
antibodies to 8-Oxo-dG.  No difference in the extent of labelling is evident between IFA controls and 
animals with EAE during the first peak of disease, or animals treated with room air and animals treated 
with normobaric oxygen. Scale bar 25 µm. (B) Fluorescence microscopy images of sections through the 
lumbar spinal cord white matter from animals with EAE during the first peak of disease, labelled with 
DHE in vivo and antibodies to 8-Oxo-dG obtained with a confocal microscope reveal co-localization of 8-
Oxo-dG-positive cells and DHE-induced fluorescence. No increase in 8-Oxo-dG or DHE-induced 
labelling is evident following treatment with normobaric oxygen as compared to room air, in fact a 
tendency to reduced labelling is observed.  Scale bar 200 m. (C) Spinal cord section labelled for 8-Oxo-
dG with the DAB detection method, and an adjacent section labelled for 8-Oxo-dG and DHE-induced 
fluorescence, The pattern of labelling observed when tissue is labelled with antibodies against 8-Oxo-dG 
using DAB as the chromogen, is the same as when tissue is labelled fluorescently in conjunction with 
DHE-induced fluorescence, confirming co-localisation of DHE and 8-Oxo-dG is real and not bleed 
through. Scale bar 25 µm. All micrographs are representative. 
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2.3.8.0 7-day combination therapy in rMOG EAE 
  Inflammation, hypoxia, and oxidative damage (although minimal in this model), have 
been shown to be features of rMOG EAE. Therefore, their relative contributions to 
functional impairment in EAE were assessed by treating these pathopysiological aspects 
of the disease, individually, and collectively. Five, 7-day treatment regimes, 
commencing on the onset of neurological deficit, comprised of groups designated as 
controls, an iNOS inhibitor (1400W), 75% normobaric oxygen, a mitochondrially 
targeted antioxidant (MitoQ), and a combination of the three (ALL) (Table 2.3.8.0).  
 Control rMOG animals followed the standard course of EAE, with an average 
peak neurological deficit score of 6.6 ± 0.5 (mean ± SEM), within three days of the 
onset of disease (Figure: 2.3.8.0). By five days following the onset of disease, animals 
in the control group entered the remission stage of the disease, with an average 
neurological deficit score of 5.3 ± 0.6 (mean ± SEM), and they remained in this stage 
until termination (n=14) (Figure: 2.3.8.0). It is worth noting that the 10-point scale used 
to evaluate the neurological deficit is by no means linear. Thus an animal with a 
neurological deficit score of 7 displays complete bilateral hindlimb weakness with 
absent or incomplete plantar placement, and is therefore unable to walk. An animal with 
a neurological deficit score of 5 displays complete tail paralysis, with an abnormal, 
wobbly gait, but is able to walk. 
 Administration of 1400W, oxygen, MitoQ, and ALL treatment regimes resulted 
in amelioration of the disease severity, compared with controls, respectively (Figure: 
2.3.8.0). Animals treated with 1400W followed an attenuated disease course, with an 
average peak neurological deficit score of 6.0 ± 0.5 (mean ± SEM), and a termination 
end score of 5.0 ± 0.5 (Figure: 2.3.8.0). The average neurological deficit score was 
significantly lower than the control group only on day one of treatment with 1400W 
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(p=0.015, n = 15). Animals treated with MitoQ, also followed an attenuated disease 
course, with an average peak neurological deficit score of 5.8 ± 0.7, and a terminal 
neurological deficit score of 5.1 ± 0.9 (Figure: 2.3.8.0). The average neurological deficit 
score on the first day of treatment with MitoQ was significantly lower than controls (p= 
0.047, n=17). However, the average neurological deficit was not significantly lower 
than control animals on any other day of treatment. Animals treated with 75% oxygen 
had an average peak neurological deficit score of 5.4 ± 0.6, and a terminal neurological 
deficit score of 3.6 ± 0.5 (Figure: 2.3.8.0). Treatment with 75% oxygen resulted in a 
statistically significant improvement after one day (p=0.028, n=15), and a significantly 
reduced neurological deficit at day 7, when compared with control animals breathing 
room air (p=0.019, n=15). Animals treated with a combination of the three treatments 
(ALL), followed a particularly attenuated disease course, with an average peak 
neurological deficit score of 4.9 ± 0.8, and a terminal score of 3.3 ± 0.8 (Figure: 
2.3.8.0). This group had a significantly lower average neurological deficit score than 
control animals, at all time points after day 1 (p< 0.05, n = 15), with the exception of 
days 4 and 5. 
 The variation in neurological deficit score observed in the oxygen and ALL 
treatment groups represented a decreased efficacy of these treatments in animals that 
were recruited when neurological deficit score at disease onset was 3 or more. Oxygen 
and combination therapy was particularly effective in animals that displayed a 
neurological deficit score of 1, at onset of disease. In these treatment groups, reversal of 
tail paralysis was frequently observed. Moreover, function was completely restored in 
some animals. Differences in the final numbers represented morbidity, or animals that 
had to be culled for ethical reasons, and were therefore omitted from the study. 
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Table 2.3.8.0: 7-day combination therapy 
treatment regime 
Days from Onset of Symptoms/Days of therapy 
Therapy 
Onset of 
Therapy 
Route of 
Administration 
1 2 3 4 5 6 7 
CONTROL n/a n/a n=17 n=17 n=17 n=17 n=17 n=15 n=15 
1400W 
Onset of 
symptoms 
Intraperitoneal n=17* n=17 n=17 n=17 n=17 n=17 n=17 
OXYGEN 
Onset of 
symptoms 
Inhalation 
(purpose-built 
chamber/tent) 
n=17* n=17 n=15 n=15 n=15 n=15* n=15* 
MITOQ 
Day of 
immunisation 
Oral (in 
drinking water) 
n=17* n=17 n=17 n=16 n=16 n=16 n=16 
ALL 
MitoQ 
treatment 
began on the 
day of 
immunizatio
n. 
 
Oxygen and 
1400W 
additionally 
administered 
at the onset 
of symptoms 
Oral, 
intraperitoneal, 
inhalation 
n=17* n=17* n=16* n=16 n=16 n=15* n=15* 
 
A 
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Figure 2.3.8.0: Combination therapy in rMOG EAE 
(A) Table showing the different treatment regimes employed and numbers of animals throughout the 
study and statistical significance (* p<0.05). (B) Graph showing the average changes in neurological 
deficit (non-linear 10 point scale) over the course of rMOG EAE following five treatment regimens; 
control, MitoQ, 1400W, 75% normobaric oxygen, and ALL. Treatment began at the onset of neurological 
deficit, and was maintained for the next 7 days. The graph shows that the ALL group had a significantly 
(* p<0.05) lower neurological deficit score than controls at all time points after day 1, with the exception 
of days 4 and 5. Notably, animals receiving the ALL treatment regimen were able to walk throughout the 
course of disease, and were significantly less affected at trial termination than control animals. Values are 
means ± S.E.M. 
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2.4.0.0 DISCUSSION 
 
The present study reveals that tissue hypoxia is quantitatively, spatially and temporally 
related to neurological dysfunction in rMOG-induced EAE, and perhaps causally 
related. Furthermore, the study provides evidence that acute and chronic treatment with 
normobaric hyperoxia partially restores lost function, and attenuates the disease 
severity, respectively.  Thus, hypoxia plays a crucial role in the development and 
progression of neurological dysfunction in rMOG EAE, a model of MS 
 
2.4.1.0 Inflammation mediates neurological dysfunction during the first 
peak of disease in rMOG EAE 
Inflammation, demyelination and axonal degeneration are the cardinal features of MS, 
however, the relationship of these pathological events to the onset, and progression of 
neurological disability is yet to be fully elucidated. Inflammation has been implicated in 
the induction of clinical deficits in MS, in the absence of demyelination (Bitsch et al., 
1999), and the current results suggest that the neurological deficit, during the first peak 
of rMOG EAE, is also mediated by inflammation alone. In the current study, the extent 
of inflammation, characterised by the presence of activated macrophages/microglia, 
correlated well with the severity of the disease. Activated macrophages and microglia 
were found most extensively at the midline and lateral borders of the dorsal columns, 
and at the superficial lamina of the dorsal grey matter, and they were present more 
diffusely in the rest of the grey matter. These sites are eloquent areas of the nervous 
system, and damage would be expected to cause neurological deficits. Neurons of the 
motor cortex, associated with hind limb movement, project to the spinal lumbar 
enlargement (Li et al., 1990), with a somatotopic arrangement of hind limb nerves in the 
mediolateral compartments of the dorsal horns (Molander and Grant, 1985; Woolf and 
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Fitzgerald, 1986; Rivero-Melián and Grant, 1991; Paxinos, 1995). Similarly, the 
ascending collaterals of primary afferent fibres are somatotopically arranged in the 
dorsal column, with fibres from the tail found close to the midline, and fibres from the 
hind limbs at the lateral borders more rostrally (Paxinos, 1995). Therefore, 
inflammation affecting these specific areas provides a possible explanation for the 
motor deficits observed in this study.  
 Activated macrophages/microglia were present at all stages of the disease, but a 
change in cell morphology was observed during remission and relapse. A typical 
amoeboid, activated phenotype was found during the first peak of disease, whereas a 
‘foamy’, phagocytic phenotype was prevalent during remission and relapse stages of 
disease, accompanied by extensive demyelination. The morphological changes 
associated with the demyelination in addition to the absence of iNOS during the 
remission and relapse stages of disease, conform to the notion that the dysfunction 
during first peak of rMOG EAE is inflammation-mediated, whereas relapse is largely 
driven by demyelination. The levels of the anti-inflammatory interleukin, IL-10, known 
to inhibit cytokine release from macrophages (Fiorentino et al., 1991), are drastically 
increased during remission (Kennedy et al., 1992), explaining the alleviation of 
neurological deficit during this stage of disease. During relapse, the widespread 
demyelination is known to be elicited by anti-MOG antibodies (Linington and 
Lassmann, 1987; Linington et al., 1988). However, despite these findings, the question 
as to how inflammation causes dysfunction still remains. 
 
2.4.2.0 Hypoxia- a mediator of neuroinflammation-induced neurological 
dysfunction 
The mechanisms through which neuroinflammation cause neurological dysfunction 
remain unclear. In the last few decades, NO has emerged as a likely culprit. Indeed, 
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moderate levels of iNOS were expressed by the activated macrophages/microglia, in the 
current study, with expression occurring primarily during the first three days following 
the onset of neurological deficit. Such a temporal pattern of expression implicates NO 
in the onset of neurological deficits. Indeed, the inhibition of iNOS has been found to 
decrease the clinical deficits and inflammation in EAE by some researchers (Cross et 
al., 1994; Zhao et al., 1996; Brenner et al., 1997). However, in the current study iNOS-
positive cells were restricted to the subpial white matter and perivascularly, not in the 
grey matter where motor neurons reside. Thus NO may only account for a part of the 
neurological dysfunction in rMOG, indicating that other factors may also play a role. 
Inflamed tissue undergoes drastic shifts in tissue metabolism. Changes include 
nutrient depletion, increased oxygen consumption, and ROS/RNS production (Taylor 
and Colgan, 2007; Kominsky et al., 2010). A common downstream consequence of 
such changes is tissue hypoxia (Kokura et al., 2002; Saadi et al., 2002; Karhausen et al., 
2004). Our findings suggest that the rat spinal cord also becomes hypoxic, during the 
inflammatory phase of rMOG EAE, confirmed by two independent methods 
immunohistochemically, using the biochemical marker pimonidazole, and an anti-HIF-
1α antibody, and optically, using an oxygen-sensitive optrode. Although different in 
principle, both methods yielded similar results in that the spinal grey matter of 
symptomatic rMOG animals had lower oxygen concentrations than that of control 
animals. However, the poor correlation between the intensity of pimonidazole labelling 
and spinal oxygen concentrations can possibly be explained by a number of factors. 
Firstly, pimonidazole is administered to the animals during a dynamic stage of the 
disease, a period when their neurological deficit is rapidly progressing, and can 
therefore change within the span of a few hours. Thus an animal with a neurological 
deficit score of 3 at the time of intravenous administration of pimonidazole may have 
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progressed to a neurological deficit score of 4 by the time of probe insertion and spinal 
oxygen measurement. Secondly, immunohistochemical detection of tissue hypoxia 
using pimonidazole, does not give an absolute oxygen value, as does the oxygen-
sensitive probe. Rather, the output is merely an arbitrary value. DAB does not follow 
Beer-Lamberts law therefore the intensity does not relate to the amount of pimonidazole 
bound.  
The hypoxia appeared to be a global epiphenomenon, affecting all cell types 
within the spinal cord, however, the grey matter labelled particularly obviously for 
hypoxia. Given that the grey matter requires greater vascular perfusion and oxygen 
delivery than the white matter (Leenders et al., 1990; Helenius et al., 2003), the fact that 
the spinal grey matter labels for hypoxia in rMOG EAE is not surprising. In line with 
the current data, the spinal cord grey matter has been found to be especially susceptible 
to ischemic insults (DeGirolami and Zivin, 1982). In the current study, neurons and 
surrounding grey matter in the lumbo-sacral cord showed a tendency to label more 
intensely for hypoxia than other segments. Interestingly, motor neurons that innervate 
the tail (Grossmann et al., 1982) and hind limbs (Mong, 1990) are most concentrated 
within this segment of the spinal cord. Thus suggesting that hypoxia may directly affect 
spinal motor neurons, resulting in dysfunction. Indeed, synaptic transmission in the 
dorsal horn has been shown to be particularly vulnerable to hypoxia (Fukuda et al., 
2006). Hypoxia can also induce metabolic depression via the downregulation of 
particular mitochondrial genes (Benita et al., 2009). Interestingly, a downregulation of 
mitochondrial genes has been observed in the normal appearing grey matter in rMOG 
EAE (Zeiss et al., 2008).  Perhaps, in the case of EAE, metabolic depression may be 
detrimental rather than protective, or protective at the expense of function.  
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The hypoxia was found to be associated temporally, spatially and quantitatively 
with the neurological deficit. Thus, the hypoxia was prevalent during the first three days 
following onset of the neurological deficit, with a descending gradient along the rostro-
caudal axis. Furthermore, the hypoxia increased with increasing neurological deficit. 
These findings suggest that tissue hypoxia may contribute to the expression, and 
progression, of a functional deficit in rMOG EAE.  
The transcription factor HIF-1α, an important mediator of hypoxia-induced 
responses, is prominently expressed within glia, macrophages and some endothelial 
cells in active MS lesions (Aboul-Enein et al., 2003). The current study reports the 
additional presence of HIF-1α in neurons and inflammatory cells of symptomatic rMOG 
animals. The intensity of the HIF-1α labelling correlated well with the intensity of the 
pimonidazole labelling, thus further strengthening the finding that the spinal cord in 
hypoxic in rMOG EAE. In cancer research the correlation between HIF-1α and 
pimonidazole has been somewhat varied. Some studies report a significant correlation 
between the labels (Goethals et al., 2006), whereas others report a poor, insignificant 
correlation (Janssen et al., 2002; Begg, 2003). These discrepancies have been attributed 
to differences in the biology of individual tumours. HIF-1α is the principal regulator of 
the adaptative response to hypoxia, and perhaps inflammation.  
 
2.4.3.0 Hypoxia-induced vascular changes  
HIF-1α has been estimated, at least in vitro, to regulate more than 50% of the genes that 
respond to hypoxia (Elvidge et al., 2006). One such gene is VEGF, a crucial mediator of 
angiogenesis. The present study reports increased vascular density at relapse and 
remission in rMOG EAE, compared to controls. Moreover these vessels had a 
fenestrated, abnormal appearance, and this is in line with previous findings in EAE 
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(Seabrook et al., 2010). Although angiogenesis is a common compensatory response 
following inflammation (Cramer et al., 2003; Walmsley et al., 2005), and hypoxia 
(LaManna et al., 1992), there is a difference between physiological and pathological 
angiogensis. Physiological angiogenesis is a tightly regulated process, mediated by a 
number of growth factors, and pro-angiogenic cytokines, as well as angiogenic 
inhibitors. A disruption in the balance of these mediators leads to aberrant angiogenesis. 
Although a pro-angiogenic environment has been reported to exist in MS lesions 
(Holley et al., 2010; Seabrook et al., 2010), and EAE (Seabrook et al., 2010), the 
fenestrated and abnormal appearance of the vessels during the angiogenic relapse stage 
of EAE, in the current study, suggests that the angiogenesis may be pathological, 
thereby propagating the disease process. This hypothesis is supported by the fact that 
the infusion of VEGF exacerbates the neurological deficit in EAE (Proescholdt et al., 
2002), whereas treatment with a VEGFR-2 receptor antagonist ameliorates neurological 
deficit (Roscoe et al., 2009).  
 
 
2.4.4.0 Potential causes of hypoxia during neuroinflammation 
Under inflammatory conditions, tissue hypoxia will ensue when the oxygen demand of 
the cells outweighs the supply. Increases in metabolic demand may result from the 
recruitment and activation of inflammatory cells such as myeloid cells, and 
lymphocytes, whereas alterations in the supply of nutrients may result from the vascular 
disturbances, such as thrombosis, or endothelial cell damage/dysfunction. 
Inflammatory cells of different lineage have significantly different metabolic 
and oxygen demands. Whereas cells of myeloid lineage, such as neutrophils and 
macrophages, rely almost exclusively on glycolysis for energy, lymphocytes 
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predominantly use oxidative phosphorylation (Fox et al., 2005; van Raam et al., 2008). 
These differences in energy metabolism are thought to influence the nature of the 
immune response. Neutrophils are primarily glycolytic, have few mitochondria, and 
therefore produce very little energy from respiration (Borregaard and Herlin, 1982). 
This unique phenotype is thought to ensure that myeloid cells can function at the very 
low oxygen concentrations that are associated with inflammatory lesions. Up-regulation 
of HIF-1α in these cells is essential to survival, and function (Cramer et al., 2003; Kong 
et al., 2004; Kong et al., 2007). T-lymphocytes, in comparison, rely heavily on 
oxidative phosphorylation, and therefore utilise glucose, amino acids and lipids as 
energy sources (Kominsky et al., 2010). Cell migration during the recruitment of 
inflammatory cells, requires large amounts of actin turnover, and is therefore 
metabolically expensive (Pollard and Borisy, 2003; Kominsky et al., 2010). In addition, 
proliferation of inflammatory cells can also be very metabolically demanding (Greiner 
et al., 1994). Once at the site of inflammation, the nutrient, energy and oxygen demands 
increase, for processes such as phagocytosis. 
 During phagocytosis, neutrophils and macrophages increase their oxygen 
consumption by as much as fifty fold in the generation of ROS (Gabig et al., 1979; 
Baboir et al., 1984). This process known as the respiratory burst, is mediated by the 
oxygen-dependent enzyme NADPH oxidase. The core enzyme itself is comprised of 
five phagocytic oxidase (phox) subunits; p40
phox
, p47
phox
, p67
phox
, p22
phox
 and p91
phox
. 
In resting leukocytes, the enzyme is kept inactive through differential distribution of 
these subunits between the plasma membrane and cytosol. The cytosolic complex 
consists of p40
phox
, p47
phox
, p67
phox
 subunits. Upon exposure to a variety of stimuli, the 
p47phox is hyperphosphorylated, resulting in the translocation of the complex to the 
plasma membrane where it associates with the remaining two subunits, to form the 
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active oxidase (Baboir, 1999). The current study provides evidence that the expression 
of NADPH oxidase subunits p22phox and p47phox is increased in rMOG animals 
expressing a neurological deficit, compared to control animals. Furthermore, co-
expression of the two subunits, indicative of functional enzyme complex, was more 
prevalent in animals with a high neurological deficit score and predominantly localised 
perivascularly. NADPH oxidase expression has recently been described in MS lesions 
(Fischer et al., 2012). In line with the present findings, Fischer et al described increased 
expression of p22phox and p47phox in ‘pre-phagocytic’ lesions. Furthermore, they 
show that NADPH oxidase subunit expression is decreased in macrophages that have 
taken up myelin debris (Fischer et al., 2012). Besides increased oxygen consumption, an 
increased affinity of glucose transporters for glucose, and thus glucose uptake, has been 
reported, during activation of the respiratory burst (Ahmed et al., 1997). Indeed, energy 
needed to fuel NADPH oxidase is primarily derived from extracellular glucose, which is 
quickly metabolised by the hexose monophosphate shunt to produce NADPH (Kiyotaki 
et al., 1984; Rist et al., 1991; Ahmed et al., 1997). Thus, the presence, and activity of 
NADPH oxidase in rMOG EAE, may account for some of the metabolic changes that 
would eventually lead to tissue hypoxia. Certainly, the perivascular localisation of the 
functional enzyme complex, in the present study, ensures a continuous supply of 
essential nutrients required for the respiratory burst.  Consequent to the perivascular 
distribution of inflammatory cells, the distance between the blood vessel and the 
surrounding tissue will be increased, and the available oxygen and glucose, for the 
remaining tissue will be decreased. Cells must be within 100-200μm from a vessel to 
prevent detrimental effects (Carmeliet and Jain, 2000; Kirk et al., 2004), thus this 
increased distance and decreased nutrient availability may pose a threat to the survival 
of the surrounding tissue. Despite this, polymorphisms in the p47phox subunit that 
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increase its expression have been shown to ameliorate the disease and pathology in EAE 
(Becanovic et al., 2006). This finding suggests that, independent of tissue damage, ROS 
may play a role in modulating the immune response (Lassmann and van Horssen, 2011). 
Blood vessels can become damaged during the inflammatory process, resulting 
in the disruption of supply and thereby tissue hypoxia. Endothelial damage or an 
inflammatory reaction at the vessel wall may result in the activation of haemostasis, 
followed by thrombotic occlusion and microcirculatory disruptions (Lassmann, 2003). 
The perivascular nature of functionally active NADPH oxidase complexes, as reported 
in the current study, represents a potent source of ROS which could easily initiate such 
a cascade of events.  Alternatively, the reaction could be the result of either an antibody 
mediated response, whereby recognition of an antigen within the vessel wall, or a 
cytokine mediated response (Lassmann, 2003), can result in endothelial activation and 
the subsequent upregulation of adhesion molecules (Millan et al., 1997; Lassmann, 
2003).  
CD8+ T-cells auto-reactive for MBP have also been suggested to play a role to 
play in vascular damage in EAE (Huseby et al., 2001). Huseby and colleagues induced 
EAE by the passive transfer of MHC class I restricted T cells directed against MBP. 
The animals developed widespread CNS inflammation, with inflammatory lesions 
characterized by perivascular tissue damage (Huseby et al., 2001). It is thought that 
myelin basic protein liberated from demyelinating lesions diffuses to nearby vessels, 
where it is presented to cytotoxic T-cells, resulting in the initiation of an inflammatory 
response (Lassmann, 2003).  
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2.4.5.0 Hypoxia during relapse 
Besides evidence of global tissue hypoxia during the first peak of disease, intense foci 
of pimonidazole labelling, were found in the white matter of animals in the relapse stage 
of disease. Indeed, these areas of hypoxia were found to be largely demyelinated, 
packed full of ‘foamy’ macrophages, positive for NADPH oxidase and relatively sparse 
in vasculature, probably as a result of dispersion due to oedema. It is reasonable to 
propose that a combination of the factors described above may result in local ischaemia, 
and thus foci of pimonidazole labelling. Alternatively, these areas may represent glial 
scars, as reactive astrocytes were evident in the foci. Astrocytes are thought to 
contribute to the pathogenesis of MS by inhibiting remyelination (Nair et al., 2008). 
They might achieve this through the formation of a glial scar, which can act as a 
physical barrier around demyelinated lesions. The scars are composed of interwoven 
astrocytic processes, held together by tight junctions (Eng et al., 1987; Reier and Houle, 
1988). Glial scars have been reported in MS (Holley et al., 2003), and EAE (Matsumoto 
et al., 1992).     
 
2.4.6.0 Oxygen therapy in rMOG EAE 
 2.4.6.1 One hour oxygen therapy 
Given the current finding that hypoxia correlates quantitatively, spatially and temporally 
with the neurological deficit in rMOG EAE, it seemed reasonable to explore the effect 
of increasing tissue oxygenation on the neurological dysfunction in this model of MS. 
The current study shows that the loss of function in rMOG EAE animals was partially 
restored following acute administration of normobaric oxygen (NBO), in the current 
study. The promptness of this restoration of function supports the suggestion that the 
neurological deficit in rMOG EAE is at least partly due to hypoxia. Indeed, hypoxia 
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may explain the occurrence of some symptoms such as fatigue, often observed in MS 
patients (Freal et al., 1984; Krupp et al., 1988; Bakshi et al., 2000), although fatigue in 
MS is complex and may be attributable to a number of factors. These findings are 
consistent with the historical observations that vasodilators such as histamine, can 
improve symptoms in patients with MS (Brickner, 1955; Brickner, 1958). In these 
studies, patients frequently displayed drastic functional improvements within only an 
hour of a histamine injection. This acute improvement became known as “relief by 
flush”, due to the flushing of the skin in response to the vasodilation (Brickner, 1955). 
Interestingly, the therapy was only efficacious in patients in which symptoms had been 
present for only a few weeks (Brickner, 1995). Consistent with this historical 
observation, the present data suggest that the oxygen-sensitive period in EAE only 
persists for the first few days following the onset of neurological deficit, implying that 
the therapeutic window is narrow and the timing of therapy crucial, for an observable 
functional benefit. 
 The promptness of the restoration of function following NBO was surprising, 
given that the arterial haemoglobin (Hb) oxygen saturation (SaO2) is normally 97% 
whilst breathing room air. However, inspiring 100% oxygen at 1 atmosphere (ATM) 
increases the SaO2 to 100% and the total oxygen content of the blood by approximately 
20 ml/L (Beynon et al., 2012). This increase is accounted for by an increase in the 
amount of oxygen dissolved in plasma (Beynon et al., 2012). Furthermore, oxygen 
delivery from capillaries has been described to occur radially, with each capillary 
supplying a cylindrical volume of tissue surrounding it (Krogh, 1919). This area of 
supply has been proposed to increase if the oxygen tension is increased (Krogh, 1919), 
as with therapeutic hypoxia. Therefore, it is understandable how an increased tissue 
oxygenation can be achieved with NBO therapy. 
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 Re-oxygenation of hypoxic tissue, particularly at high atmospheric pressures, 
has previously been associated with an increase in oxidative stress and damage (Clark, 
2008). However, the current preliminary histological examination of ROS and oxidised 
DNA did not reveal evidence of such damage. This finding is consistent with previous 
studies that also show no detectable increase in oxidative damage, following NBO 
(Singhal et al., 2002). However, the safety of prolonged oxygen administration remains 
unclear and requires further investigation. 
  
 2.4.6.2 One hour oxygen therapy reverses labelling for hypoxia 
Given that NBO can partially restore function in rMOG EAE, it was of interest to 
determine whether it could also reverse the labelling for hypoxia. Indeed, a decrease in 
the labelling for markers of hypoxia was observed in control and symptomatic animals.  
Furthermore, the labelling in rMOG animals that exhibited a neurological deficit and 
were treated with NBO, was lower than that in IFA control animals exposed to NBO. 
Although this observation is difficult to interpret, it may represent differences in the 
physiological properties of the tissue in the respective groups. It seems reasonable to 
propose that the inflammation and subsequent oxygen debt in the spinal cords of rMOG 
animals creates a steep oxygen diffusion gradient, resulting in more oxygen being 
extracted from the blood. Conversely, there is no such inflammation or oxygen debt in 
the spinal cords of control animals, thus a smaller diffusion gradient would exist, 
resulting in less oxygen to be extracted from the blood. Increased oxygen concentrations 
in the tissue will lead to rapid metabolism and excretion of pimonidazole (Arteel et al., 
1998), and rapid degredation of HIF-1α (Maxwell et al., 1999; Ivan et al., 2001; 
Jaakkola et al., 2001; Kilmova and Chandel, 2008). Therefore, if more oxygen is 
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available in spinal cord tissue of rMOG animals, there will be a decrease in the 
immunoreactivity of these markers. 
  
2.4.6.3 7-day combination therapy 
Due to its ability to impair axonal conduction (Redford et al., 1997; Shrager et al., 1998) 
and mitochondrial energy metabolism (Bolanos et al., 1994; Brown et al., 1995), NO 
has been viewed as a key inflammatory mediator of neurological dysfunction. More 
recently, a role for ROS/RNS has also emerged (Qi et al., 2006; Nikić et al., 2011). 
Accordingly, the present study set out to identify the relative contributions of each of 
these factors, in addition to hypoxia, to the development and progression of 
neurological dysfunction in rMOG EAE. The present results describe a transient 
improvement of animals treated with 1400W, an iNOS inhibitor, and MitoQ, a 
mitochodrially targeted antioxidant, compared with non-treated controls, thereby 
suggesting a role for NO and superoxide in the production of neurological deficits. 
Although the administration of these agents individually did not result in a statistically 
significant improvement in the neurological deficit score, when the agents were 
administered together with oxygen a significant, and biologically important, 
improvement in walking ability was achieved. The improvement was evident in the first 
few days following the onset of disease, when iNOS is expressed within the tissue. 
During this period, NO likely promotes mitochondrial dysfunction (Bolanos et al., 
1994; Brown et al., 1995), thereby exacerbating an energy deficit resulting from 
inadequate oxygenation.   
 The decreased efficacy of 1400W and MitoQ, when administered alone was 
somewhat surprising. We have found the expression of iNOS to be very variable 
between different EAE trials, suggesting that although NO can be an important cause of 
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neurological dysfunction it may not be the only factor involved. Previous studies have 
reported conflicting results with iNOS inhibition in EAE, with some reporting a 
functional benefit (Zhao et al., 1996; Brenner et al., 1997), whilst others report a 
worsening of neurological dysfunction (Willenborg et al., 1999). These discrepancies 
may either reflect the heterogeneous nature of different EAE models, differences in the 
type of inhibitor employed, or differences in the timing of the therapy. Mitochondrial 
membrane potential drives MitoQ uptake and accumulation into the mitochondrial 
matrix (Liberman and Skulachev, 1970; Ross et al., 2005). Therefore, although the 
administration of MitoQ had some effects on the disease course, its therapeutic efficacy 
may have been attenuated by the loss of mitochondrial membrane potential. Indeed, 
mitochondrial pathology and loss of membrane potential has been described in EAE (Qi 
et al., 2006; Nikic et al., 2011). 
 The present results suggest an important role for hypoxia in the 
production of neurological deficits in rMOG EAE, and that the therapeutic window is 
narrow. This finding may explain why many of the hyperbaric oxygen (HBO) trials 
failed, 30 years ago (Bennett and Heard, 2010). Many of the trials were designed to 
detect an effect of daily, short exposures to HBO on disease course over the course of a 
few months, rather than an acute effect on symptoms. Thus, the trials did not aim to 
recruit patients with early disease, or during relapses. Such factors have been 
highlighted as key determinants of therapeutic benefit in the current study; we therefore 
believe that the HBO trial data are not relevant in this context.  
 
2.4.7.0 Conclusion 
The current study provides chemical, physical and therapeutic evidence that 
neurological deficits in rMOG EAE can arise from tissue hypoxia. Moreover, the 
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hypoxia is quantitatively, spatially and temporally associated with the onset and 
distribution of neurological dysfunction. Early treatment with NBO not only alleviates 
the hypoxia, but is also effective in reducing the severity of the neurological deficit. 
Although further studies are necessary to investigate the best therapeutic regimen, these 
novel findings provide further insight into the pathogenesis and pathophysiology of 
EAE, and perhaps also MS.  
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CHAPTER THREE 
 
THE DORSAL COLUMN LPS LESION 
 
3.1.0.0 INTRODUCTION 
Demyelination is a cardinal feature of MS, but the mechanism(s) by which it occurs 
remain uncertain.  Many favour an autoimmune mechanism, but examination of the 
early forming lesion indicates roles for innate immunity (Barnett and Prineas, 2004) and 
‘hypoxia-like’ (Aboul-Enein et al., 2003) mechanisms. The intraspinal injection of LPS 
into the rat dorsal column induces a focal, inflammatory demyelinating lesion (Felts et 
al., 2005) and has been demonstrated to be an accurate model of the MS Pattern III 
lesion (Marik et al., 2007). Pattern III lesions are characterised by the preferential loss 
of MAG, which is associated with nuclear condensation and fragmentation in 
oligodendrocytes (Lucchinettti et al., 2000). HIF-1α positive oligodendrocytes, 
astrocytes and endothelial cells are also found within areas of MAG loss in Pattern III 
lesions (Aboul-Enein et al., 2003). These pathological findings are similar to that seen 
in white matter stroke, thereby leading to the suggestion that a common mechanism of 
injury exists, that is, a ‘hypoxia-like‘ metabolic tissue injury (Aboul-Enein et al., 2003). 
Indeed, loss of the mitochondrial proteins of COX-I and COX-IV of respiratory 
complex IV, and general reduction of mitochondrial density, has also been found in 
Pattern III lesions (Mahad et al., 2008). In agreement with this, microarray studies on 
the NAWM of MS patients have revealed an up-regulation of a number of genes 
consistent with an energy deficit (Graumann et al., 2003). To date, however, the data 
have been interpreted as a hypoxic pre-conditioning, rather than hypoxia per se. Thus, 
the demyelination in the Pattern III MS lesion has been attributed to an energy deficit 
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arising from NO-mediated mitochondrial inhibition (Aboul-Enein et al., 2003).  Indeed 
NO is capable of interfering with mitochondrial function in the brain, through the 
inhibition of respiratory chain complex II, III and especially IV activity (Bolanos et al., 
1994), and reversibly inhibiting oxygen consumption (Schweizer and Richter, 1994). 
Despite this, NO may not be sufficient to induce structural damage acting alone. Indeed, 
treatment with dexamethasone was found to suppress iNOS activity, but did not affect 
the extent of demyelination (Felts et al., 2005). Besides NO, increases in ROS and 
hypoxia (Taylor and Colgan, 2007) are also evident within the inflammatory milieu. NO 
itself can promote mitochondrial superoxide production via NO-mediated mitochondrial 
damage, and subsequent ATP depletion (Murphy, 2009), and can increase the 
vulnerability of cells, such as oligodendrocytes, to hypoxia, by raising the apparent Km 
of mitochondrial complex IV for oxygen (Brown and Cooper, 1994). Thus we propose 
an alternative mechanism for causing demyelination involving hypoxia, NO and 
superoxide, and have therefore, examined the animal model of the human lesion for 
evidence of these pathological features. 
 
3.1.1.0 Aims 
1. To determine whether the DC LPS lesion labels for hypoxia. 
2. To identify whether superoxide production is increased within the lesion. 
3. To investigate the pathological factors that may contribute to the ‘hypoxia-like’ 
demyelination. 
 
3.1.2.0 Hypothesis 
Hypoxia precedes demyelination in the experimental Pattern III lesion. 
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3.2.0.0 MATERIALS AND METHODS 
3.2.1.0 Surgery 
A laminectomy was performed between T12 and T13 vertebral levels in adult male 
Sprague Dawley rats (312g ± 31.9, mean ± S.D.). A small hole was made in the dura, a 
drawn glass micropipette inserted into the right dorsal column, and 0.5μl of LPS 
(Salmonella enteric serotype abortus equi, Sigma-Aldrich) (100ng/µl saline) injected at 
depths of 0.7 and 0.4 mm, respectively (n = 3 rats per time point). The location of the 
injection site was marked with charcoal. Control animals received injections of saline 
alone (n = 2 per time point).  
 
3.2.2.0 Tissue Processing 
Pimonidazole (60 mg/kg in sterile saline), and DHE (1μg/ml in DMSO) were 
administered intravenously into the saphenous veins of all animals, under light 
anaesthesia (2% isofluorane), with recovery, 4 hours prior to perfusion. Animals were 
perfused trans-cardially with PBS, followed by 4% PFA, at 0.5, 1, 2, 3, 7 and 14 days 
post-LPS injection and the spinal cord harvested. Spinal cords were transected at the 
site of the injection and the rostral portion processed for resin sections and the caudal 
portion processed for cryosections. Tissue was post-fixed overnight in 4% PFA prior to 
either post-fixation in 4% glutaraldehyde in 0.15M phosphate buffer, or cryoprotection 
in 30% sucrose in PBS, for resin processing or immunohistochemical analysis, 
respectively. Frozen tissue used for immunohistochemistry was processed as described 
previously (section 2.2.5). 
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3.2.3.0 Histology  
 3.2.3.1 IHC/IF 
Spinal cord sections were air dried for a few hours prior to any histology. Spinal cord 
tissue from the site of the injection of LPS was examined immunohistochemically using 
a range of markers for inflammation, hypoxia, and ROS (Table 3.2.3.1). Briefly, 
sections were washed with PBS, prior to incubation with either 0.3% H2O2 in neat 
methanol, or neat methanol alone for IHC and IF, respectively. Sections were blocked 
in the appropriate blocking buffer for 30 minutes, before incubation in primary antibody 
overnight at 4
o
C. Primary antibodies were visualised either using the DAB/peroxidase 
or fluorescent reporter systems. For the detection of superoxide production, spinal cord 
sections were washed in PBS and mounted in Vectashield medium, prior to confocal 
microscopy. 
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Table 3.2.3.1: Antibody Details for IHC/IF 
 
Antibody 
 
Target Isotype 
Pre- 
Treatment 
Blocker Dilution Supplier 
Rabbit 
Anti-iNOS 
 
Inducible Nitric Oxide 
Synthase 
 
 N/A 
 
5% goat serum 
mixed in PBS 
containing 0.1% 
Triton X-100 
 
1/200 
BD 
Transductions 
Laboratories 
Franklin Lakes, 
NJ 
Mouse 
Hydroxyprobe-
1-Mab anti-
pimonidazole 
 
Pimonidazole 
adducts 
 
 NaBH4 
 
0.25% casein  
mixed in PBS 
containing 0.1%  
Triton X-100 (for 
IHC) 
 
5% goat serum 
mixed in PBS 
containing 0.1% 
Triton X-100 (for 
IF) 
 
1:500 
 
 
 
 
 
1:200 
HPI Inc 
Rabbit 
Hydroxyprobe-
1-Mab anti-
pimonidazole 
 
Pimonidazole 
adducts 
 
 NaBH4 
 
5% goat serum 
mixed in PBS 
containing 0.1% 
Triton X-100 
 
1/200 HPI Inc 
Rabbit 
Anti-HIF-1α 
 
Active Hypoxia Inducible 
Factor-1α 
 
 NaBH4 
 
5% goat serum 
mixed in PBS 
containing 0.1% 
Triton X-100 
1/500 
Milipore Inc 
Billerica, MA 
Rabbit 
Anti-GLUT-1 
 
 
Glucose transporter  N/A 
 
5% goat serum 
mixed in PBS 
containing 0.1% 
Triton X-100 
1/200 Abcam 
Mouse 
Anti-VEGF 
Vascular endothelial  
growth factor 
 
 N/A 
 
5% horse  mixed 
in PBS containing 
0.1% Triton X-
100 
 
1/500 
Abcam 
 
 
Mouse 
Anti-GFAP 
 
 
Astrocytes  NaBH4 
 
5% goat serum 
mixed in PBS 
containing 0.1% 
Triton X-100 
 
1/400 Sigma 
 
Rabbit 
Carbonic 
anhydrase 2 
(CA2) 
 
Oligodendrocytes  NaBH4 
5% goat serum 
mixed in PBS 
containing 0.1% 
Triton X-100 
 
1/200 
Kindly 
provided by Dr 
N. Gregson 
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 3.2.3.2 Resin Sections 
Spinal cord tissue was cut into 0.5 mm thick segments and post-fixed in 1.5% osmium 
tetroxide in 0.15 M phosphate buffer, with subsequent dehydration in graded alcohols, 
passed through propylene oxide and embedded in resin (Taab Laboratories, 
Aldermaston, UK). Sections were cut to a thickness of 1 µm on an ultramicrotome 
(Leica Microsystems, UK), and stained with 0.1% thionin acetate and 1% aqueous basic 
acridine orange. Stained sections were then mounted in DPX mounting medium and 
examined with light microscopy. 
 
3.2.4.0 Microscopy 
 3.2.4.1 Light Microscopy and Quantification 
Tissue developed using the peroxidase detection system was viewed using an Axiophot 
light microscope (Zeiss, Germany) and pictures taken with a Nikon D300 camera 
(Nikon, USA). All analysis and quantification was performed blind. Analysis of the 
intensity of the labelling with pimonidazole was performed by tracing around the spinal 
cord sections (white and grey matter, and grey matter alone), and measuring the pixel 
intensity using Image J (National institute of health, USA). Quantification of iNOS and 
HIF-1α positive cells was carried out using Image J. Briefly, the images were made 
binary, and then the dorsal columns of each spinal cord section were delineated using 
the freehand selection tool, before using the ‘analyze particles’ tool to count the number 
of positive cells. The same criteria were used for each image, and area measurements 
were carried out concurrently. 
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3.2.4.2 Confocal Laser Microscopy 
Fluorescent images were obtained using a Zeiss LSM5 pascal confocal microscope, 
with a 40x objective. Excitation wavelengths of 488 nm and 543 nm were provided by 
argon and helium-neon gas lasers, respectively. Emission filters BP505-530, BP505-
570, and LP560 were used for obtaining the images. 
 
3.2.5.0 Statistical Analysis 
All data were tested for normality using either the Kolmogorov-Smirnov or the Shapiro-
Wilk test, depending on the size of the data set, and for stability of variances using the 
Levene’s test. Data that were not normally distributed were evaluated using non-
parametric statistics as indicated. P-values of 0.05 (*), 0.01 (**) and 0.001 (***), were 
considered as statistically significant.  All statistical analyses were carried out using 
SPSS version 14.0 (USA). 
 
3.2.5.1 Statistical Analysis of Pimonidazole Intensity 
The pixel intensity of the pimonidazole labelling was normally distributed in all spinal 
cord sections examined.  Therefore, the percentage of pixels labelled with an intensity 
greater than the control mean plus one standard deviation were counted and compared 
to the appropriate vertebral segment-matched control using a two-way ANOVA; the 
room air treatment group and saline-injected group served as controls in each of the 
respective experiments.  
 
2.3.6.2 Statistical Analysis of Other Labels 
A linear regression model was used to compare the iNOS, HIF-1α and RECA-1 
cell densities between LPS-injected animals and saline-injected controls. This was 
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followed by a pairwise comparison at the different time points using an independent t-
test. 
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3.3.0.0 RESULTS 
 
3.3.1.0 Intraspinal injection of LPS induces a focal demyelinating lesion 
The intraspinal injection of LPS into the dorsal columns induced a focal demyelinating 
lesion commencing around 3 days post injection (Figure 3.3.1.0). At the early time 
points (0.5, 1 and 2 days), tissue integrity was largely maintained although evidence of 
inflammation was observed in the dorsal white matter. At 3 days post injection, the 
tissue was largely oedematous and there was evidence of demyelination, particularly at 
the base of the dorsal columns. By 7 days, post injection, the demyelination was more 
extensive, and was localised to the ventral half of the dorsal column, with some 
evidence of tissue oedema (Figure 3.3.1.0). Debris-filled macrophages were also 
observed within the lesion at 7 days. At 14 days post injection, the lesions were 
comprised of demyelinated axons, axons associated with cells (Felts et al., 2005), and 
debris-filled macrophages (Figure 3.3.1.0).  
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Figure 3.3.1.0: Formation of a demyelinating lesion following intraspinal LPS 
injection 
(A-C) Light micrographs of transverse spinal cord sections at the level of the injection of saline (A) or 
LPS (B, C). (A) In saline-injected control animals, tissue appears to be relatively normal, with no 
apparent pathology. (B, C) Following the intraspinal injection of LPS, a focal demyelinating lesion 
appears to form between 3 and 7 days post-injection. In the acute lesion (0.5-2 days post-injection), little 
or no demyelination is present. At 3 days post-injection, several debris-filled macrophages are evident in 
the dorsal columns of LPS-injected animals (C iv, arrowheads). (C v) At 7 days post-injection the lesion 
is oedematous, with some evidence of demyelination. (C vi) By 14 days, the lesion contains demyelinated 
axons, several debris filled macrophages (arrowheads) and axons in association with cells (arrows). Scale 
bars 200µm (A, B), and 100µm (C). All Micrographs are representative. 
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3.3.2.0 The acute DC LPS lesion labels positive for hypoxia 
 
3.3.2.1 Acute transient pimonidazole labelling in the DC LPS lesion 
The intravenous probe pimonidazole was used to detect tissue hypoxia in the DC LPS 
lesion. Pimonidazole immunoreactivity was evident in the grey matter and dorsal 
columns of LPS-injected animals at all the time points examined (Figure 3.3.2.1 A, B). 
However, labelling for pimonidazole was only statistically significantly increased in the 
grey matter of LPS-injected animals at 1 day (p< 0.001) and 2 days (independent t-test, 
p = 0.014) post injection, compared with saline-injected controls. In the acute lesion, 
before any demyelination was evident, labelling for pimonidazole was prominent, 
particularly at 1 day post injection, with a band of intense labelling visible in the 
adjacent grey matter ‘cradling’ the base of the dorsal column (Figure 3.3.2.1 A). The 
grey matter labelling was specific to neuronal cell bodies and the surrounding 
extracellular matrix. Of all the time points examined, labelling for hypoxia was most 
intense at 1 day post LPS injection (Figure 3.3.2.1 A, B).  By 2 days, the intensity of 
pimonidazole labelling decreased in the grey matter, although this still remained 
increased in comparison with saline-injected controls. The Spearman‘s Rank order 
correlation test identified that the intensity of pimonidazole labelling in the acute DC 
LPS lesion strongly correlated with the iNOS cell density (p = 0.08, r
2
 = 0.701, n = 9), 
suggesting that the intensity of pimonidazole labelling increases concomitantly with the 
iNOS cell density.  
Although pimonidazole does not label myelin, leading to the less obvious 
labelling of the white matter, some punctate, cell-specific labelling was observed in the 
dorsal columns of LPS injected animals, particularly evident at 1 day post injection 
(Figure 3.3.2.1 A). Morphological analysis of these cells suggested that they may be 
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composed of oligodendrocytes and astrocytes, therefore double label IF was carried out 
to confirm their identity. This revealed that pimonidazole-positive cells co-labelled with 
CA2, a marker of oligodendrocytes (Ghandour et al., 1980), and GFAP, a marker of 
astrocytes (Figure 3.3.2.1 C). No such labelling was present in saline-injected controls. 
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Figure 3.3.2.1: Pimonidazole immunohistochemistry in the LPS dorsal column 
lesion 
(A) Spinal cord sections at the level of the injection of saline (0.5 days post-injection) or LPS, at 0.5, 1, 2, 
7 and 14 days post-injection labelled with an antibody against bound pimonidazole adducts. Labelling for 
pimonidazole is substantially increased in the grey matter and the dorsal columns of animals injected with 
LPS, compared with saline-injected controls, particularly in the acute lesion (0.5-2 days post-injection). 
Scale bar 200µm. (B) Graphical representation of the intensity of pimonidazole labelling over the time 
course of the LPS dorsal column lesion (control n=2 per time point; LPS n=3 per time point). Labelling 
for pimonidazole is most intense at 1 day post-LPS injection, but decreases thereafter. Statistical 
significance was determined by an independent t-test, comparing saline-injected and LPS-injected 
animals at each time point, * p<0.05, *** p<0.001. Values are mean ± SD. (C-top) Double label 
immunofluorescence with antibodies against pimonidazole (false-coloured red) and CA2 (green) showing 
that a subset of oligodendrocytes label positively for pimonidazole. (C-bottom) Double label 
immunofluorescence with antibodies against pimonidazole (false-coloured red) and GFAP (blue), 
showing that a subset astrocytes also label for pimonidazole. Scale bar 100 µm. All micrographs are 
representative. 
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3.3.2.2 HIF-1α expression in increased in LPS-injected animals 
HIF-1α is expressed in some MS lesions, therefore immunohistochemistry was used to 
identify whether HIF-1α is expressed in the dorsal columns of LPS-injected animals, to 
corroborate our findings with pimonidazole. HIF-1α expression was increased in the 
dorsal columns of LPS-injected animals, compared with saline-injected controls (Figure 
3.3.2.2 A, B). Labelling for HIF-1α was statistically significantly increased at 0.5 days 
(p = 0.022) and 2 days (p = 0.004), post injection. Although extensive labelling was also 
observed at 1 day post-injection, this did not reach statistical significance in our sample 
(p = 0.059). Cytoplasmic and nuclear HIF-1α labelling was seen as early as 0.5 days 
post injection, in the dorsal columns of LPS-injected animals, and at all other time 
points examined (Figure 3.3.2.2 A). Up to, and including, 2 days post injection, these 
HIF-1α-expressing cells, identified as glial cells based on their morphology, were found 
scattered throughout the dorsal columns and did not show a preference for the injection 
side. Moreover, labelling for HIF-1α was also increased in the adjacent grey matter in 
these animals. However, at the subsequent time points the expression of HIF-1α was 
primarily localised to the injection side of the dorsal white matter. The labelling for 
HIF-1α was particularly impressive at 3 days post-LPS injection, where it seemed to be 
expressed by activated macrophages/microglia, within the demyelinating lesions and 
surrounding vessels. At 14 days post LPS injection, endothelial expression of HIF-1α 
was also evident, in addition to the glial expression observed at the earlier time points. 
Saline-injected controls only displayed basal levels of HIF-1α expression within the 
dorsal white matter: very little HIF-1α was observed in the adjacent grey matter (Figure 
3.3.2.2 A, B). 
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Figure 3.3.2.2: HIF-1α immunohistochemistry in the LPS dorsal column lesion 
(A) Spinal cord sections at the level of the injection of saline (0.5 day post-injection), and LPS at 0.5, 1, 
2, 3, 7 and 14 days post-injection, labelled with an antibody against HIF-1α. HIF-1α immunoreactivity is 
increased in LPS-injected animals compared with saline-injected control animals.  HIF-1α positive cells 
are evident in the dorsal column, and adjacent grey matter, of LPS-injected animals. Scale bar 200 µm. 
All micrographs are representative. (B) Graphical representation comparing the HIF-1α cell density 
between saline-injected and LPS-injected animals at all the time points examined. Values are mean ± S.D. 
(n=2 for controls, per time point; n=3 for LPS, per time point). Statistical significance determined by an 
independent t-test comparing the mean cell density between LPS-injected and saline-injected animals, at 
each time point, * p<0.05, **p<0.01. 
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3.3.2.3 The expression of Hypoxia inducible proteins is increased following LPS 
injection 
HIF-1α regulates the transcription of a number of genes. GLUT-1 and VEGF are two 
such genes, and their increased expression in response to hypoxia is well established. 
GLUT-1, expressed on both endothelial cells and glia within the CNS, was increased in 
the dorsal columns of LPS-injected compared with saline-injected controls (Figure 
3.3.2.3 A), particularly at 0.5 days post injection. In the dorsal columns of saline-
injected animals, GLUT-1 was primarily expressed on endothelial cells (Figure 3.3.2.3 
A), however, at the early time points (0.5 and 1 day post LPS-injection), GLUT-1 
expression was seen on endothelial and glial cells. This change in pattern of expression 
probably contributed to the increase in GLUT-1 labelling observed at these early time 
points. By 2 days, the expression of GLUT-1 decreased to that observed in saline-
injected controls (Figure 3.3.2.3 A), with expression restricted to endothelial cells. 
Similarly at the subsequent time points, the extent of GLUT-1 labelling in LPS-injected 
animals was comparable to that seen in saline-injected controls.  
VEGF, a key signal protein responsible for the stimulation of neovascularisation 
and angiogenesis, was clearly expressed in the dorsal columns of LPS-injected animals, 
at all time points examined (Figure 3.3.2.3 A). In the acute lesion, particularly at 0.5 and 
1 day post injection, VEGF was diffusely distributed throughout the dorsal columns, 
with no preference for the injection side (Figure 3.3.2.3 A). However, at the subsequent 
time points, the labelling was observed on endothelial cells. Saline-injected controls did 
not show any evidence of such labelling.  
 Despite the expression of VEGF, there was no apparent increase in vascular 
density within the dorsal columns of LPS injected animals, at any of the time points 
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examined, compared with saline-injected controls. Rather, the vascular density of the 
dorsal white matter in LPS-injected animals was decreased, if not comparable to that of 
control animals (Figure 3.3.2.3 B). However, a considerable degree of variation in the 
vascular density was observed in the control group at different time points (Figure 
3.3.2.3 B). 
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Figure 3.3.2.3: Expression of HIF-1α regulated genes in the LPS dorsal column 
lesion 
(A, left) Spinal cord sections at the level of the injection of saline (0.5 days post-injection), and LPS at 
0.5, 1, 2, 3, 7 and 14 days post-injection, labelled with an antibody against GLUT-1. GLUT-1 
immunoreactivity is increased in the dorsal columns of LPS-injected animals compared with saline-
injected control animals. The increase in immunoreactivity is particularly evident in the acute lesion (0.5-
1 day post-injection), due to the additional expression of GLUT-1 in glia (arrow). (A, right) Spinal cord 
sections at the level of the injection of saline (0.5 days post-injection), and LPS at 0.5, 1, 2, 3, 7 and 14 
days post-injection, labelled with an antibody against VEGF. VEGF immunoreactivity is evident in the 
dorsal columns of animals injected with LPS, at all time points examined. In the acute lesion (0.5-2 days 
post-injection), VEGF immunoreactivity is dispersed throughout the dorsal white matter, however, at the 
subsequent time points, VEGF immunoreactivity is largely restricted to endothelial cells No such 
labelling is evident in the spinal cords of saline-injected controls. Scale bar 200µm. All micrographs are 
representative. (B) Graphical representation of the vascular density within the dorsal columns of animals 
injected with saline or LPS at 0.5, 1, 2, 3, 7, and 14 days post-injection (control n=2 per time point; LPS 
n=3 per time point). Vascular density was relatively comparable between the two groups at all the time 
points examined, with the exception of day 7 post-injection. Values are means ± S.E.M. 
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3.3.3.0 Reactive oxygen and nitrogen species  
 
3.3.3.1 Lateralisation of superoxide production in the acute DC LPS lesion 
Superoxide production was assessed using the intravenous fluorescent probe DHE, and 
was present at basal levels in the spinal cords of saline-injected animals (Figure 3.3.3.1). 
In these animals, uniform superoxide production was typically observed within the 
dorsal columns and grey matter, with particularly prominent neuronal labelling. 
Following the intraspinal injection of LPS, superoxide production appeared to be 
elevated in the dorsal columns and/or grey matter, at most, if not all, the time points 
examined, compared with saline-injected controls (Figure 3.3.3.1). Interestingly, at 1 
day post-injection, there was a lateralisation of superoxide production in the adjacent 
grey matter, on the side of the injection (Figure 3.3.3.1).  
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Figure 3.3.3.1: Lateralisation of superoxide production following LPS-injection 
Confocal laser micrographs of spinal cord sections at the level of the injection of saline (left) and LPS 
(right) at 1 day post-injection, examined for DHE-induced fluorescence. DHE-induced fluorescence is 
evident in saline-injected controls in the grey matter (GM) and dorsal white matter (DC). Following the 
injection of LPS, there is a complete lateralisation of DHE-induced fluorescence in the adjacent grey 
matter, on the side of the injection. Scale bar 200µm. All micrographs are representative.  
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3.3.3.2 Acute iNOS expression following intrapinal LPS injection 
The expression of iNOS is a well documented feature of MS lesions, and its expression 
was acutely increased in the dorsal columns following the intrapinal injection of LPS. 
The expression of iNOS was observed at the earliest time point examined, 0.5 day post 
LPS injection (p< 0.001), but the iNOS-positive cell density was greatest at 1 day (p<  
0.001), before decreasing considerably by 2 days (p = 0.011) post-injection (Figure 
3.3.3.2 A, B). iNOS positive cells were primarily found dispersed diffusely throughout 
the dorsal columns of LPS-injected animals, with no clear preference for the side 
injected. However, some positive cells were also found in the adjacent grey matter, with 
a dense cluster localised in the grey matter at the base of the dorsal columns (Figure 
3.3.3.2 A). This pattern of labelling was particularly obvious at 1 day following the 
injection of LPS. No such labelling was present in saline-injected controls, or in LPS-
injected animals after 2 days post-injection (Figure 3.3.3.2 A, B). 
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Figure 3.3.3.2: iNOS immunoreactivity in the LPS dorsal column lesion 
(A) Spinal cord sections from saline-injected and LPS-injected animals, 0.5, 1 and 2 days post-injection, 
at the site of the injection. iNOS positive cells are prominently expressed at 0.5 and 1 day following LPS 
injection. Positive cells can be seen scattered throughout the dorsal columns, with large clusters in the 
adjacent grey matter. The expression of iNOS is considerably decreased by 2 days post-injection. No such 
labelling is evident in saline-injected controls. Scale bar 200µm. Micrographs are representative. (B) 
Graphical representation comparing the iNOS cell density between saline-injected and LPS-injected 
animals at 0.5, 1 and 2 days post-injection. Values are mean ± S.D. (n=2 for controls, per time point; n=3 
for LPS, per time point). Statistical differences were determined by an independent t-test, * p<0.05, *** 
p<0.001. 
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3.3.3.3 Labelling for nitrotyrosine residues follows the spatio- temporal pattern 
of iNOS 
Nitrotyrosine is the molecular footprint of peroxynitrite, and its transient expression was 
observed in the dorsal columns of LPS-injected animals (Figure 3.3.3.3). The labelling 
followed the spatio-temporal pattern of labelling seen with iNOS. Accordingly, 
nitrotyrosine was present as early as 0.5 days post LPS injection, but most prominent at 
1 day, before decreasing by 2 days post-injection (Figure 3.3.3.3). Nitrotyrosine-
positive cells were observed diffusely dispersed throughout the dorsal columns, with 
aggregates of nitrotyrosine-positive cells at the base of the dorsal column. As with other 
labels, there was no apparent lateralisation of labelling for nitrotyrosine on the side of 
the injection. No such labelling was evident in saline-injected controls (Figure 3.3.3.3) 
or in LPS-injected animals after 2 days post-injection. 
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Figure 3.3.3.3: Nitrotyrosine immunoreactivity in the acute lesion 
Micrographs of spinal cord sections at the level of the injection of saline (top row) or LPS (bottom row), 
labelled with an antibody against 3-NT. In the acute lesion (0.5-2 days), immunoreactivity for 3-NT is 
evident in the dorsal columns of LPS-injected animals, but is absent in saline-injected controls. NT-
positive cells can be seen dispersed throughout the dorsal white matter, however clusters of NT-positive 
cells are also observed in the adjacent grey matter and at the base of the dorsal columns. By 2 days post-
injection, immunoreactivity for NT is decreased considerably. Scale bar 200µm. Micrographs are 
representative.  
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3.4.0.0 DISCUSSION 
The results show that the direct intraspinal injection of LPS into the rat spinal cord 
results in acute, transient tissue hypoxia, with a concomitant increase in NO and 
superoxide production, prior to the onset of demyelination. Moreover this ‘toxic trio’ 
appears to influence the exact topographical location of the demyelinated lesion that 
forms two weeks later.  
 
3.4.1.0 Hypoxia is an early feature of the DC LPS lesion 
LPS is a common inflammagen that is frequently used to induce an innate immune 
response in the CNS (Andersson et al., 1992; Bell and Perry, 1995; Stern et al., 2000). 
In the CNS this endotoxin exerts its actions via Toll-like receptor 4 (TLR4) (Hoshino et 
al., 1999) on resident microglia (Lehnardt et al., 2003), initiating a cascade of events 
that can ultimately lead to neurodegeneration. Sites of inflammation are often hypoxic, 
due to the altered metabolism of the tissue and vascular disturbances. Accordingly, the 
current study demonstrates that prior to the occurrence of demyelination, the rat spinal 
grey and white matter labels positive for pimonidazole, a marker of hypoxia, with the 
extent of labelling greatest at 1 day post LPS injection. The labelling of the grey matter 
for hypoxia was not surprising given that it represents a highly metabolic compartment 
of the CNS that is dominated primarily by excitatory synapses (Abeles, 1991; 
Braitenberg and Schuz, 1998). These synaptic terminals are rich in mitochondria, 
highlighting synapses as major consumers of metabolic energy (Wong-Riley, 1989; 
Wong-Riley et al., 1998). Considering that the majority of the energy used by the grey 
matter goes on signalling processes (Attwell and Laughlin, 2001), one can assume that 
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although the grey matter is well vascularised, the demand for oxygen simply outweighs 
its supply, rendering it vulnerable to becoming hypoxic. 
Besides, the grey matter labelling, the current study reports that 
oligodendrocytes and astrocytes, within the dorsal white matter label positive for 
pimonidazole, 1 day post LPS injection.  These results suggest that oligodendrocytes 
and astrocytes that reside in the base of the dorsal column are vulnerable to hypoxia 
following the intraspinal injection of LPS. This is in line with previous studies that have 
shown that chronic hypoperfusion of the rat forebrain causes preferential death of 
oligodendrocytes, in vivo (Masumura et al., 2001). The vulnerability of 
oligodendrocytes to hypoxia/ischemia is increasingly being recognised, and is largely 
attributed to a number of their intrinsic properties. During myelination, 
oligodendrocytes synthesise approximately three times their weight in membrane per 
day, and eventually support this membrane which accounts for up to a hundred times 
the weight of the cell body (McLaurin and Yong, 1995; Connor and Menzies, 1996; 
Ludwin, 1997; McTigue and Tripathi, 2008; Bradl and Lassmann, 2010). Thus, 
oligodendrocytes are particularly metabolically demanding cells that need to consume 
large amounts of ATP and oxygen (McTigue and Tripathi, 2008) to support and 
maintain their extensive membrane. This high metabolic rate inevitably leads to the 
production of the toxic by-products H2O2 and ROS. Furthermore, the enzymes required 
to synthesise the myelin require iron as a co-factor, resulting in extremely high 
intracellular concentrations of ROS and iron. Indeed, oligodendrocytes contain the 
largest intracellular stores of iron in the brain (Cheepsunthorn et al., 1998; Thorburne 
and Juurlink, 1996), which can predispose them to ROS-mediated damage by evoking 
free radical formation and lipid peroxidation (Braughler et al., 1986; Juurlink, 1997) via 
the fenton reaction. Despite their high ROS-generating potential, oligodendrocytes have 
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a limited capacity to scavenge ROS, containing very low levels of glutathione 
(Thorburne and Juurlink, 1996). Under inflammatory conditions, where the metabolic 
demands of the tissue are higher than the supply of oxygen, it is not surprising that 
oligodendrocytes were found to be hypoxic in the current study.  
The study also found that some astrocytes become hypoxic following LPS-
injection. Astrocytes, unlike oligodendrocytes, have inherent hypoxia-inducible and 
anti-oxidant (Eftekharpour et al., 2000) responses. Moreover, astrocytes are the 
principal site for glycogen storage in the CNS (Phelps, 1972), and they are able to up-
regulate anaerobic isoforms of glycolytic enzymes in response to hypoxia (Marrif and 
Juurlink, 1999). Nevertheless, functional disturbance of astrocytes, defined by the 
retraction of astrocytic foot processes at the glia limitans, loss of aquaporin IV (AQ-4), 
and the loss of connexins, which are of fundamental importance for the formation of 
gap junction between astrocytes and oligodendrocytes, has been recently described in 
the LPS dorsal column lesion (Sharma et al., 2010). Although astrocytes can adapt to 
hypoxic conditions by glycolytic ATP production alone (Swanson, 1992), they are 
particularly vulnerable to the resultant acidosis (Giffard et al., 1990; Swanson et al., 
1997). This sensitivity has been attributed to the fact that astrocytes express an 
electrogenic sodium bicarbonate co-transporter that mediates an inward sodium current 
(Chen and Swanson, 2003), and is thought to explain astrocytic death following 
prolonged hypoxia (Giffard et al., 2000). Therefore, perhaps hypoxia precedes and 
potentially acts as a precursor to the functional disturbances noted in astrocytes 
following the injection of LPS into the dorsal column. 
The transcription factor HIF-1α, an important mediator of hypoxia-induced 
responses, has been found to be prominently expressed within glia, macrophages and 
some endothelial cells, in active MS pattern III lesions (Aboul-Enein et al., 2003). The 
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current study reports the presence of HIF-1α positive cells in the dorsal column of 
animals injected with LPS, at all time points examined. Evidence of HIF-1α expression 
was observed as early as 0.5 days post-injection, with the number of HIF-1α positive 
cells greatest at 1 day post-injection. Moreover, genes, whose expression is under the 
transcriptional control of HIF-1α, were also increased in the dorsal columns following 
LPS injection. This finding is consistent with previous studies that show HIF-1α 
expression in oligodendrocytes, astrocytes and some endothelial cells within Pattern III 
lesions (Aboul-Enein et al., 2003).  
At first glance, one might assume that the stabilisation and accumulation of HIF-
1α confirms that the cells within the dorsal columns of LPS-injected animals are 
hypoxic. However, the interpretation of HIF-1α expression is more complex owing to 
the fact that this transcription factor is not only stabilised under hypoxic conditions via 
stabilisation of oxygen-sensitive enzymes involved in its degradation (Semenza, 2007), 
but is also stabilised by a variety of other mechanisms, including the action of NO 
adducts (Mateo et al., 2003; Kasuno et al., 2004; Peyssonnaux et al., 2005) and ROS 
(Brunelle et al., 2005; Guzy et al., 2005; Mansfield et al., 2005). Therefore, determining 
the exact trigger of HIF-1α stabilisation in an environment where both inflammation 
and hypoxia are present is complicated. Indeed, the expression of HIF-1α occurring 
simultaneously with pimonidazole labelling, particularly at the early time points, makes 
one more inclined to believe that it is the declining concentration of oxygen itself that 
leads to stabilisation of the transcription factor in this model. 
Different cell types would be expected to react differently to low oxygen 
concentrations depending on their capacity to adapt to such an environment. Indeed, the 
stabilisation and subsequent nuclear translocation of HIF-1α in macrophages under 
inflammatory conditions can occur in an oxygen-dependent and oxygen-independent 
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manner (Peyssonnaux et al., 2005). However, hypoxic activation is important, 
potentiating the bactericidal activities of these inflammatory cells (Cramer et al., 2003; 
Peyssonnaux et al., 2005). Active immune cells are adapted to survive in a hypoxic 
milieu, and one such adaptation is a switch to glycolysis (Oda et al., 2006), which is 
facilitated by the expression of HIF-1α. This is consistent with the finding that 
macrophage-like appearing cells label positive for HIF-1α at 3 days post LPS injection 
in the current study.  
HIF-1α supports glycolysis in a number of ways, one of which is the up-
regulation of glucose transporters, namely GLUT-1, a glucose transporter expressed by 
endothelial cells and glial cells. The present study found an increase in expression of 
GLUT-1 in the dorsal columns of LPS-injected animals, which is consistent with 
previous findings that hypoxia induces an up-regulation of this glucose transporter 
(Boardo and Pardridge, 2002), in what appeared morphologically to be endothelial cells 
and glia. Curiously, glial expression of GLUT-1 was only evident in animals injected 
with LPS, and in saline-injected controls GLUT-1 expression was restricted to 
endothelial cells. This shift in the pattern of expression implies that glial cells within the 
dorsal columns may have switched to glycolysis, in response to HIF-1α signalling, and 
additional glucose is required to fuel this process to prevent ATP depletion and 
subsequent cell death. Indeed, astrocytes are capable of switching to glycolytic ATP 
production under hypoxic conditions (Swanson, 1992), and are the primary glial cell 
that express GLUT-1 transporters. Perhaps the astrocytes that up-regulate their 
expression of GLUT-1 are also the ones that do not label for hypoxia. 
A major function of HIF-1α under inflammatory conditions is the promotion of 
angiogenesis (Cramer et al., 2003; Walmsley et al., 2005). VEGF is crucial for 
angiogenesis, and its expression is controlled by HIF-1α. VEGF initiates angiogenesis, 
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allowing the tissue to increase its oxygen supply. We report evidence of VEGF 
expression in the LPS dorsal column lesion at all the time points examined. The 
expression of VEGF in the lesion was initially suspected to represent a compensatory 
response to increase the delivery of oxygen and other metabolic substrates by increasing 
vascularisation (Shweiki et al., 1992; Marti and Risau, 1999). However, an increase in 
the vascular density was not observed following the injection of LPS in the current 
study. This finding may be explained by the pattern of expression of VEGF throughout 
the time course of lesion development. At the early time points, labelling was 
predominantly cellular, whereas at the later time points labelling progressively became 
restricted to endothelial cells. This perhaps suggests that VEGF may exert a 
pathological effect in the LPS DC lesion. VEGF is a known mediator of vascular 
permeability (Dobrogowska et al., 1998; Rosenstein et al., 1998; Proescholdt et al., 
1999; Croll et al., 2004), and recent evidence shows that glial-derived VEGF drives 
BBB disruption and subsequent neuroinflammation in mice (Argaw et al., 2012). 
Moreover, hypoxia-induced VEGF expression has also been reported to cause vascular 
leakage (Schoch et al., 2002). Given that the early expression of VEGF appears to 
coincide with tissue hypoxia in the LPS DC lesion, BBB disruption and vascular 
leakage may represent functions of VEGF during the early stages of neuroinflammation. 
Croll et al (2004) showed that low doses of VEGF infused directly into the neocortex of 
rats does not result in any significant vascular proliferation, even following 7 days of 
infusion.  Furthermore, VEGF-mediated changes in vascular permeability have been 
found to precede the angiogenic response in vivo (Croll et al., 2004). Perhaps, a similar 
situation exists in the LPS DC lesion, and angiogenesis may be evident if searched for 
at subsequent time points.  
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3.4.2.0 NO, superoxide and nitrotyrosine are present in the acute DC LPS 
lesion 
NO is a messenger molecule, which has been studied extensively for its physiological 
and pathophysiological functions. The inducible isoform of NOS, iNOS, is expressed in 
a number of tissues including the CNS, and is regarded as a key source of ROS/RNS 
(Licinio et al., 1999). Pattern III MS lesions show profound up-regulation of iNOS 
(Marik et al., 2007). As described previously (Felts et al., 2005), the intraspinal 
injection of LPS into the dorsal column results in an acute, transient expression of 
iNOS. This NOS isoform produces large amounts of NO, resulting in its rapid 
summation within a local region. The diffusion of NO away from its cellular source is 
thought to be more significant than reactions within the NO producing cell itself 
(Lancaster, 1994). NO is estimated to diffuse in and out of cells thousands of times in a 
second (Beckman and Koppenol, 1996). Although NO has a multitude of potentially 
toxic effects, many of these are probably mediated by the oxidation products of NO. 
One such oxidation product is the highly potent peroxynitrite anion, formed when NO 
reacts with superoxide. The current study reports that the intraspinal injection of LPS 
results in an increase in superoxide production, particularly in the acute lesion, as 
detected by DHE fluorescence. Visualisation of ROS in vivo has previously been proven 
extremely challenging, due to their highly reactive and unstable nature. However, DHE, 
by virtue of its ability to permeate cell membranes is increasingly being employed to 
monitor superoxide production (Bindokas et al., 1996; Owusu-Ansah et al., 2008). 
Initially, DHE was thought to react with superoxide to produce ethidium, which 
intercalates with DNA resulting in red fluorescence (Rothe and Valet, 1990; Carter et 
al., 1994). However, recent studies suggest the DHE and superoxide in fact react to 
produce 2-hydroxyethidium (Zhao et al., 2003; Zhao et al., 2005). Similar to ethidium, 
2-hydroxyethidium also intercalates with DNA resulting in a red fluorescence that is 
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distinctly different from the fluorescence of ethidium (Zhao et al., 2003; Zhao et al., 
2005). Thus, if the correct excitation wavelengths are employed, DHE can be used as an 
in vivo probe for the detection of superoxide production. During inflammation, 
excessive superoxide may be produced enzymatically by NADPH oxidases, which are 
located on the cell surface of polymorphonuclear cells and macrophages (Babior, 2000; 
Babior et al., 2002; Vignais, 2002), and non-enzymatically by dysfunctional 
mitochondria. However, superoxide is relatively unstable, and therefore spontaneously 
dismutates to form oxygen and hydrogen peroxide (Fridovich, 1978). When NO levels 
are elevated, superoxide reacts with NO in a diffusion-limited manner (Huie and 
Padmaja, 1993) such that almost every collision results in the irreversible formation of 
peroxynitrite (Beckman and Koppenol, 1996). Peroxynitrite is a highly reactive free 
radical, with a very short half-life, and therefore interacts with proteins near the site of 
generation.  3-Nitrotyrosine is a putative footprint of tyrosine residues that have been 
nitrated by peroxynitrite, and is considered a useful measure of NO-mediated damage. 
Labelling for 3-nitrotyrosine is evident in the dorsal column following the intraspinal 
injection of LPS, and corresponds precisely with the pattern of iNOS expression. This 
finding strengthens the argument that NO and superoxide are present in the acute lesion, 
and lead to the formation of peroxynitrite. Nitrotyrosine residues are also a feature of 
acute, but not chronic MS lesions (Liu et al., 2001). The nitration of tyrosine residues in 
proteins results in the inhibition of phosphorylation, which is crucial to cellular 
regulation and signal transduction (Martin et al., 1990). However, the transient presence 
of 3-nitrotyrosine suggests that some kind of repair/removal mechanism exists to take 
care of damaged proteins, and potentially limit the propagation of damage. The fate of 
nitrated proteins currently remains unclear. Protein nitration is typically viewed as a 
cumulative, destructive process, however, evidence suggests that nitrated proteins are 
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either degraded (Souza et al., 2000) or subjected to enzymatic ‘denitration’ (Gow et al., 
1996; Kamisaki et al., 1998), the latter of which implies that protein nitration is a 
dynamic process which is reversible (Aulak et al., 2004).  
      
3.4.3.0 Hypoxia, NO and superoxide can coalesce to promote ‘hypoxia-like’ 
demyelination 
The demyelination consequent to the intraspinal injection of LPS has been described as 
‘hypoxia-like‘, and so it resembles the human MS Pattern III lesion that has previously 
been attributed to mitochondrial dysfunction as a result of exposure to NO (Aboul-
Enein et al., 2003). Although NO probably plays a key role, it may not be sufficient to 
cause damage alone. Indeed, treatment with dexamethasone, despite reducing the 
inflammation and suppressing iNOS expression, does not reduce the extent of 
demyelination following the intraspinal injection of LPS (Felts et al., 2005). In the LPS 
dorsal column lesion, the demyelination occurs primarily at the base of the dorsal 
column, but there is no tendency for iNOS positive cells to accumulate in this area. 
Instead, clusters of iNOS positive cells are seen in the adjacent grey matter, cradling the 
base of the dorsal column. This adjacent grey matter also labels intensely for hypoxia, 
and excessive superoxide production. Moreover, labelling for this ‘toxic trio’ is greatest 
at 1 day post LPS injection, 2 days prior to oligodendrocyte loss within the lesion 
(Schonberg et al., 2007). Thus, the results suggest that perhaps hypoxia, NO and 
superoxide may work synergistically to induce damage in vulnerable cells such as 
oligodendrocytes, thereby promoting ‘hypoxia-like’ demyelination. Indeed, the spatio-
temporal nature of the hypoxia, NO and superoxide in LPS-injected animals, appears to 
determine the exact topographical location of the demyelinated lesion two weeks later, 
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suggesting that these toxic mediators may work together to mediate the structural 
damage.  
Although hypoxia, NO and superoxide are all independently capable of inducing 
mitochondrial damage (Bolanos et al., 1994; 1995; 1997; Brorson et al., 1999; Heales et 
al., 1999; Weinberg et al., 2000), collectively they become a formidable force. NO 
increases the apparent Km of respiration for oxygen (Brown and Cooper, 1994; Mander 
et al., 2005), i.e. the amount of oxygen required for cellular respiration, thus sensitising 
the brain and/or spinal cord to hypoxia (Mander and Brown, 2004). Furthermore, 
prolonged exposure to NO leads to a persistent, non-competitive inhibition of complex I 
and other respiratory enzymes by S-nitrosylation (Clementi et al., 1998; Beltran et al., 
2000), and this has been found to be enhanced by hypoxia (Frost et al., 2005). The 
presence and aberrant production of superoxide increases the potential for damage, 
firstly by elevating free iron levels (Flint and Emptage, 1990; Liochev and Fridovich, 
1994; Keyer and Imlay, 1996), thereby increasing the rate of DNA damage, and 
secondly by promoting the formation of peroxynitrite. Excessive peroxynitrite leads to 
the nitration of proteins, inhibition of mitochondrial proteins, depletion of cellular 
energy, DNA damage, and eventually cell death (Virag et al., 2003; Korhonen et al., 
2005).  Oligodendrocytes have a limited capacity to scavenge ROS and they contain 
enormous intracellular stores of iron (Thorburne and Juurlink, 1996; Cheepsunthorn et 
al., 1998), rendering them particularly vulnerable to such an insult.  
On one hand, the presence of hypoxia in addition to elevated NO is 
counterintuitive. One would expect an increase in oxygen concentration, or hyperoxia, 
to result from mitochondrial inhibition by NO. However, molecular oxygen is an 
essential substrate required for the production of NO (Stuehr and Nathan, 1989; Leone 
et al., 1991), and previous studies have reported that after 24 hours of macrophage 
 
 
157 
 
activation in vitro, all the oxygen consumed by these cells is non-mitochondrial, and 
that 90% of this is due to iNOS activity (Garedew and Moncada, 2008). Indeed, NOS 
requires 2 oxygen molecules for every NO molecule produced. Given that the half-life 
of NO in vivo is approximately 1 s, then 170 nmol of oxygen/min would be required per 
gram of tissue to maintain a steady concentration of 1 µM NO (Beckman and Koppenol, 
1996). Tissue dysoxia, a characteristic feature of septic shock, has been attributed to the 
overproduction of NO, which induces a mitochondrial defect and leads to a decrease in 
oxygen extraction by tissues (Rees et al., 1998; Garedew and Moncada, 2008). Indeed, 
copious amounts of NO are produced during chronic inflammatory and degenerative 
disorders such as MS; therefore, a similar mechanism to that of septic shock may exist 
in such conditions (Moncada and Erusalimsky, 2002) perpetuating the hypoxic 
environment. By virtue of its ability to inhibit cytochrome oxidase, NO shifts the 
electron transport chain to a more reduced state, which is known to enhance superoxide 
formation (Boveris and Chance, 1973). Studies utilising isolated mitochondria have 
shown that exogenous NO can also generate superoxide anions (Poderoso et al., 1996). 
Paradoxically hypoxia-induced ROS production has been shown to occur in a number 
of different tissues, in vitro (Chandel et al., 1998; Guzy et al., 2006). This mechanism of 
superoxide generation, which occurs at the level of complex III, is thought to involve 
the stabilisation of HIF-1α (Chandel et al., 2000), thus mediating the response to 
hypoxia. In this mechanism, the mitochondrial respiratory chain acts as an oxygen 
sensor, by the concomitant release of hydrogen peroxide with superoxide, the former of 
which decreases the activity of PHD thereby stabilising HIF-1α (Chandel et al., 1998; 
Guzy and Schumacker, 2006). Furthermore, this stabilisation can be blocked with 
mitochondrial-targeted antioxidants (Chandel et al., 1998; Guzy and Schumacker, 
2006). Besides its ability to induce mitochondrial ROS formation, hypoxia can also 
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enhance iNOS expression. The promoter region of iNOS contains a hypoxic response 
element (HRE), and its expression can therefore be regulated by HIF-1α (Melillo et al., 
1995; Palmer et al., 1998). Furthermore, hypoxia-induced iNOS expression has been 
demonstrated in vivo (You and Kaur, 2000; Kaur et al., 2006a). It is of interest that 
hypoxia, NO and superoxide, are all associated with one another, such that NO can 
promote both hypoxia (Rees et al., 1998; Garedew and Moncada, 2008) and superoxide 
(Poderoso et al., 1996), whilst hypoxia can promote the formation of NO (Melillo et al., 
1995; Palmer et al., 1998; You and Kaur, 2000; Kaur et al., 2006) and superoxide 
production (Chandel et al., 1998; Chandel et al., 2000; Guzy and Schumacker, 2006). 
Thus this ‘toxic trio’ may not only lead to cell damage, but may also potentiate the 
toxicity via interacting with one another. The toxic effects of the hypoxia, NO and 
superoxide presumably spread to neighbouring tissue, potentially explaining why the 
lesion forms where it does. 
Collectively, the current findings suggest that hypoxia, NO and superoxide may 
work in concert to induce an energy deficit in vulnerable cells such as oligodendrocytes 
in the LPS dorsal column lesion. Oligodendrocytes, by virtue of their dependence on 
oxidative metabolism, large surface area, and high polyunsaturated fatty acid content, 
are presumably highly susceptible to such an insult. Indeed, oligodendrocytes are 
vulnerable to hypoxia (Husain and Juurlink, 1995; Back et al., 2002), in addition to NO 
(Mitrovic et al., 1994), and NO mediated damage. In an environment that is 
simultaneously governed by all three toxic mediators, one might suspect that 
oligodendrocytic mitochondria may become dysfunctional. This in part, is probably due 
to enhanced production of superoxide anion, and thereby peroxynitrite formation.  
Hypoxia has been found to increase the inhibitory effect of NO on mitochondria (Frost 
et al., 2005), and increase the formation of ROS, potentiating the extent of 
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mitochondrial dysfunction (Li and Jackson, 2002; Dada et al., 2003; Schumacker, 
2003). In the LPS dorsal column model, the oligodendrocytes reside in an actively 
inflammed environment, with large populations of iNOS positive cells. Therefore, there 
is increased potential for the formation of ROS/RNS, and hence, a scope for 
mitochondrial dysfunction. The ensuing mitochondrial damage would impinge on the 
ability of mitochondrial to produce ATP (Murphy, 2009), thereby leading to an energy 
deficit in affected oligodendrocytes, and demyelination. Despite these findings, 
however, a recent study has found that oligodendrocytes can survive without functional 
mitochondrial complex IV, and do so by increasing their glycolytic capacity 
(Fünfschilling et al., 2012). Although this novel finding has important implications for 
CNS metabolism, the study was carried out in normal animals, in which there would 
presumably be a continuous supply of nutrients required to sustain an increased 
glycolytic rate in oligodendrocytes. During neuroinflammation, however, the metabolic 
demand of the tissue may outweigh the supply of nutrients such as glucose that is 
essential for glycolysis. Thus, perhaps during pathological conditions, such as 
neuroinflammation, this mechanism of increasing the glycolytic capacity in 
oligodendrocytes to ensure survival would fail. 
 
3.4.4.0 Conclusion 
Demyelination in this proven model of the hypoxia-like, Pattern III MS lesion is 
preceded by labelling for hypoxia, NO and superoxide, all of which can compromise 
energy production. These toxic mediators can independently impair mitochondrial 
function, but they can also act synergistically to suppress ATP production further, 
eventually causing cell death.  The findings suggest that within the inflamed CNS, 
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oligodendrocytes are particularly vulnerable to an energy crisis that is mediated by this 
‘toxic trio’, resulting in ‘hypoxia-like’ demyelination. Furthermore, the 
pathophysiological alterations observed in some astrocytes, namely labelling for 
hypoxia, may be indicative of a role for dysfunctional astrocytes in the development of 
a demyelinating lesion. 
Clearly, the findings of this study warrant further research. Identifying the cause 
of hypoxia in these lesions, and the mechanisms through which it causes damage, may 
provide further insight into the sequence of events that lead to demyelination in MS. 
Thus therapeutic strategies targeted to increase oxygen delivery, inhibit iNOS and 
scavenge ROS, may prove beneficial in limiting the extent of structural damage. 
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CHAPTER FOUR 
 
VULNERABILITY OF THE CNS TO HYPOXIA 
 
4.1.0.0 INTRODUCTION 
The brain is a metabolically expensive organ, consuming 20% and 10% of the total 
oxygen (Afifi and Bergman, 2005) and glucose (McKenna et al., 2006), consumed by 
the body, respectively. Despite this, due to the toxicity of oxygen (Acker, 2005 ), many 
mechanisms exist not only to maintain low oxygen conditions in the brain during ‘rest’, 
but also to increase oxygenation during periods of activity (Allison et al., 2000). Thus, 
the oxygen tension of the brain is spatially and temporally heterogeneous. It seems 
reasonable to presume that due to the vascular architecture, limited glycogen stores, and 
other intrinsic characteristics, the brain is inherently susceptible to hypoxic insults. 
Indeed, cortical atrophy has been found in Everest climbers (8848m), and subcortical 
lesions in inexperienced climbers (Fayed et al., 2006).  In addition to such regional 
vulnerabilities, selective cellular vulnerabilities also exist. Neurons (Goldberg and Choi, 
1993) and oligodendrocytes (Husain and Juurlink, 1995; Lyons and Kettenmann, 1998) 
are particularly vulnerable to perturbations of oxygen concentration, compared with 
microglia and astrocytes, in culture (Lyons and Kettenmann, 1998). This selective 
vulnerability is thought to be due to differences in their metabolic make-up (Belanger et 
al., 2011), and susceptibility to oxidative stress, essentially due to cellular differences in 
the capacity to scavenge free radicals effectively (Juurlink et al., 1997).  
Although hypoxia is an important signal that regulates a wide range of 
physiological responses, it is also a feature of a number of pathological conditions, 
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including inflammation. However, the role hypoxia plays in such conditions is unclear. 
Hypoxia essentially results in the depletion of cellular ATP stores and a subsequent 
switch to anaerobic glycolysis, which requires a continuous supply of glucose. Given 
that vascular disruption and nutrient supply are frequently associated with 
inflammation, one can imagine that hypoxia may potentiate the inflammatory response, 
even in the CNS. Indeed, severe hypoxia is increasingly being recognised as a 
neuroinflammagen (Ock et al., 2005), with hypoxia-induced microglial activation 
suggested to contribute to neuronal damage in stroke as well as in neurodegeneration 
(Gonzalez-Scarano and Baltuch, 1999). Despite this, little is known about the effects of 
acute, moderate hypoxia on the naïve spinal cord. MS lesions, characterised by chronic 
neuroinflammation, show a predilection for the spinal cord. The current study therefore 
aims to investigate the histopathological correlates of acute hypoxia in the rat spinal 
cord, to gain an insight into how it may contribute to neuropathology. 
  
 4.1.1.0 Aims 
1. Identify regions of vulnerability to hypoxia, in the rat spinal cord. 
2. Identify cellular vulnerabilities to hypoxia. 
3. Determine histopathological changes in response to acute hypoxia. 
 
4.1.2.0 Hypothesis 
Regional and cellular vulnerabilities to hypoxia exist in the rat spinal cord. 
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4.2.0.0 MATERIALS AND METHODS 
4.2.1.0 Animals 
Female Dark Agouti (DA) rats (163.7g ±7.8, mean ± standard deviation; SD) were 
exposed to normobaric hypoxia by substituting oxygen with nitrogen using a ProOx 110 
controller (Biospherix Ltd, Salem, NY) in a closed hypoxia chamber (Biospherix Ltd). 
The hypoxic environment was gradually introduced by decreasing the oxygen from 21 
to 10% over 20 minutes, prior to continuous exposure to 10% oxygen for 6 hours (h) (n 
=3), 24 h (n = 6), 48 h (n = 6) and 72 h (n = 6). Control animals were kept in the same 
chamber, on different days, but exposed to room air (21% oxygen) (n = 6). Food and 
water were available ad libitum. 
 
4.2.2.0 Tissue Processing 
A pimonidazole (HPI Inc, Burlington, MA) dose of 180 mg/kg body weight was 
administered intravenously into the saphenous vein of all animals, under light, brief 
anaesthesia, with 2% isoflurane, 4 hours prior to perfusion. All animals were terminally 
anaesthetised with isoflurane, and trans-cardially perfused with phosphate-buffered 
saline, and then 4% paraformaldehyde (PFA) for fixation. To visualise the spinal cord 
vasculature, animals exposed to 6 hours of 10% oxygen were additionally perfused with 
the fluorescent carbocyanine lipophilic dye, DiI (Molecular Probes, Eugene, OR) prior 
to PFA perfusion, as previously described (Li et al., 2008). The spinal cords were 
harvested and post-fixed in 4% PFA overnight, prior to cryoprotection in 30% sucrose. 
The spinal cords were then segmented into 1cm pieces, and frozen by immersion in 
isopentane pre-cooled in liquid nitrogen, and samples stored at -80
0
C until cut. Twelve 
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micron thick transverse sections (or 20 µm-thick sections for the study of the 
vasculature) were cut with a cryostat (Leica Microsystems, Germany) at -20
0
C, and 
thaw-mounted onto glass slides. The sections were stored frozen at -20
0
C until use. 
  
4.2.3.0 Histology 
 4.2.3.1 IHC/IF 
Cyrosections (12μm thick) were air dried and examined immunohistochemically or 
immunofluorescently for a range of markers (Table 4.2.3.1), as described previously 
(section 2.2.3.1). 
4.2.3.2 Double label IHC  
Double label IHC with anti-pimonidazole and anti-RECA1 antibodies was performed 
on tissue from animals exposed for 6 hours to 10% oxygen and perfused with DiI, to 
identify areas of vulnerability to hypoxia. Double label IHC with anti-pimonidazole and 
OX-6 antibodies, was also performed on tissue from animals exposed to 24, 48 and 72 
hours 10% oxygen, to determine whether there was a tendency for cells capable of 
antigen presenting to become activated in hypoxia-susceptible areas of the cord. 
Sections of spinal cord containing vasculature labelled with the lipophillic dye 
DiI (Invitrogen, UK), were imaged using a LSM 5 Pascal confocal microscope (Zeiss), 
prior to proceeding with the IHC protocol. The sections were then processed as above 
(section 2.2.3.1) with mouse monoclonal antibody against pimonidazole. After 
developing with DAB, the sections were rinsed in running tap water before incubating 
in 3% H2O2 in PBS for 20 minutes. Next, the sections were incubated with avidin for 15 
minutes, briefly rinsed in PBS, and then incubated with biotin for 15 minutes 
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(Avidin/Biotin Blocking kit; Vector Laboratories Ltd). PBST (0.1% BSA in PBS 
containing 0.2% Triton-X 100) washes were performed between each step.  Sections 
were incubated with blocker (10% horse serum in PBS containing 0.1% Triton X-100) 
for at least 30 minutes before incubating with either mouse anti-RECA1 or mouse OX-6 
primary antibodies, overnight at 4
o
C. The following day, the sections were processed as 
normal by incubating with biotinylated horse anti-mouse secondary antibody followed 
by incubation with ABC. Finally, RECA-1 and/or OX-6 immunoreactivity was 
developed using DAB-Ni (Vector Labs), which yields a black colour, followed by 
dehydration and mounting, as described above. 
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Table 4.2.3.1: Antibody details for IHC/IF 
Antibody 
Target 
 
Isotype 
Pre- 
Treatment 
Blocker Dilution Supplier 
Mouse 
Hypoxyprobe-1-
Mab Anti-
pimonidazole 
Pimonidazole 
adducts 
Mouse 
IgG1 
NaBH4 
0.25% casein (VWR 
International, UK), 
in PBS containing 
0.1%  Triton X-100 
1:500 
 
HPI Inc 
 
 
Mouse Anti- 
Ox-6 
MHC-II Ia 
Mouse 
IgG1 
N/A 
5% horse serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
10% horse serum for 
double label IHC 
1:600 
 
Abcam 
 
Mouse 
Anti-RECA-1 
Rat Endothelial 
Cells 
Mouse 
IgG1 
N/A 
5% horse serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
10% horse serum for 
double label IHC 
1:200 Abcam 
Mouse 
Anti-rat ED1 
 
Activated 
Macrophages 
/Microglia 
(phagocytes) 
Mouse 
IgG1 
N/A 
 
5% horse serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
 
1:200 
Serotec 
 
Mouse Anti-
GFAP 
Astrocytes 
Mouse 
IgG1 
N/A 
 
5% horse serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
 
1:200 Sigma 
Rabbit Anti-
pimonidazole 
Pimonidazole 
adducts 
Rabbit  
IgG 
NaBH4 
 
5% goat serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
 
1:200 
 
HPI Inc 
 
 
Rabbit Anti-
TLR4 
Toll-like receptor 
4 
 
 
IgG 
 
 
Target retrieval 
solution, pH6.1 
(DAKO) at 40oC 
for 40 minutes 
 
 
5% goat serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
 
1:200 Abcam 
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Rabbit Anti-
inducible nitric 
oxide synthase 
(iNOS) 
iNOS 
(activated 
macrophages/ 
microglia) 
Rabbit 
IgG 
N/A 
 
5% goat serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
 
1:200 
BD 
Transductions 
Rabbit Anti-
GFAP 
Astrocytes 
Rabbit 
IgG 
N/A 
 
5% goat serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
 
1:500 DAKO 
 
Rabbit Anti- 
carbonic 
anhydrase 2 
(CA2) 
 
Oligodendrocytes 
Rabbit 
IgG 
NaBH4 
 
5% goat serum 
mixed in PBS 
containing 0.1% 
Triton X-100 
 
1/200 
Kindly provided 
by N. Gregson 
Rabbit  
Anti-NG2 
Chondroitin 
sulphate 
proteoglycan 
(oligodendrocyte 
precursor cells) 
 
 
IgG 
 
Target retrieval 
solution, pH6.1 
(DAKO) at 40oC 
for 40 minutes 
 
 
5% goat serum 
(Sigma) in PBS 
containing 0.1% 
Triton X-100 
 
1:500 Millipore 
Goat Anti-P-
Selectin 
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4.2.4.0 3D Reconstruction  
In order to determine the distribution of pimonidazole labelling in relation to the 
vasculature, a 3D reconstruction was performed on serial sections that were double 
labelled with anti-pimonidazole and anti-RECA1 antibodies using a software 
programme known as Reconstruct (Fiala, 2005). Briefly, micrographs of the serial 
sections, of a region of interest, were loaded into the software (Figure: 4.2.4.0 A), prior 
to manual alignment of individual sections. Next, areas of pimonidazole labelling and 
the vasculature were manually delineated in each section (Figure: 4.2.4.0 B-C), and 
linked to one another, so that one vessel or pimonidazole region in one section was 
recognised in an adjacent section. DiI confocal images were then overlaid onto their 
respective DAB-labelled sections to confirm whether all the delineated vessels were, in 
fact vessels. Subsequently, the sections were reconstructed into a 3D scene, using the 
software, and the distances between individual vessels and pimonidazole labelled 
regions were calculated.  
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Figure 4.2.4.0: 3D reconstruction of serial histological sections  
(A) Serially immunolabelled sections (pimonidazole: brown, RECA-1: black) were photographed and 
imported into the software. (B) Sections were manually aligned, and pimonidazole positive regions 
(yellow), and RECA-1
+ 
vessels (blue), delineated. (C) This was repeated for every section to enable 
accurate reconstruction. 
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 4.2.5.0 Microscopy 
4.2.5.1 Light Microscopy and Quantification 
Tissue stained with DAB was viewed using an Axiophot light microscope (Zeiss, 
Germany) and pictures taken with a Nikon D300 camera (Nikon, USA). The 
illumination was kept constant throughout image acquisition. Analysis of the intensity 
of the labelling with pimonidazole was carried out by tracing around the spinal cord 
sections (white and grey matter, and grey matter alone), and measuring the pixel 
intensity using Image J (National institute of health, USA). Quantification of OX-6 
positive cells, and phenotype, was carried out manually, at different levels of the cord 
using Image J. Quantification of all other markers was carried out using the ‘analyse 
particles’ tool, on thresholded images, to determine the number, and occasionally the 
size, of positively labelled cells. The same criteria were used for each image, and area 
measurements were carried out concurrently.  
 
 4.2.5.2 Confocal Laser Microscopy 
Confocal fluorescent images were obtained using a Zeiss LSM5 Pascal confocal 
microscope, with a 40x objective. Excitation wavelengths of 488 nm and 543 nm were 
provided by argon and helium-neon gas lasers, respectively. Emission filters BP505-530 
and LP560 were used for obtaining the images. 
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4.2.6.0 Statistical Analysis  
All data were tested for normality using either the Kolmogorov-Smirnov or the Shapiro-
Wilk test, and the stability of variances assessed using the Levene’s test. Data that were 
not normally distributed were evaluated using non-parametric statistics as indicated. P-
values of p<0.05 (*), p<0.01 (**) and p<0.001 (***), were considered as statistically 
significant.  All statistical analyses were carried out using SPSS version 14.0 (USA). 
 
4.2.6.1 Statistical Analysis of Pimonidazole Intensity 
The pixel intensity of the pimonidazole labelling was normally distributed in all spinal 
cord sections examined.  Therefore, the percentage of pixels labelled with an intensity 
greater than the control mean plus one standard deviation were counted and compared 
to the appropriate vertebral segment-matched control using a two-way ANOVA; the 
room air treatment group and saline-injected group served as controls in each of the 
respective experiments.  
 
4.2.6.2 Statistical Analysis of Other Labels 
The data obtained from sections labelled with RECA-1 followed a normal distribution, 
therefore, the independent t-test was used to compare the RECA-1 cell density, at each 
spinal cord segment, between the four groups (24h 10%, 48h 10%, 72h 10% and 21% 
oxygen) in the acute hypoxia study. The data obtained from sections labelled with OX-6 
did not follow a normal distribution, and were therefore analysed using the Mann-
Whitney U test. A repeated measures ANOVA was used to compare the cumulative 
RECA-1 and OX-6 cell densities, between 10% and 21% oxygen. Regression analysis 
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followed by a Mann-Whitney U test (pairwise comparison) was used to compare the 
mean cell density of IBA, TLR4 and NG2 data between the two experimental groups. 
Pearson’s Correlation was used to determine if there was any correlation between the 
intensity of pimonidazole labelling and RECA cell density.  
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4.3.0.0 RESULTS 
4.3.1.0 Exposure to mild hypoxia induces weight loss in DA rats 
Exposure of DA rats to 10% oxygen for 24, 48 or 72 hours induced loss of body weight 
(Figure: 4.3.1.0). The weight loss, recorded as a percentage of the initial body weight, 
increased with the duration of exposure to 10% oxygen. Following 24 hours of 
sustained 10% oxygen exposure, an average of 5% of the initial body weight was lost, 
increasing to 7% and 9% following 48 and 72 hours of 10% oxygen, respectively. No 
weight loss was observed in the animals exposed to 21% oxygen; in fact they gained 1% 
of their initial body weight.  
 
 
Figure 4.3.1.0: Effect of hypoxia on body weight 
A graph showing the percentage loss in body weight in the experimental groups. Values are means. N = 6 
per group. 
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4.3.2.0 Pimonidazole labelling is increased in animals exposed to 10% 
oxygen 
Reducing the inspired oxygen to 10% revealed regions of clear pimonidazole labelling, 
and thus regions seemingly vulnerable to hypoxia in the rat spinal cord. The white 
matter of the spinal cord was found to be particularly vulnerable to decreases in inspired 
oxygen, with the base of the dorsal column, the ‘wing’ tips, the areas just below the 
dorsal horns, and a ‘halo’ of white matter surrounding the grey matter (Figure: 4.3.2.0 
A) labelling most strongly for pimonidazole.  Such labelling was frequently, if not 
always, present in all animals exposed to 10% oxygen for 6 hours (Figure: 4.3.2.0 B). 
At the base of the dorsal column, these areas of pimonidazole labelling were 
approximately 225-900 µm in length longitudinally, whereas, in the ‘wing’ tips, the 
areas of intense labelling were approximately 225-300 µm in length longitudinally. 
Areas of intense pimonidazole labelling were not observed in the white matter of 
animals kept at 21% oxygen (Figure: 4.3.2.0 B). 
 To determine the spatial distribution of labelling for pimonidazole in relation to 
the location of vessels, double labelled IHC was carried out on serial spinal cord 
sections from animals exposed to 10% oxygen for 6 hours.  3D reconstruction of a 1 
mm length of dorsal column spinal cord tissue, labelled for pimonidazole, RECA1 and 
DiI, the latter administered transcardially during perfusion, revealed that these pockets 
of pimonidazole labelling actually occur in between vessels (Figure: 4.3.2.0 C), and 
particularly in areas where the vessel density is low, such as the ‘wing-tip’ areas and the 
base of the dorsal columns.  
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Figure 4.3.2.0: Pimonidazole labelling following 6h 10% oxygen 
(A) Schematic showing areas of the spinal cord that frequently label with pimonidazole following 
exposure to 10% oxygen delineated in brown (WT: ‘wing-tip’ regions of the dorsal column; B: base of 
the dorsal column; AP: white matter directly below the superficial dorsal horns; H: a ‘halo’ of white 
matter surrounding the grey matter. (B) Spinal cord sections from animals exposed to 10% or 21% 
oxygen, labelled with pimonidazole, showing positive labelling for pimonidazole in the animal exposed to 
10% oxygen, and negative labelling in the animal exposed to 21% oxygen. Scale bar 500µm. (Ci) 
Sections of spinal cord from an animal exposed to 10% oxygen, and labelled with pimonidazole (brown) 
and RECA-1 (black), showing that areas of intense pimonidazole labelling at the base if the dorsal 
column, occur between vessels. Bar 200 µm. Inset shows of an area of pimonidazole labelling (yellow 
outline), superimposed on an image with DiI labelled vessels (red fluorescence), showing that areas of 
pimonidazole labelling appear to occur in-between vessels (blue circles/ red fluorescence).  Image taken 
from the base of the dorsal column. (D) 3D reconstruction of the dorsal column from an animal exposed 
to 10% oxygen, showing the location of areas of intense pimonidazole labelling (yellow), and thus the 
increased vulnerability of the base of the dorsal column to hypoxia. The illustration on the left shows the 
dorsal column as viewed from the head to the tail, while the illustration on the right shows the dorsal 
column as viewed from the side. Micrographs are representative. 
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4.3.3.0 Acute hypoxia and the spinal cord 
 
4.3.3.1 Pimonidazole labelling occurs in a spatio-temporal manner in animals 
exposed to 10% oxygen 
 
To identify areas of vulnerability to hypoxia in animals exposed to 24, 48 and 72 hours 
of 10% oxygen, pimonidazole IHC was carried out on spinal cord sections at different 
vertebral levels. As described in section 4.3.2.0, both grey and white matter labelling for 
pimonidazole was observed (Figure: 4.3.3.1 A). Specifically, two patterns of white 
matter labelling emerged, namely cell-specific labelling (see section 4.3.3.2) and foci of 
pimonidazole labelling (see section 4.3.3.3) (Figure: 4.3.3.1 A). No such labelling was 
observed in animals exposed to 21% oxygen (Figure: 4.3.3.1 A). The mean differences 
in the intensity of the pimonidazole labelling of the total cord (grey matter and white 
matter combined), and the white matter alone, in animals exposed to 10% or 21% 
oxygen were statistically significant (p = 0.04, p = 0.01, respectively). However, there 
was not a statistically significant difference in the intensity of pimonidazole labelling of 
the grey matter (p= 0.088), between the two groups. The length of exposure to 10% or 
21% oxygen did not affect the extent of pimonidazole labelling (total: p = 0.998; white 
matter: p = 0.891; grey matter: p = 0.915). In all animals exposed to 10% oxygen, there 
appeared to be a rostro-caudal gradient of pimonidazole labelling, regardless of the 
duration of exposure (Figure: 4.3.3.1 B-D). When taking into account the labelling of 
the white matter and grey matter combined, the intensity of pimonidazole labelling 
increased in the thoracic and cervical spinal cord (Figure: 4.3.3.1 B). A similar pattern 
was found when just measuring the intensity of the white matter, however, the increased 
labelling within these two areas of the spinal cord was more prominent (Figure: 4.3.3.1 
C). The labelling for pimonidazole in the grey matter, however, showed a noticeable 
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decrease in the thoracic spinal cord (Figure: 4.3.3.1 D). Interestingly, the different 
spinal cord levels examined showed a different response to 10% oxygen. The lumbar 
spinal cord was most affected by 72 hours of 10% oxygen, whereas the upper thoracic 
spinal cord was most affected by 24 hours of 10% oxygen (Figure: 4.3.3.1 B-D).  
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Figure 4.3.3.1: Pimonidazole labelling following exposure to 10% oxygen 
(A) Micrographs of sections of spinal cord from the upper lumbar and mid-thoracic levels from animals 
exposed to either lifetime 21%, 24h 10%, 48h 10% or 72h 10%, oxygen, labelled with pimonidazole. 
Pimonidazole labelling is increased following exposure to 10% oxygen, in both the white and grey matter. 
Scale bar 500 µm. (B-C) The intensity of pimonidazole labelling varies rostro-caudally in animals 
exposed to 10% oxygen. The intensity of pimonidazole labelling in the grey matter is increased in the 
upper lumbar, lower thoracic and mid-cervical cord, but is considerably decreased in the mid-thoracic 
region, compared with 21% control. (B). There is also a shift from increased labelling in the caudal 
portions of the cord in animals exposed to 10% oxygen for longer periods, to increased labelling in the 
rostral portions of cord in animals exposed to 10% oxygen for shorter periods. (C) Labelling in the white 
matter, is increased in the upper lumbar, mid-thoracic and mid-cervical cord, but decreases in the lower 
cervical cord. Values are means ± S.D. N=6 per group. 
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4.3.3.2 Cell-specific labelling with pimonidazole, following acute hypoxia 
 
Besides the grey matter labelling for pimonidazole, a number of cells within the spinal 
white matter also labelled for pimonidazole (Figure: 4.3.3.2 A), following exposure to 
acute hypoxia. The positive cells, morphologically, had the appearance of glia, and 
endothelial cells, therefore double label immunofluorescence was performed to 
determine their identity.  
 Arrays of cells labelled positive for pimonidazole in longitudinal sections 
following exposure to 10%, oxygen at all time points, but co-localisation with GFAP 
was not observed suggesting that the labelled cells were not astrocytes (Figure: 4.3.3.2 
B). Similarly, microglia did not co-localise with pimonidazole at any time point 
following exposure to 10% oxygen (Figure: 4.3.3.2 C). However, the microglia were 
found to be closely associated with the pimonidazole-positive cells, often adjacent to, or 
in between, the array of positively labelled cells (Figure: 4.3.3.2 C). Further double 
label immunofluorescence with an antibody directed against oligodendrocytes 
confirmed that these pimonidazole-positive cells were oligodendrocytes (Figure: 4.3.3.2 
D). Beautiful arrays of pimonidazole and CA2 positive cells were observed, at all time 
points following exposure to 10% oxygen. Most, if not all, oligodendrocytes were found 
to co-label for pimonidazole. Some endothelial cells also co-labelled with pimonidazole 
in animals exposed to 10% oxygen, at all time points examined (Figure: 4.3.3.2 E).     
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Figure 4.3.3.2: Cell types that label with pimonidazole in the white matter  
(A) Transverse spinal cord section from an animal exposed to 10% oxygen, labelled with pimonidazole. 
The micrograph shows intense cellular labelling in the dorsal column white matter at high magnification. 
Scale bar 25μm. (B-E) Confocal laser images of spinal cord sections double-labelled to determine the 
cellular identity of the cells that label for pimonidazole in the dorsal columns. (B) Double label 
immunofluorescence with anti-pimonidazole (green) and anti-GFAP (red) revealed that astrocytes do not 
tend to label for pimonidazole following exposure to 10% oxygen, at any of the time points examined. (C) 
Similarly, microglia (red) also do not label with pimonidazole (green). Rather, the microglia are found in 
very close proximity to pimonidazole positive cells (arrows). (D) Double label immunofluorescence with 
anti-pimonidazole (green) and anti-CA2 (red), revealed that most, if not all, oligodendrocytes label 
intensely for pimonidazole, following exposure to 10% oxygen, at all time points examined. (E) Some 
endothelial cells (green) were also found to label with pimonidazole (red). Scale bar 100μm. All 
micrographs are representative. 
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4.3.3.3 What cells label in intense pimonidazole white matter foci? 
In addition to the cell-specific labelling with pimonidazole (section 4.3.3.2), foci of 
pimonidazole labelling were also evident within the white matter, as described in 
section 4.3.2.0, following exposure to 10% oxygen. Microscopically, these foci 
comprised of a number of intensely labelled cells, surrounded by a ‘halo’ of intensely 
labelled tissue (Figure: 4.3.3.3 A). Morphologically, the positively labelled cells, within 
the foci of pimonidazole labelling, had the appearance of oligodendrocytes and 
microglia. Thus, double label immunofluorescence was performed, to identify these 
cells.  
 Some minimal overlap of labelling was observed with GFAP, primarily with 
astrocytic processes (Figure: 4.3.3.3 B-top), however, no clear co-localisation was 
observed with either microglia or oligodendrocytes (Figure: 4.3.3.3 B-middle, bottom). 
Rather, a decrease in cellular labelling for oligodendrocytes was observed in these foci.  
Further double label fluorescence studies performed with NG2, an antibody directed 
against oligodendrocyte precursor cells (OPCs), revealed that the cells that label so 
intensely for pimonidazole in the white matter foci were generally NG2 positive cells 
(Figure: 4.3.3.3 C). Morphologically, these cells resemble resting microglia, with long, 
slender processes. Despite the punctuate cellular co-localisation in the centre of the 
white matter foci, a loss of NG2 immunoreactivity, immediately adjacent to, and 
surrounding, the NG2/pimonidazole positive cells, was often frequently observed 
(Figure: 4.3.3.3 D). 
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Figure 4.3.3.3: Cell types that label in intense pimonidazole white matter foci 
(A) Transverse spinal cord section from an animal exposed to 10% oxygen. The micrograph shows an 
area of intense pimonidazole labelling in the dorsal column white matter, at high magnification. Scale bar 
25 μm. (B) Double label immunofluorescence with markers for astrocytes (GFAP; red), microglia (IBA; 
red) and oligodendrocytes (CA2; red), revealed that none of these cell types co-labelled with 
pimonidazole in these intense foci. (C) Co-labelling with an anti-NG2 antibody (red), revealed that 
oligdendrocyte precursor cells label for pimonidazole in intense pimonidazole white matter foci. 
Moreover, there is a loss of NG2 immunoreactivity in the vicinity immediately surrounding the NG2-
pimonidazole co-labelled cell (white dashed line), at all time points examined. Scale bar 100μm. All 
micrographs are representative. 
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4.3.4.0 The effects of acute hypoxia on neurons 
In 21% control animals, neurons did not label with pimonidazole, however, following 
exposure to 10% oxygen, intense neuronal labelling with pimonidazole was observed 
(Figure: 4.3.4.0). The intensity of labelling was not dependent on the duration of 
exposure to 10% oxygen, but rather on the decrease in oxygen availability alone. The 
labelling was mainly localised to the cytoplasm of neurons, but labelling of the 
surrounding extracellular matrix was also observed.  
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Figure 4.3.4.0: Pimonidazole labelling of neurons following acute hypoxia. 
Transverse spinal cord sections from animals exposed to 21% oxygen, and 24h, 48h and 72h 10% 
oxygen, labelled with pimonidazole. The micrographs show the ventral horn grey matter at high 
magnification. There is no apparent neuronal labelling in the grey matter of the 21% oxygen control, 
however there is a considerable amount of labelling within the neurons and the surrounding parenchyma 
of animals exposed to 10% oxygen. Scale bar 25 μm. All micrographs are representative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    21% Oxygen            24h 10% Oxygen        48h 10% Oxygen               72h 10% 
Oxygen 
 
 
192 
 
4.3.5.0 Microglial changes in response to acute hypoxia 
 
4.3.5.1 Exposure to acute hypoxia causes an increase in microglial number 
The microglial cell density, as indicated by IBA immunoreactivity, was elevated 
following exposure to 10% oxygen (Figure: 4.3.5.1). This initial increase was evident 
within the first 24h of exposure to 10% oxygen (p< 0.001). Subsequently, following 
exposure to 48h (p = 0.012) and 72h (p<0.001) 10% oxygen, the number of microglial 
cells did not increase further, but remained somewhat stable. A range of different 
morphological phenotypes was observed following exposure to 10% oxygen, ranging 
from ramified cells to amoeboid cells.  
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Figure 4.3.5.1: IBA labelling in animals exposed to acute hypoxia 
Graph showing the average IBA cell densities in animals exposed to either room air or 10% oxygen, for 
different durations. Acute hypoxia increases the density of IBA-positive cells, compared with 21% 
control animals. Values are mean ± S.E.M. Statistical significance was determined by a Mann-Whitney U 
test, * p<0.05, *** p<0.001. N=6 per group 
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4.3.5.2 Exposure to 10% oxygen causes an increase in the number of MHC-II 
expressing cells 
To identify whether modulating the oxygen concentration of inspired gas to 10% can 
initiate an inflammatory response, we looked for evidence of microglial activation. 
Immunohistochemistry with an anti-MHC class II antibody (OX-6) revealed that these 
molecules are constitutively expressed in the spinal cord of all animals, i.e. those 
exposed to 10%, or 21% oxygen (Figure: 4.3.5.2 A-C). However exposure to 10% 
oxygen significantly increased the number of cells expressing MHC class II (Figure: 
4.3.5.2 A-C). In all the different spinal levels examined, there was a significant increase 
in the number of cells that labelled positively for MHC class II in animals exposed to 
24h of 10% oxygen (upper-lumbar: p = 0.014; mid-thoracic: p = 0.014; lower-cervical: 
p = 0.011; mid-cervical: p = 0.011), 48h of 10% oxygen (upper-lumbar:  p = 0.033; 
mid-thoracic p = 0.011; lower-cervical: p = 0.014; mid-cervical: p = 0.011), and 72h of 
10% oxygen (upper-lumbar: p = 0.019; mid-thoracic: p = 0.011; lower-cervical: p = 
0.027; mid-cervical: p = 0.014) compared with 21% oxygen control animals (Figure:. 
4.3.5.2 C). These MHC class II expressing cells were primarily located in white matter, 
predominantly that of the dorsal and ventral columns, with a fewer number of cells in 
the lateral columns (Figure: 4.3.5.2 A). However a few MHC class II-expressing cells 
were also found in the grey matter, with some adjacent to motor neurons in the ventral 
horns (Figure: 4.3.5.2 Aii). Although the number of MHC class II-expressing cells was 
found to decrease with the duration of exposure to 10% oxygen, their morphology 
appeared to change with longer exposures. Following 24 hours of 10% oxygen 
exposure, ramified MHC class II expressing cells with long, slender processes were 
observed, in addition to very faint labelling of what appeared to be cellular processes 
(Figure:. 4.3.5.2 Di; Type I). As the duration of exposure to 10% oxygen was increased, 
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there was also a progressive increase in the proportion of MHC class II positive cells 
displaying a more ‘activated’ phenotype: a ramified morphology with no apparent cell 
body labelling (Figure: 4.3.5.2 Dii; Type II), a ramified morphology with labelling of 
the cell body (Figure: 4.3.5.2 Diii; Type III), rod-like cells with elongated cell bodies 
and bushy processes (Figure: 4.3.5.2 Div; Type IV), or rounder, amoeboid-like cell 
bodies with thick retracted processes (Figure: 4.3.5.2 Dv; Type V, Figure: 4.3.5.2 E). 
This array of microglial phenotypes was observed primarily in the white matter. Double 
label immunofluorescence confirmed that the MHC class II-expressing cells were 
microglia (Figure: 4.3.5.2 F). Occasionally, MHC class II positive cells were evident in 
regions that labelled for hypoxia (Figure: 4.3.5.2 G), although this was fairly rare. 
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Figure 4.3.5.2: MHC class II expression following exposure to acute hypoxia 
(Ai) Micrographs of spinal cord sections from animals exposed to either 21% oxygen, 24h 10% oxygen, 
48h 10% oxygen or 72h 10% oxygen, labelled with OX-6, a marker of MHC class II molecules, and 
counterstained with haematoxylin. Increased expression of MHC class II molecules can be seen in all 
animals exposed to 10% oxygen, in the dorsal (scale bar 200 µm), ventral ( scale bar 200 µm) and lateral 
( scale bar 100 µm) columns, compared to 21% controls. (Aii) MHC class II positive cells can also be 
found adjacent to motor neurons in the grey matter of animals exposed to 10% oxygen (scale bar 25 µm). 
(B) Graphical representation comparing the MHC class II cell density between animals exposed to 10% 
oxygen for 24h, 48h,and 72h, and animals exposed to 21% oxygen. Values are means ± SD (n=6 per 
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group). Statistical differences were determined by a repeated measures ANOVA, *** p<0.001. (C) The 
rostro-caudal distribution of MHC class II positive cells, showing that the largest numbers of MHC class 
II positive cells are present in the mid-thoracic and lower cervical cord. Values are means ± SEM. (D) 
Morphological classification of MHC class II positive cells. (Type I; i) Faint OX-6 labelling of cellular 
processes, (Type II; ii) ramified cells with long, slender processes, but no apparent cell body labelling, 
(Type III; iii) rounded cell bodies that label with OX-6, cells have long, slender processes, (Type IV; iv) 
rod-like cells, with elongated cell bodies, and long processes, and (Type V; v) amoeboid-like cell bodies 
with retracted, thick, or no processes. Scale bar 25µm. (E) Graphical representation of MHC class II cells 
based on their morphological phenotype. Values are mean percentage. (F) Confocal microscopy of double 
label immunofluorescence showing co-localisation of OX-6 (green) IBA (red), confirming that the MHC 
class II positive cells are microglia/macrophages, most probably microglia. Scale bar 200µm. (G) 
Micrographs of spinal cord sections from animals exposed to 10% oxygen, showing MHC class II 
positive cells (black) in areas that label intensely for pimonidazole (i: arrows) and areas that do not label 
for pimonidazole (ii). Scale bar 25 µm. All Micrographs are representative.  
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4.3.5.3 Microglia in animals exposed to 10% oxygen do not express the 
phagocytic marker ED1 or iNOS 
As microglia in animals exposed to 10% oxygen appeared to express MHC-II at 
increased levels compared with control animals exposed to 21% oxygen, we sought 
identify their activation status further. Immunohistochemistry with an antibody against 
ED1, a marker of phagocytic cells, revealed that microglia in the spinal cord of animals 
exposed to 10% oxygen for 24, 48 and 72 hours do not express the ED1 antigen, thus 
there was no difference between animals exposed to 10% oxygen and animals exposed 
to 21% oxygen with respect to ED1 expression (Figure: 4.3.5.3 A). Similarly, labelling 
for iNOS, another marker of microglial activation, revealed that exposure to acute 
hypoxia did not induce the expression of iNOS (Figure: 4.3.5.3 B). 
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Figure 4.3.5.3: ED1 and iNOS labelling following exposure to 10% hypoxia 
(A) Transverse spinal cord sections from animals exposed to 21% or 10% oxygen, labelled with an anti-
ED1 antibody, and counterstained with hematoxylin. Micrographs show the dorsal column region of the 
cord, revealing that exposure to 10% oxygen does not induce ED1 expression. Scale bar 200μm. (B) 
Labelling with an anti-iNOS antibody also revealed that iNOS expression is not induced following 
exposure to acute hypoxia. Scale bar 500μm. All micrographs are representative.  
 
 
 
 
 
 
 
 
 
        21% Oxygen     24h 10% Oxygen       48h 10% Oxygen          72h 10% Oxygen 
E
D
1
 
iN
O
S
 
A 
B 
 
 
202 
 
4.3.5.4 Acute hypoxia results in an increase in white matter TLR4 expression 
Exposure to acute hypoxia resulted in a statistically significant increase in TLR4 
expression in the white matter (48 hours 10% oxygen p = 0.050; 72 hours 10% oxygen 
p<0.001). Expression was particularly evident microscopically, with the intensity of 
TLR4 immunoreactivity progressively increasing with the duration of exposure to 10% 
oxygen (Figure: 4.3.5.4 A). Moreover, the density of TLR4-positive cells increased in a 
linear manner following exposure to 10% oxygen (Figure: 4.3.5.4 B). TLR-4 positive 
cells morphologically resembled ramified microglia, with round cell bodies and long 
slender, arborous processes. 
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Figure 4.3.5.4: The effects of acute hypoxia on TLR4 expression 
(A) Micrographs of spinal cord sections from animals exposed to 21% oxygen, or 24h, 48h or 72h 10% 
oxygen, labelled with an anti-TLR4 antibody. In 21% oxygen controls, there is some faint labelling of 
TLR4 positive cells, however, following exposure to 10% oxygen, there is increased expression of TLR4, 
indicated by the intensity of the labelling. Scale bar 25 μm. (B) Graph showing the TLR4 cell density is 
most increased following exposure to 72h 10% oxygen. Values are mean ± S.E.M, n=6 per group. 
Statistical significance was determined by a Mann-Whitney U test, * p<0.05, *** p<0.001. N=6 per 
group. All micrographs are representative. 
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4.3.6.0 Effects of acute hypoxia on oligodendrocyte cell lineage 
 
4.3.6.1 NG2-expressing cells and hypoxia 
OPCs were found to label particularly intensely for pimonidazole, therefore their 
response to acute hypoxia was investigated. In control animals breathing room air 
(21%), NG2-positive cells were plentiful in number, scattered throughout the spinal 
parenchyma. Morphologically, they resembled resting microglia, with small cell bodies 
and ramified, arborous processes (Figure: 4.3.6.1 A). Although exposure to 10% oxygen 
did not result in a dramatic change in NG2 cell density, except for at 72 hours 10% 
oxygen (p = 0.016) (Figure: 4.3.6.1 A, B), some NG2 positive cells became 
progressively hypertrophied as the duration of exposure to 10% increased (p< 0.001) 
(Figure: 4.3.6.1 A, C). The hypertrophied state was characterised by an enlarged, 
swollen cell body, with thick retracted processes. Thus, by 72h of exposure to 10% 
oxygen, the average size of the NG2 cells was more than double that in 21% control 
animals (Figure: 4.3.6.1 C). 
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Figure 4.3.6.1: The effects of acute hypoxia on oligodendrocyte precursor cells  
(A) Transverse spinal cord sections from animals exposed to 21% oxygen, or 24h, 48h, or 72h 10% 
oxygen, labelled for NG2. Micrographs show the dorsal column white matter at high magnification. NG2 
cell density does not seem to change in response to acute hypoxia; however, the cells seem to become 
more hypertrophied and amoeboid. Scale bar 25µm. (B) Graph showing there is no substantial change in 
NG2 cell density following exposure to 10% oxygen at any of the time points examined. Values are 
means ± S.E.M. (C) Graph of the average NG2 cell size showing a proportional increase in cell size with 
duration of hypoxia. Values means ± S.E.M. Statistical significance was determined by a Mann-Whitney 
U test, * p<0.05, *** p<0.001. N=6 per group. All micrographs are representative. 
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4.3.6.2 The expression profile of NG2 following acute hypoxia 
Besides OPCs, NG2 has also been described to be expressed by microglia and pericytes 
(Dore-Duffy et al., 2006; Moransard et al., 2011), therefore, double label 
immunofluorescence was performed to determine whether acute hypoxia had an effect 
on the expression profile of NG2. In animals breathing room air, NG2 was not found to 
co-localise with astrocytes (Figure: 4.3.6.2 A), microglia (Figure: 4.3.6.2 B) or 
endothelial cells (Figure: 4.3.6.2 C). In these animals, some overlap of NG2 and GFAP 
immunofluorescence was observed (Figure: 4.3.6.2 A), however, this appeared to be a 
close association of two distinct cell types, rather than co-localisation per se. Such an 
association was also observed in animals exposed to 10% oxygen, in which the 
hypertrophied NG2-positive cells were often found surrounding astrocytes (Figure: 
4.3.6.2 A). As with the 21% control animals, NG2 was not found to co-localise with any 
of the cell types in animals exposed to 10% oxygen (Figure: 4.6.6.2). However, double 
label studies with NG2 and RECA-1 (endothelial cells) revealed some interesting 
findings. In 21% control animals, NG2 positive cells were generally located throughout 
the parenchyma, with no close association with the vasculature. However, as the 
duration of exposure to 10% oxygen increased, hypertrophied NG2 cells were found to 
progressively move closer to the vessels (Figure: 4.3.6.2 C). By 72h of exposure to 10% 
oxygen, a number of hypertrophied NG2 cells appeared to completely surround and 
enclose the vessels in the spinal white matter.  
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Figure 4.3.6.2: NG2 expression profile following exposure to 10% oxygen 
(A-C) Confocal laser images from animals exposed to 21% oxygen, or 24h, 48h or 78h 10% double 
labelled for NG2 (red), and astrocytes (A; green), MHC-II (B; green) and endothelial cells (C; green). (A) 
Following exposure to 10% oxygen, NG2 does not co-localise with GFAP, however, NG2 positive cells 
are sometimes closely associated with astrocytes. (B) Similarly, NG2 does not co-localise with MHC-II, 
following exposure to 10% oxygen. (C) In 21% oxygen controls, NG2 positive cells are found scattered, 
without any close association with endothelial cells. Following exposure to 24h and 48h 10% oxygen, 
hypertrophied NG2 positive cells are found in close proximity to endothelial cells. Following 72h 10% 
oxygen, the number of hypertrophied NG2 positive cells increases, and they are found enclosing the 
endothelial cells in the vicinity. Scale bar 100μm. All micrographs are representative. 
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4.3.7.0 The effects of acute hypoxia on endothelial cells 
 
4.3.7.1 Vascular density is not increased in response to acute hypoxia 
As expected, acute exposure to 10% oxygen did not affect the vascular density (total: p 
= 0.307; grey matter: p = 0.427; white matter: p = 0.517; Table 4.3.7.1). However, there 
was a considerable amount of inter-animal variation (Figure: 4.3.7.1 B) in normal 
tissue.  For example, in the lumbar spinal cord grey matter in animals exposed to 21% 
oxygen, the vascular density of the grey matter ranged from 774 to 1095 cells/mm
2
.  
Correlation between the intensity of pimonidazole labelling and the vascular 
density in the grey and white matter combined (total) was assessed using Pearson’s 
correlation coefficient test. No correlation was found to exist between the intensity of 
total pimonidazole labelling and the total vascular density (r = -0.198, p = 0.093), or 
between the grey matter pimonidazole labelling and the grey matter vascular density (r 
= -0.209, p = 0.076). However, a mild negative correlation, which was statistically 
significant, was found between the intensity of pimonidazole labelling and the vascular 
density in the white matter (r = -0.294, p = 0.012), suggesting that in the white matter 
the intensity of pimonidazole labelling increases as the vascular density decreases.  
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 Table 4.3.7.1: Spinal cord vascular density  
 
 
 
 
 
 
 
 
 
 
 Spinal Cord RECA1 Density  (cells/mm
2
) 
 Total Grey Matter White Matter 
24h 10% Oxygen 365.28 ± 39.35 795.38 ± 64.20 186.83 ± 29.96 
48h 10% Oxygen 370.93 ± 49.73 838.25 ± 81.95 186.63 ± 27.40 
72h 10% Oxygen 378.93 ± 66.24 817.24 ± 56.38 196.80 ± 52.83 
21% Oxygen 407.22 ± 53.73 868.22 ± 99.22 221.22 ± 35.93 
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Figure 4.3.7.1: Vascular Density 
(A) Spinal cord sections from the upper lumbar region of animals exposed to 21% oxygen, or 24h, 48h or 
72h 10% oxygen, labelled with RECA-1.Scale bar 500 µm. Micrographs are representative. (Table 3.1.4) 
Table showing the cumulative vascular density in the grey and white matter (total), grey matter and white 
matter. Values are means ± S.D. N=6 per group. (B) A scatter plot of the vascular density in the grey 
matter of animals exposed to 21% oxygen, showing the inter-animal variation, at different levels of the 
spinal cords. 
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4.3.7.2 Exposure to acute moderate hypoxia does not induce IgG leakage 
Severe, or prolonged, acute hypoxia is believed to induce vascular leakage in the brain 
(Schoch et al., 2002), therefore immunohistochemistry with an antibody against IgG 
was performed. No evidence of IgG immunoreactivity was found in the spinal cords of 
animals exposed to either 21% (controls) or 10% oxygen, at any of the time points 
investigated (Figure: 4.3.7.2).  Thus, blood-spinal cord barrier integrity appeared to be 
maintained. 
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Figure 4.3.7.2: BBB and acute hypoxia 
Micrographs of spinal cord sections from animals exposed to 21% oxygen, or 24h, 48h or 72h 10% 
oxygen labelled for IgG leakage. Exposure to 10% oxygen does not lead to BBB breakdown and IgG 
leakage. Scale bar 500μm. All micrographs are representative. 
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4.3.7.3 Exposure to acute hypoxia results in an increase in P-selectin on 
endothelial cells 
P-selectin was expressed at low levels on endothelial cells in the spinal cords of control 
animals (Figure: 4.3.7.3 A). Following exposure to 10% oxygen, the P-selectin 
immunoreactivity on endothelial cells increased (Figure: 4.3.7.3 A). The increase was 
evident within the first 24h of hypoxia, from which point it remained elevated. In some 
instances, by 72h of exposure to 10% oxygen, intense, prominent P-selectin labelling 
was also observed on endothelial cells (Figure: 4.3.7.3 B). 
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Figure 4.3.7.3: The effects of acute hypoxia on endothelial P-selectin expression  
(A-B) Spinal cord sections from animals exposed to 21% oxygen, or 24h, 48h or 72h 10% oxygen, 
labelled with an anti-P-selectin antibody. (A) Some endothelial P-selectin expression is seen in 21% 
control animals, however, the expression of endothelial P-selectin is increased in animals exposed to 10% 
oxygen. (B) Some vessels in animals exposed to 72h 10% oxygen showed substantial P-selectin 
expression. Scale bar 25 μm. All micrographs are representative. 
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4.4.0.0 DISCUSSION 
 
The present study provides evidence that reducing the concentration of inspired oxygen 
can expose regions of increased vulnerability to hypoxia in normal rat spinal cord. 
Accordingly, both a spatial vulnerability, and a heterogeneous cellular vulnerability, to 
hypoxia have been revealed. Notably, the results show that acute hypoxia induces 
microglial activation, suggesting that hypoxia can initiate an inflammatory response. 
The potential relevance of this finding to understanding MS is discussed. 
 
4.4.1.0 Hypoxia-induced weight loss 
The brain and spinal cord rely on a continuous supply of oxygen to meet the metabolic 
needs of the tissue. It has been suggested that the oxygen supply to the CNS occurs on a 
‘just sufficient’ basis (LaManna et al., 2004), in which the CNS exists in a 
physiological, but predominantly low-oxygen state (LaManna et al., 2003). The 
physiological state of relative hypoxia is maintained by structural and functional 
adaptations, which also respond to changes in supplied oxygen tension (raised or 
lowered) to compensate for the change and prevent pathology and cell death. Systemic 
adaptations to prolonged hypoxia are fairly well understood, and include increased 
ventilation and hematocrit, decreased core temperature, bicarbonate ion excretion and a 
loss of body mass. The current study shows that exposure of rats to 10% oxygen 
(balance nitrogen) for 24, 48 and 72 hours results in a linear decrease in body mass 
(LaManna et al., 1992). Indeed, appetite suppression and decreased food intake are 
frequently observed due to hypoxia at high altitude (Westerterp et al., 1994; Westerterp 
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et al., 1999; Shukla et al., 2005). Moreover, some studies have found that hypoxia 
induces an increase in the levels of circulating leptin, a hormone with a central role in 
fat metabolism (Chaiban et al., 2008; Ling et al., 2008). Others have also found a direct 
effect of hypoxia on protein synthesis, with a decrease in whole-body insulin sensitivity 
and muscle-specific glucose utilisation (Iiyori et al., 2007), and intestinal dysfunction 
(Boyer and Blume, 1984; Quintero et al., 2010). Nevertheless, the mechanisms of 
weight loss under hypoxic conditions remain unclear. 
 
4.4.2.0 Spatial and regional vulnerability to hypoxia 
Labelling for hypoxia in the current study has revealed ‘hypoxia-vulnerable’ areas in the 
spinal white matter of animals exposed to 10% oxygen. Moreover, these pockets of 
pimonidazole labelling appear to occur between vessels, even though the drug is 
administered via the vasculature. It is easy to understand this finding, namely that 
regions of white matter that are more remote from vessels may be inherently vulnerable 
to hypoxia. Indeed, the local capillary tissue oxygen tension decreases from the arterial 
to the venular end of the vessel (Cater et al., 1961; Nair et al., 1975; Smith et al., 1977) 
and so it seems reasonable to propose that the pockets of pimonidazole labelling 
described in the current study may occur between the distal portions of white matter 
capillaries, although this remains to be investigated. In particular, the regions of hypoxia 
are likely to occur near veins, as venular blood is the most deoxygenated.   
Interestingly, the white matter just below the dorsal horns, the ‘wing-tip’ regions 
of the dorsal columns, and the base of the dorsal columns, were shown to have 
increased susceptibility to hypoxia. The base of the dorsal columns is occupied by the 
dorsal corticospinal tract that is comprised primarily of small diameter axons. Small 
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diameter axons, by virtue of their surface to cytoplasmic volume ratio, may both have a 
relatively high oxygen demand, contributing to hypoxia, and also be predisposed to 
hypoxic damage. Indeed, axon size is an important determinant of susceptibility to 
degeneration in MS (Evangelou et al., 2001), with energy deficiency implicated as a key 
pathogenic mechanism (Stys, 2005; Dutta et al., 2006). Given that hypoxia can deplete 
metabolic energy vital for maintaining physiological processes, it seems reasonable to 
suggest that hypoxia may contribute to the selective vulnerability of small diameter 
axons to degeneration in MS (Evangelou et al., 2001). 
Regional differences in the labelling for hypoxia were also found, with the 
thoracic segment of the spinal cord particularly vulnerable. Indeed, the vascular 
organisation is such that it creates intrinsic watershed zones at particular levels of the 
spinal cord (Tveten, 1976), and one of these zones has been reported to be the thoracic 
spinal cord. Despite this, due to the difference in size of the respective segments, blood 
flow values at the thoracic level are comparable to those at lumbar and cervical levels 
(Hayashi et al., 1983). In addition, no significant difference in local tissue oxygen 
metabolism exists between the various levels (Hayashi et al., 1983). Thus, factors other 
than differences in vascular density must influence the vulnerability of the thoracic 
segment to hypoxia, and watershed concepts provide a plausible explanation. 
 
4.4.3.0 Selective cellular vulnerability to hypoxia 
4.4.3.1 Oligodendrocyte vulnerability to hypoxia 
Oxygen, among other substrates, is a vital requirement of cells, necessary for 
physiological function and survival. Thus, tight coupling between supply and demand 
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exists, to ensure effective energy metabolism. Moreover, cells within the CNS have 
different metabolic profiles, and preferentially utilise different pathways of energy 
metabolism, enabling them to meet the metabolic demands for specialised physiological 
function. This diversity, however, renders particular cell types more vulnerable to 
hypoxic insults. Accordingly, the current study provides evidence that neurons, and 
cells of oligodendrocyte lineage, in the rat spinal cord, are particularly vulnerable to 
becoming hypoxic and potentially hypoxia-induced damage. This finding is in 
agreement with previous studies, in vitro (Husain and Juurlink, 1995), and in vivo (Back 
et al., 2002). Indeed, due to their higher energy requirements, neurons rely heavily on a 
high rate of oxidative metabolism. Despite this, neurons ironically have a limited 
capacity to defend against oxidative stress (Shih et al., 2003; Belanger et al., 2011). 
Rather, neurons appear to depend on the high antioxidant potential of astrocytes for 
their own defence against oxidative stress (Dringen, 2000; Belanger et al., 2011). The 
metabolic profile of oligodendrocytes, is also specialised, and favours the synthesis of 
lipids, presumably to make myelin (Sánchez-Abarca et al., 2001). As with neurons, 
oligodendrocytes also have a limited capacity to defend against oxidative stress. Given 
that hypoxia can induce ROS production (Chandel et al., 1998; Guzy et al., 2006), it is 
not surprising that neurons and oligodendrocytes are selectively vulnerable to hypoxia-
induced damage. Moreover, oligodendrocytes have a high iron and lipid content, which 
increases the potential for ROS generation, further increasing the vulnerability of this 
cell type. However, a recent study (Fünfschilling et al., 2012) contradicts this traditional 
view of oligodendrocyte vulnerability. Fünfschilling and colleagues appear to show that 
mature, post-myelinating oligodendrocytes can survive without functional 
mitochondrial complex IV. The authors propose that mature oligodendrocytes survive 
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by simply increasing their glycolytic capacity, releasing lactate as an end product, which 
is rapidly utilised by myelinated axons (Fünfschilling et al., 2012).  
In contrast, astrocytes and microglia were found to be relatively resistant to 
becoming hypoxic, in the current study, as indicated by the lack of pimonidazole 
labelling. Astrocytes, in particular, exhibit greater metabolic plasticity than neurons 
(Almeida et al., 2001; Vega et al., 2006), i.e., they are able to adapt their energy 
metabolism in response to environmental challenges (Belanger et al., 2011), owing to 
their resistance to hypoxic stresses. For example, following NO-induced mitochondrial 
inhibition, astrocytes increase glucose metabolism via glycolytic pathways, thereby 
preventing ATP depletion (Almeida et al., 2001). Similarly, the resistance of microglial 
cells to hypoxia has been attributed to their ability to easily adapt, and overcome non-
physiological conditions (Yun et al., 1997).  
  
 4.4.3.2 OPCs display a reactive phenotype following exposure to acute hypoxia 
Besides oligodendrocyte vulnerability, NG2
+
 OPCs in the spinal cord were also affected 
by exposure to acute hypoxia in the current study. NG2
+
 OPCs represent a 
subpopulation of glial cells that are antigenically distinct from other glial cells (Levine 
et al., 1993; Nishiyama et al., 1997; Reynolds and Hardy, 1997; Keirstead et al., 1998; 
McTigue et al., 1998; Butt et al., 1999; Ong and Levine, 1999; Dawson et al., 2003), 
and are found not only during development but are also abundant in the adult rodent 
brain (Levine et al., 1993; Nishiyama et al., 1996; Reynolds and Hardy, 1997), 
distributed quite uniformly throughout the white and grey matter. These intriguing cells 
are inherently plastic, and once activated are able to rapidly proliferate and mature into 
oligodendrocytes. They display heterogeneity with regard to the different cell types into 
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which they can develop (Belachew et al., 2003; Alonso, 2005; Cassiani-Ingoni et al., 
2006), and function (Bergles et al., 2000; Jabs et al., 2005; Karadottir et al., 2005; 
Kukley et al., 2007; Ziskin et al., 2007). In the current study, clusters of ‘hypoxic’ 
NG2+ cells within foci of intense labelling for hypoxia within the white matter, were 
often surrounded by a paucity of cells labelling for NG2. Whether this loss represents 
maturation of NG2+ OPCs, cell death, or migration, remains to be investigated. Indeed, 
hypoxia has been found to induce premature differentiation of OPCs in vitro, and it is 
thought to contribute to hypomyelination in the developing hypoxic brain (Akundi and 
Rivkees, 2009). Furthermore, OPCs are particularly vulnerable to hypoxia in vitro 
(Husain and Juurlink, 1995).  
The current study also demonstrates that hypoxia induces OPC hypertrophy and 
clustering around vessels, in a time-dependent manner. It seems reasonable to propose 
that a morphological change such as hypertrophy may represent a reaction of the NG2
+
 
cells to potentially damaging stimulus. Indeed, this is supported by their perivascular 
location following 72h of prolonged hypoxia in the present study. Lesions that disrupt 
the BBB have been shown to induce NG2
+
 OPC hypertrophy (Rhodes et al., 2006). 
Although, such a response is not evident following lesions where the BBB remains 
intact (Rhodes et al., 2006), the present findings suggest that NG2
+
 cells display 
surveillance-like functions, allowing them to detect changes within the tissue 
microenvironment, as has been previously proposed (Dawson et al., 2003; Rhodes et al., 
2006). 
  
4.4.4.0 Hypoxia-induced microglial activation 
Hypoxia is an important event that regulates a wide range of physiological responses. 
Microglia represent the first line of immune defence within the CNS, and increasing 
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evidence suggests that hypoxia-induced microglial activation contributes to neuronal 
damage in stroke, in addition to the neurodegeneration that results from the direct loss 
of oxygen and glucose (Gonzalez-Scarano and Baltuch, 1999; Suk, 2005). The present 
data demonstrate that exposure to acute hypoxia induces mild microglial proliferation 
and activation, as assessed by the respective density of IBA+ cells and the number of 
cells expressing MHC class II. Indeed, proliferation and MHC class II expression are a 
common response of microglia to pathological stimuli. Consistent with the current 
findings, microglial proliferation (Mander et al., 2005) and activation have previously 
been described in the brain (Wang and Kaur, 2000) and retina (Kaur et al., 2006b) 
following hypoxia. An increase in microglial density and number of cells expressing 
MHC class II may represent a precursor for pathology in an otherwise normal-appearing 
CNS, or a type of priming or sensitization in the event of a subsequent insult. However, 
a western blot would confirm whether MHC class II expression is increased in response 
to hypoxia. Interestingly, activated microglia have been observed in cortical grey matter 
and normal appearing white matter, remote to areas of active demyelination in MS post-
mortem tissue (Allen et al., 2001; De Groot et al., 2001). These preactive lesions are 
characterised by clusters or nodules of microglial cells expressing the MHC class II 
antigen. The absence of BBB leakage, leukocyte infiltration and demyelination, in these 
lesions has led to the suggestion that MS may result from the intrinsic activation of the 
innate immune system. However, the ‘trigger’ of this activation remains unknown. The 
ability of hypoxia to induce similar changes to those seen in preactive lesions is 
particularly interesting, and will be discussed in further detail later. 
Microglia are characterised by their high responsiveness to atypical events, 
responding robustly to minor pathological challenges to the CNS (Kreutzberg, 1996). 
They are able to respond in a graded manner to changes in their local environment, 
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giving rise to an array of phenotypes (Graeber, 2010). Many studies have reported 
constitutive MHC class II expression in microglia (Lowe et al., 1989; Zhang et al., 
2002), however it is thought that this expression is kept to a minimum through contact-
dependent inhibition by neurons. Therefore, if neurons reduce this inhibition as a 
consequence of degeneration or ‘distraction’ due to hypoxia, the loss of such inhibitory 
control may represent a potential mechanism through which hypoxia-induced microglial 
MHC class II could be amplified to cause a wider nidus of inflammation.  
A potential avenue of microglial activation is via breakdown of the BBB, and 
subsequent vascular leakage, and indeed hypoxia is reported to induce such a leakage in 
vivo (Schoch et al., 2002).  The consequent exposure of microglia to serum proteins 
such as fibrinogen would engage CD11b/CD18 integrin heterodimers (Adams et al., 
2007), leading to microglial activation.  However, arguing against this possibility, no 
evidence of serum protein leakage was found in the present study.  
The current study shows that the morphological phenotype of MHC class II 
positive microglia varies following hypoxia, such that the percentage of microglia 
displaying a more activated phenotype increases with the duration of the hypoxia. 
Microglial activation is a dynamic process, thought to occur in a graded manner 
(Kreutzberg, 1996). The dynamics of microglial activation have been elegantly shown 
by time-lapse confocal microscopy in vitro (Stence et al., 2001) and in vivo 
(Nimmerjahn et al., 2005). The latter study has drawn attention to the on-going 
surveillance of brain tissue by the constant ‘probing’ of their environment with fine 
processes (Nimmerjahn et al., 2005).   
Activated, amoeboid microglia often display phagocytic properties, normally 
representing one extreme of their capability. The antibody ED1, which recognises an 
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antigen in lysosomal membranes, is a useful marker of phagocytosis, since the 
expression of the antigen in macrophages increases with phagocytic activity 
(Damoiseaux et al., 1994). To determine the activation state of the microglia within the 
spinal cord following exposure to 10% oxygen, immunohistochemistry with an ED1 
antibody was performed, however no evidence of ED1 immunoreactivity was found. It 
seems that hypoxia causes an activation of microglia (i.e. their density and expression of 
MHC class II increases) but that activation stops short of the expression of ED1.   
Microglia are crucial effector cells of the innate immune system, and following 
activation they can initiate signalling pathways that can be either protective or 
destructive. Although the exact mechanisms remain unclear, the cytokine profile and 
expression of certain proteins in microglia can give an indication of whether the 
activation is destined to be protective or destructive. The expression of the enzyme 
iNOS in microglia is usually a good indicator of the activation of a pro-inflammatory 
signalling pathway. Moreover, the gene responsible for iNOS production has a HRE in 
its promoter region, and can therefore be induced by hypoxia via HIF-1α (Melillo et al., 
1995; Palmer et al., 1998). Although iNOS expression was not evident following 
exposure to 10% oxygen in the current study, previous research has shown that hypoxia 
can induce iNOS expression in microglia, in vitro (You and Kaur, 2000). This 
discrepancy may reflect differences in the severity of the hypoxia, and/or the differences 
between in vivo and in vitro conditions.  
TLRs play a pivotal role in the innate immune response against invading 
pathogens. To date, more than 10 mammalian TLRs have been identified (Kawai and 
Akira, 2006), however, microglial TLR4 plays an especially important role in the 
immune and inflammatory response in the CNS (Jung et al., 2005). The current study 
demonstrates that TLR4 expression within the spinal cord increases with the duration of 
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hypoxia, in vivo. This is consistent with previous in vitro findings in both microglia 
(Ock et al., 2006) and macrophages (Kim et al., 2010). TLR4 expression is dynamically 
modulated, and its levels at an infected site are critical for an appropriate inflammatory 
response:  for example, TLR4 deficient mice exhibit a decreased inflammatory response 
and thereby smaller lesions following brain ischaemia (Caso et al., 2007). Thus, TLR4 
is instrumental to inflammatory and pathological responses, and has also been shown to 
mediate inflammatory neurodegeneration (Lehnardt et al., 2003). The present findings 
imply that hypoxia may exacerbate inflammatory responses to infections by up-
regulating TLR4 expression on microglia, and may therefore have implications for the 
pathogenesis of neurodegenerative diseases such as MS, a point that I will return to later 
in the thesis.  
 
 4.4.5.0 Regional and inter-animal vascular differences 
Adaptive responses are a well-recognised feature during hypoxic insults, and essentially 
act to minimise the effect of the decreased oxygen availability. One such response is 
angiogenesis, beginning around day four of mild hypoxic exposure (Xu and LaManna, 
2006) and complete by 3 weeks (Pichiule and LaManna, 2002). Consistent with these 
previous findings, the relatively short duration of exposure to 10% oxygen in the current 
study did not result in an increase in the vascular density of the spinal cord.  
The activated microglia and hypoxia-positive NG2 cells were almost exclusively 
present in the white matter.  It seems likely that this pattern correlates with the much 
lower vascular density of the white matter (compared with that of the grey matter), 
which is presumably associated with the decreased metabolic activity of this 
compartment (Rawe and Perot, 1977; Hayashi et al., 1983b).  In addition, the blood 
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flow in the white matter is significantly lower than the grey matter (Hayashi et al., 
1983b).  Aside from these considerations, the white matter is primarily served by blood 
that has initially passed through the grey matter and this anatomical organisation 
renders the white matter especially vulnerable to hypoxia due to prior oxygen extraction 
and ‘vascular steal’ by more proximal spinal tissue.   
Besides such a regional and compartmental variation in vascular density, a 
considerable amount of inter-animal variation in the vascular density was also observed 
in the current study. This finding suggests that individual animals may have different 
vulnerabilities to hypoxia as dictated by their vascular anatomy. Indeed, there are 
regional differences in the vascular density in the hippocampus; the CA1 region, which 
is particularly vulnerable to degeneration due to mild ischaemia (reviewed in Schmidt-
Kastner and Freund, 1991), has a significantly lower vascular density than the CA3 
region (Cavaglia et al., 2001), which is more resistant to ischaemic damage than CA1 
(reviewed in Schmidt-Kastner and Freund, 1991). Thus, inter-individual variations in 
vascular density may perhaps explain the predilection for MS lesions to form in specific 
regions of the CNS. I will return to this point later in the thesis.   
 
4.4.6.0 Hypoxia induces changes in endothelial cells  
By virtue of their location, endothelial cells have to cope with alterations in the 
composition of the blood. One such alteration is hypoxia, and it is thought to have 
profound effects on endothelial cell function. Hypoxia alone can induce endothelial 
activation (Dore-Duffy et al., 1999), thereby initiating a cascade of events culminating 
in neutrophil adherence and recruitment (Milhoan et al., 1992; Arnould et al., 1993; 
Ginis et al., 1993; Baudry et al., 1998). The current study shows that endothelial cells 
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become hypoxic following exposure to 10% oxygen, resulting in an increase in the 
expression of endothelial P-selectin. P-selectin is a cell adhesion molecule expressed on 
activated endothelial cells and platelets. In unactivated endothelial cells, P-selectin is 
stored in Weibel-Palade bodies (WPBs) (Bonfanti et al., 1989; Harrison-Lavoie et al., 
2006), so that it can be rapidly transported to the endothelium upon activation. Hypoxia 
has been shown to induce a calcium dependent exocytosis of WPBs (Pinsky et al., 
1996), resulting in the overexpression of P-selectin, which then initiates neutrophil 
binding. Accordingly, hypoxia-induced neutrophil adherence can be blocked using 
antibodies against P-selectin (Arnould et al., 1993; Rainger et al., 1995). Thus the 
present findings suggest that hypoxia can facilitate the inflammatory response by 
modulating the expression of cell adhesion molecules on endothelial cells. This point 
will be discussed in more detail later in this thesis. 
 
 
4.4.7.0 Conclusion 
The present study provides evidence that the rat spinal cord has selective vulnerabilities 
to hypoxia expressed at the regional (thoracic segment), compartmental (white matter) 
and cellular (oligodendrocytes and OPCs) levels. These selective vulnerabilities may be 
in part dictated by the vascular architecture of the spinal cord, and the intrinsic 
properties of these levels.  Moreover, hypoxia appears to sensitize the spinal cord, 
firstly by promoting adherence of leukocytes to the endothelium through the 
upregulation of the CAM P-selectin, and secondly by increasing the responsiveness of 
microglia, by increasing the number of cells expressing MHC class II and TLR4 
molecules. Given that hypoxia is a common feature of inflammation, it seems 
reasonable to propose that it may perpetuate damage by propagating the immune 
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response, rather than representing an innocent bystander of the inflammatory milieu. 
Additionally, the ability of hypoxia to sensitize or prime the resident microglia, may 
decrease the threshold required for activation of an innate immune response. These 
findings may have implications for the pathogenesis of number of neurodegenerative 
diseases, including MS, and the ideas will be brought together later in the thesis to form 
a hypothesis relevant to this disease.   
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CHAPTER FIVE 
 
 
GENERAL DISCUSSION 
 
 
This thesis demonstrates that true tissue hypoxia, a common, yet underestimated feature 
of inflammatory lesions, appears to be involved in two of the three of the cardinal 
features of MS. First, hypoxia is involved in the loss of neurological function observed 
in MOG-induced EAE, second, and in the development of demyelination in the 
experimental Pattern III lesion. Finally, this thesis provides evidence that selective 
regional and cellular vulnerabilities to hypoxia exist in the normal rat spinal cord, and 
that hypoxia can sensitise resident microglia, thereby decreasing the threshold required 
to initiate an immune response, or propagating micorglial activation during periods of 
inflammation . Curiously, despite increasing evidence supporting the notion that the 
oxygen concentration within active MS and EAE lesions may be low (Simmons et al., 
1982; Juhler, 1987; Aboul-Enein et al., 2003; Graumann et al., 2003), the possibility 
that hypoxia may be a key factor in MS has not been explored until now.  
 
Increasing evidence suggests that an energy failure may represent an important 
mechanism involved in the pathogenesis of the cardinal features of MS (Aboul-Enein et 
al., 2003; Mahad et al., 2008; Trapp and Stys, 2009), however, hypoxia, per se, is often 
regarded as an unlikely cause of such a failure because under normal circumstances 
hypoxia has to be quite profound before it impairs mitochondrial respiration. This is due 
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to the fact that mitochondrial complex IV has a very low Km for oxygen (<1µM), and 
so mitochondria are capable of making use of even very low oxygen concentrations for 
oxidative phosphorylation. However, this advantage fails in inflamed tissue because of 
the presence of NO. Even very low concentrations of nitric oxide can dramatically raise 
the mitochondrial Km for oxygen (Brown and Cooper, 1994), meaning that even greater 
oxygen concentrations than normal may be required to sustain mitochondrial function. 
Accordingly, even a small change in local oxygen tension may have a large effect on 
cellular function, when coupled with inflammation involving NO production. 
Furthermore, elevated levels of ROS, such as superoxide, are also associated with the 
inflammatory milieu, thereby further increasing the potential for toxicity. Therefore the 
pathophysiological significance of hypoxia is magnified in neuroinflammatory lesions, 
such as in MS. 
 
 
5.1.0.0 Hypoxia and loss of neurological function 
This thesis provides chemical, physical and therapeutic evidence that hypoxia, on a 
background of inflammation, can reversibly induce neurological dysfunction in an 
animal model of MS, in the absence of demyelination. Traditionally, neurological 
dysfunction in MS has been attributed to abnormalities in axonal conduction, such as 
those arising from demyelination (McDonald, 1986).  However, more recently, studies 
have emphasised the potential role of inflammation (Youl et al., 1991; Moreau et al., 
1996, and Bitsch et al., 1999), but the exact mechanisms responsible have remained 
unclear.  A role for NO has been invoked (Redford et al., 1997; Shrager et al., 1998), 
due to the prominence of NO production in some MS lesions (Bo et al., 1994; Bagasra 
et al., 1995; Johnson et al., 1995), and findings that NO can block axonal conduction in 
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normal and demyelinated axons.  We believe that NO may well be involved, but that its 
potency may require the concurrent presence of hypoxia.   
There are several mechanism(s) by which hypoxia may compromise 
neurological function.  For example, neurons of different brain regions have been 
shown to exhibit depolarizing and/or hyperpolarising responses following short periods 
of hypoxia (Fujiwara et al., 1987; Leblond and Kmjevic, 1989). These typical responses 
are a consequence of a marked decline in intracellular ATP levels (Fujiwara et al., 1987; 
Nieber et al. 1995), and thereby an energy insufficiency that is mediated by hypoxia.  
The depolarisation has been attributed to the failure of the Na+/K+ ATPase pump 
(Fujiwara et al. 1987; Nieber et al. 1995), whereas the hyperpolarisation is thought to be 
mediated by the opening of ATP-dependent K+ channels (KATP) (Zhang and Krnjevic, 
1993; Fujimura et al. 1997; Finta et al., 1993; Nieber et al. 1995). Changes in membrane 
potential such as these essentially result in a reversible loss of function, as seen in 
rMOG EAE.  Furthermore, hypoxia has been found to inhibit myelin phosphorylation in 
oligodendrocytes (Qi and Dawson, 1993), thus disturbing myelination, which could also 
result in abnormal conduction, although this seems less likely as a leading mechanism 
of loss of function in view of the prompt restoration of function by breathing oxygen.   
Although most neurological deficits in MS are probably due to demyelination 
and degeneration, this research shows that hypoxia can also cause loss of function, and 
so it provides a possible explanation for brief relapses that cannot easily be explained by 
demyelination and degeneration. This realisation opens the door to understand that 
some more persisting deficits are not necessarily caused only by the demyelination and 
degeneration to which they are currently attributed.  So the current findings introduce 
hypoxia as a new additonal mechanism for loss of function in MS. At present, the extent 
to which hypoxia plays a role in causing loss of function in MS remains unclear.  
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Hypoxia may be a key mechanism responsible for loss of function early in a relapse, 
before the same symptoms become consolidated by demyelination and degeneration.   
 
5.2.0.0 ‘Hypoxia-like’ demyelination 
Neuropathological studies on the human Pattern III MS lesion have led to the 
suggestion that ‘hypoxia-like’ demyelination is a consequence of an energy 
insufficiency, attributed to mitochondrial dysfunction mediated by NO (Aboul-Enein et 
al., 2005). However, this thesis demonstrates that tissue hypoxia, in association with NO 
and superoxide, not only precedes demyelination in experimental ‘hypoxia-like’ Pattern 
III lesions, but may actually be causally involved in inducing the formation of such 
lesions. Thus the spatio-temporal nature of the hypoxia, NO and superoxide, appears to 
determine the exact location of the demyelinated lesion that formed approximately a 
week later.  Notably, the lesion forms at the base of the dorsal column, a region that our 
results show is particularly vulnerable to hypoxia. This finding is particularly interesting 
given that the demyelination in both the human Pattern III and experimental lesion has 
been described to occur via a mechanism that is ‘hypoxia-like’ (Aboul-Enein et al., 
2003). Presumably, the increased vulnerability of the base of the dorsal column to 
hypoxia reduces the threshold of toxicity required to induce damage. Accordingly, 
vulnerable cell types, such as oligodendrocytes, shown in this thesis to be particularly 
hypoxic, succumb to a profound energy deficit due to the combined effects of hypoxia, 
NO and superoxide, leading to ‘hypoxia-like’ demyelination. This observation may 
perhaps help to explain lesion topography in MS. Indeed, some regions of the CNS are 
vulnerable to to disturbances in vascular perfusion, and hypoxia-mediated damage. 
These so-called watershed regions are located between two major arterial supplies, and 
one such area is the periventricular region of the brain where MS lesions are commonly 
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found. These regions will presumably have a reduced threshold for toxicity and so may 
not withstand the barrage of toxic mediators during periods of acute and chronic 
inflammation, resulting in preferential structural damage. 
 
5.3.0.0 Hypoxia and degeneration 
Axonal damage can be a major cause of irreversible neurological deficit in patients with 
MS (Trapp et al., 1998; Bjartmar and Trapp, 2003; Dutta and Trapp, 2007). Although 
axonal injury is evident in acute MS lesions (Ferguson et al., 1997; Trapp et al., 1998), 
at this stage the damage may remain clinically silent. However, there is a concomitant 
on-going, chronic ‘slow-burning’ of axons that can persist for years (Lassmann, 2007; 
Trapp and Nave, 2008; Dutta and Trapp, 2011), and is thought to be responsible for the 
transition to progressive disease. Due to several lines of evidence suggesting a state of 
impaired mitochondrial energy production (Smith and Lassmann, 2002; Bechtold and 
Smith, 2005; Dutta et al., 2006; Mahad et al., 2008), in addition to increased energy 
demand consequent to the greater expression of leaky sodium channels along the 
denuded axolemma (Craner et al., 2004), demyelinated axons have been suggested to be 
subjected to a chronic state of ‘virtual hypoxia’ (Stys, 2004). It is easy to appreciate that 
this prolonged state of energy insufficiency can promote chronic necrosis and 
degeneration of axons in the MS brain. Perhaps more important is the fact that a chronic 
energy insufficiency will render the axons more vulnerable to the wide range of insults 
that will occur over the years, but it may also directly cause degeneration. For example, 
the lack of energy substrates disrupts the ionic gradient across the axolemma, resulting 
in the intracellular accumulation of sodium and calcium, and the loss of potassium (Stys 
and LoPachin, 1996), resulting in the initiation of calcium-mediated cell death 
signalling pathways. Indeed, such a mechanism is well established in hypoxic/ischemic 
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models, hence the term ‘virtual hypoxia’. However, in the light of the current findings, 
it seems reasonable to hypothesise that demyelinated axons may be in fact rendered to a 
state of actual tissue hypoxia, rather than ‘virtual hypoxia’. Given that none of the 
current therapies reduce the ‘slow-burning’ destruction of axons, the current finding that 
actual tissue hypoxia may be involved in the pathogenesis of MS may provide a better 
understanding of why chronically demyelinated axons degenerate, and possibly 
introduce the opportunity to develop  novel therapeutic strategies. Nevertheless, the role 
of hypoxia in axonal degeneration is yet to be elucidated. 
 
5.4.0.0 Hypoxia and the normal spinal cord-implications for MS?  
Despite the considerable progress in MS research over the years, the aetiology of the 
disease remains elusive, although evidence suggests that a complex interplay of genetic 
and environmental factors is involved (Noseworthy, 1999). It has been traditionally 
assumed that a dysregulation of the adaptive immune repertoire against one or more 
CNS antigens may represent the primary trigger of MS (McFarland and Martin, 2007), 
and this view has long been upheld by the EAE model of MS that mimics the disease. 
However, increasing evidence suggests that the disease may in fact result from the 
activation of the innate immune system (Allen and McKeown, 1979; De Groot et al., 
2001; Barnett and Prineas, 2004; Marik et al., 2007; van Horssen et al., 2012). Despite 
these findings, it is not clear how the innate immune system would become activated, in 
the absence of BBB breakdown, leukocyte infiltration and demyelination (De Groot et 
al., 2001). In this regard it is interesting to consider the current findings that the spinal 
cord exhibits regional and cellular vulnerabilities to hypoxia. Furthermore, hypoxia can 
activate cells of the innate immune system, namely microglia, but also induce the 
expression of P-selectin on endothelial cells, thereby facilitating leukocyte 
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transmigration into the CNS. Needless to say, such a microglial response may reflect a 
protective strategy rather than a phenotypic change that is deleterious. Indeed the lack of 
induction of iNOS and ED1 expression are suggestive of a response that is not 
damaging. However, the nature of microglial activation following hypoxia, either 
protective or deleterious, requires further investigation. 
It seems clear that hypoxia can make the innate immune system more receptive 
to the induction of inflammation, e.g. by responding to an ongoing viral or bacterial 
infection, but it is less clear whether hypoxia can itself induce inflammation of a 
sufficient magnitude to result in the formation of an MS lesion. The former mechanism 
is particularly interesting given that the human herpes Epstein-Barr virus (EBV) is 
hypothesised to play a role in the aetiology of MS (Ascherio et al., 2001; Thorley-
Lawson, 2001; Haahr and Höllsberg, 2006; Pohl et al., 2006; Thacker et al., 2006; 
Ascherio and Munger, 2007a). Acute infection with EBV is followed by a life-long 
presence of the latent virus (Golden et al., 1973), which can be reactivated to lytic 
replication. EBV infection has been described in MS post mortem brain tissue, with the 
majority of the cells harbouring the latent virus (Serafini et al., 2007; Tzartos et al., 
2012). In addition to EBV infection, smoking is also considered a risk factor for MS 
(Ascherio and Munger, 2007b). Conflicting studies investigating the combined effects 
of high anti-EBVNA (EBV nuclear antigen) titres and smoking on MS risk, with some 
studies describing a strong association (Simon et al., 2010) and others describing no 
association (Sundqvist et al., 2012). Considering that smoking can lead to acute periods 
of tissue hypoxia (Sagone et al., 1973; Jensen et al., 1991) and hypoxia can reactivate 
latent EBV in vitro (Jiang et al., 2006), it seems reasonable that hypoxia-mediated 
reactivation of latent EBV in smokers may represent a pathogenetic mechanism of MS, 
particularly given that EBV infection can elicit an inflammatory response (Tzartos et al., 
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2012). Alternatively, the sensitisation of microglia by hypoxia may make the CNS more 
‘receptive’ to invading pathogens that may otherwise not elicit an immune response. It 
seems reasonable that the magnitude of the hypoxia would be increased in individuals 
who smoke, thereby reducing the threshold required for the activation of the innate 
immune system. However, this remains to be investigated.   
The current observation that there is considerable inter-individual variation in 
vascular density may also have implications for MS. It seems reasonable to assume that 
an individual with a decreased vascular density would be more vulnerable to becoming 
hypoxic than, say, an individual with a greater vascular density. Such a variation in 
vascular density may explain why MS is such a heterogeneous disease. Interestingly, a 
decreased vascular density of the hippocampal CA1 region has been associated with its 
increased vulnerability to hypoxia/ischaemia, in comparison with other hippocampal 
regions (Cavaglia et al., 2001), supporting such a theory.  
 
5.5.0.0 Future directions 
This thesis demonstrates that acute neuroinflammatory lesions are hypoxic, and that the 
severity of the hypoxia is sufficient to cause functional and structural consequences, in 
diseases such as MS. Furthermore, this thesis provides evidence that hypoxia may 
represent a potential cause of the disease itself. However, these findings give rise to a 
number of questions that should form the basis of future projects. 
1) Despite the observation that hypoxia is a feature of acute neuroinflammation, the 
exact cause of the hypoxia itself remains unclear. Hypoxia ensues when the demand of 
oxygen outweighs its supply, so it is important to determine the contribution of 
individual factors involved in this balance to deduce the cause of the hypoxia during 
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neuroinflammation. There are a number of likely causes for an impaired oxygen supply 
including, but not restricted to a) obstruction of venous drainage due to perivascular 
cuffing by inflammatory cells; b) thrombotic occlusion of the microvasculature; c) 
reduction in CBV; and d) alterations in CBF. The most likely causes of increased 
oxygen demand include a) increased cellular load due to the massive infiltration of 
inflammatory cells; b) increased oxygen consumption for the formation of NO and 
superoxide, including during respiratory burst activity via NADPH oxidase; and perhaps 
c) increased metabolic demand to fuel ATP production. All these issues can be 
addressed experimentally in vivo, and would lead to a deeper understanding of the 
mechanisms involved. 
 
2) The therapeutic benefit of normobaric oxygen was touched on in the current thesis, 
however, the optimal treatment regime still needs refining. The length, duration, and 
frequency of exposure are all important factors to consider. Alternative treatments 
aimed at increasing oxygenation may also prove beneficial, and may warrant 
investigating. One example is the use of perfluorocarbons (PFC) (reviewed in Spahn, 
1999). PFCs are chemically inert synthetic molecules that have the ability to dissolve 
significant amounts of oxygen. PFCs, by virtue of their small size (<0.2 µm in 
diameter), are able to perfuse even the smallest of capillaries (4-5 µm in diameter), 
where blood may not flow under certain conditions. All the oxygen carried by PFCs is 
in the dissolved state, therefore increasing the partial pressure of oxygen in the 
microcirculation and augmenting the oxygen diffusion into the tissue. Such an 
application would presumably have a considerable affect in EAE, given that the 
maximal tissue oxygenation possible with normobaric oxygen alone is somewhat 
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limited. Additionally, the safety of prolonged normobaric oxygen exposure requires 
particular attention as there is a danger of promoting oxidative damage. 
3) Finally, the hypothesis that hypoxia may play a role in inducing MS requires further 
research. Currently, the data are very preliminary. Examining the long-term effects of 
acute hypoxia is expected to reveal interesting findings. Additionally, identifying 
whether acute hypoxia can sensitise the CNS to subsequent systemic infections, using 
agents such as LPS, will be of particular interest.  
 
5.6.0.0 Concluding remarks 
This thesis provides novel observations that hypoxia may be a hitherto-unrecognised, 
yet potentially important factor in two of the three cardinal features of MS, namely 
inflammation-mediated neurological dysfunction and demyelination. The data are 
consistent with the notion that neurological dysfunction and structural damage occur 
due to an energy insufficiency in vulnerable cell types, and suggest that this energy 
deficit is at least partly mediated by hypoxia. Furthermore, this thesis provides evidence 
that selective regional and cellular vulnerabilities to hypoxia exist in the normal spinal 
cord, which may help explain why some cell types are preferentially affected in MS. 
The findings have implications for our understanding of MS, leading to a deeper 
understanding of the mechanisms involved and novel potential strategies for therapy.  
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